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ABSTRACT
Currently, over one-third of the global population is infected with tuberculosis (TB), one
of the world’s most deadly infectious diseases. The current gold standard for TB
diagnosis is microbiological culture, which can take up to 6-8 weeks, which is not
conducive to timely treatment. There are no reliable diagnostics for TB. Disease
manifestation and outcome of diagnostic tests for TB are influenced by co-morbidities
such as HIV co-infection, further complicating diagnostics development. Thus, there is a
need for reliable diagnostics for TB. This is especially true in pediatric populations
where the differential disease presentation further complicates outcomes.
This dissertation describes the development and evaluation of new tailored
methods-lipoprotein capture and membrane insertion- for the discriminative detection of
an amphiphilic mycobacterial biomarker, lipoarabinomannan (LAM), for diagnosis of TB
in adult and pediatric populations. LAM is released by Mycobacterium tuberculosis
during active infection and associates with serum lipoproteins such as high and lowdensity lipoproteins (HDL/LDL) in the human host. The guiding hypothesis of this work
v

is that the sequestration of LAM in immune complexes and by lipoprotein carriers in the
host contributes to difficulty in the detection of the amphiphilic antigen in the blood. To
this end, we have evaluated the use of tailored amphiphile detection assays to process
and measure sequestered LAM in host blood, and examined the application of this
methodology in adults and children with TB disease. In addition, we have developed
and studied an in vitro cell model to further extrapolate the impact of the association of
LAM with host carriers on its ability to induce innate immune processes, to better refine
and design strategies for its direct detection. Overall, our conclusions indicate that the
amphiphilic biochemistry of LAM and its interaction with lipoproteins is a feature, which
should be taken into account for the effective development of diagnostics.
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Chapter 1.
Introduction

1.1 Tuberculosis Disease Burden and Epidemiology
Tuberculosis (TB) is one of the world’s oldest and most formidable diseases1. Often
referenced as a scourge on humanity1, the disease has affected humans for
thousands of years, and has caused more deaths in last 200 years than any other
infectious disease worldwide. TB is so prevalent, that nearly one quarter of the
world’s population (~2 billion) is infected, and ~1.4 million people succumb to the
disease every year2,3. So devastating is the effect of the disease, that the World
Health Organization (WHO) declared TB a global health emergency in 19934–6.
Regardless of extensive research in therapeutics, vaccines and diagnostics, TB is
still a major cause of concern around the globe7. According to a 2020 report from
the WHO, 10 million new people were infected, ~1.2 million HIV-negative individuals
and ~208,000 HIV positive people (Figure 1.1 A and B) died from the disease. .
Eight countries accounted for two-thirds of the global total: India (26%), China
(8.4%), Indonesia (8.5%), the Philippines (6%), Pakistan (5.7%), Nigeria (4.4%),
Bangladesh (3.6%) and South Africa (3.6%) (Figure 1.2). The estimate is slowly
increasing in the Americas after several years of decline. Men and women of all
ages are affected, but men represent a greater fraction (56% in 2019) compared
to women (32%)3. Meanwhile, children (<15 years) account for 12% of all TB cases
(Figure 1.1 C).

1

Figure 1.2. Estimated TB incidence in 2019, for countries with at least 100 000 cases. Reprinted with
permission from WHO. Global tuberculosis report, 2020, World Health Organization,
https://www.who.int/tb/publications/global_report/en/, accessed on November 1, 2020.

Historical evidence has demonstrated that TB-related mortality trends suffer from
geographic inconsistencies8. Between the years 1900-1980, TB-related deaths in
Western Europe and the United States decreased by more than 100-fold. Since most of
this decline was prior to the advent of anti-TB drugs, improvements in hygiene and
socioeconomic conditions were credited. As access to these interventions has improved
over time, the mortality rate has become relatively stable overall. However,
geographically, the disease mortality varies greatly with WHO African and South-East
Asia regions accountable for 85% of total deaths in 2019 with India alone responsible
for 31% of total TB deaths. Even though the overall number of incident cases and
deaths fell between 2000 and 2019, additional work is still needed to end the TB
epidemic. Faster reduction in TB deaths can be achieved by improving accessibility to
TB diagnosis and treatment.
2

One of the complicating features of TB disease is the fact that many individuals
infected

with

the

pathogen

are

asymptomatic for extended periods –
a condition referred to as latency
(Figure 1.3). This latent period can
last

until

the

infected

individual

encounters one or more risk factors
that challenge the immune system and
enables activation of the disease. The
transition
Figure
1.3.
Latent
and
active
TB.
Mycobacterium tuberculosis (MTB) is contained
in the granuloma (left) until the immune system is
weakened
and
MTB
escapes
(right).
BioRender.com

from

latency

to

active

disease is defined as a spectrum – as
described in the disease presentation

of this manuscript. Several factors influence activation of the disease from latency such
as HIV co-infection (15-22x), malnutrition and air pollution9, tobacco usage (2x risk)10,11,
excessive alcohol consumption (3x risk)12 or affliction with diabetes mellitus13. Among
all these, HIV is the most common co-infection for the progression of the disease to the
active state14. Statistics indicate that up to 8.2% of all TB patients may be co-infected with
HIV. Age is another major determinant in the activation of TB disease. Infants are at a
much higher risk of developing active TB. Between 2-11 years of age, risk of developing
an active infection is much lower, but begins increasing again during adolescence until
25 years of age, where risk plateaus and remains high for the remainder of adult life15.
Aerosol transmission facilitates the rapid spread of TB, and influences its global
burden. On average, a person with active TB infects 3-10 people per year, some of
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whom will progress to active TB16. In patients with active TB, the average period of
communicability is >1 year (in high burden areas), which highlights the magnitude of the
problem for controlling disease transmission17, especially if the disease is left untreated.
In fact, the true extent of TB disease remains unknown, with a large gap existing
between reported (7 million, 2019) and estimated (10 million, 2019) cases.
Underreporting of detected cases and inadequate diagnosis are the most probable
reasons for this gap18.

These potential missing cases pose a major challenge to

ongoing efforts geared towards controlling further transmission and spread of disease.
This disparity is especially profound in younger populations, with estimates suggesting
that 55% of pediatric cases have not been reported to surveillance programs19. This
discrepancy amongst children further varies with the age group of children being
considered, with 69% of cases unreported in children younger than 5 years of age
compared to 40% in children 5-14 years19. These facts become especially poignant
when one realizes that these children are living with TB, not receiving treatment, and
possibly spreading the disease even further.
1.2 Disease presentation
One of the factors about TB disease that is responsible for the global prevalence and
mortality is the complex nature of disease presentation.
Disease spectrum: Tuberculosis is a complex disease caused by the bacterium,
Mycobacterium tuberculosis (MTB), and spreads via inhalation into the respiratory tract.
Traditionally, TB has been characterized into latent and active infection stages
depending on the absence or presence of clinical symptoms. However, recent work in

4

Figure 1.4. The disease spectrum of TB. Mycobacterium tuberculosis infection to active
(pulmonary) TB disease, figure created with BioRender.com, adapted from Pai, M. et al.
(2016) Tuberculosis Nat. Rev. Dis. Primers doi:10.1038/nrdp.2016.76

animal models and humans shows a more complex pathogenesis profile where infection
can lead to either active disease or complete immune clearance18. As a result of these
observations, TB disease is now described as a spectrum (Figure 1.4), spanning from
asymptomatic infections to fatal disease18,20,21. To improve the characterization of
clinical TB pathogenesis, Drain et al. proposed a new framework for dividing the TB
disease spectrum into five infection stages: eliminated, latent, incipient, subclinical, and
active. Eliminated individuals are those that have been exposed to MTB before but have
successfully cleared it either owing to the immune system or due to anti-TB drugs. In
individuals with the latent disease, MTB can stay dormant in the lungs for years with no
clinical, radiological or microbiological evidence of active TB disease22,23. This is the
most prevalent form of TB disease and affects almost one-quarter of the world’s
population. Incipient infection shares many similar traits with latent TB, and in this case,
the patient expresses no clinical, radiological or microbiological evidence to confirm
5

active disease even though they are infected with viable bacteria. Subclinical disease
involves a unique manifestation of the disease, where the patient shows microbiologic
and radiologic symptoms indicative of active TB, but is still asymptomatic. The final
aspect of spectrum of disease is individuals presenting with active TB, where patients
are symptomatic with clinical and microbiological evidence and can transmit the
disease24. Thus, whereas individuals that present with the disease in various ranges of
the spectrum above can be contagious, some of them may not even be aware of their
disease status, fueling further transmission of MTB.
Disease Presentation in Individuals with Active Disease: Another complicating aspect
of active TB is that it can manifest as pulmonary or extra pulmonary forms. Pulmonary
TB (PTB) commonly presents as a cough that lasts greater than 4 weeks, and is often
accompanied by dyspnea, asthenia, chest pain, hemoptysis, persistent evening fever,
night sweats, and weight loss. The hematogenous spread of MTB either due to
reactivation of latent TB or progression of primary infection, results in extrapulmonary
TB (EPTB). EPTB can be disseminated throughout the body and can manifest in the
genitourinary, gastrointestinal, cerebral, lymphatic, or skeletal systems25. EPTB
presents an even greater diagnostic challenge due to nonspecific clinical presentation.
Because of the uncharacteristic presentation, the requisite treatment regimen is often
unclear, making the disease much more difficult to treat and control in both children and
adults.
Disease Presentation in Children: The disease presentation in children is different as
compared to adults, more likely due to an immature immune system. Children present
with disseminated or EPTB more often than adults26. Pediatric TB and co-infection with
6

both TB and HIV often result in paucibacillary disease, where clinical samples and
isolates from infected patients contain few bacteria, making culture and isolation of the
causative agent challenging27,28. For this reason, pediatric TB is considered a minor
contributor to the spread of infection. However, young children and people with HIV
have a high risk of disease progression following infection, and are more likely to
develop severe or disseminated disease. In children, these symptoms can be easily
mistaken for other childhood respiratory diseases, making it more difficult to diagnose
the disease. The childhood TB, disease presentation and diagnostics are discussed in
more detail in chapter 3 of this manuscript.

1.3 Mycobacterium tuberculosis
MTB is the causative agent of TB and was discovered, isolated and cultured by Robert
Koch in 188229. These are rod-shaped bacilli measuring about 1-4 µm in length and 3060 nm in width30. MTB belongs to genus Mycobacterium, and are classified as acid-fast,
since the cell wall is impermeable to the classic Gram stain, and therefore requires the
use of heat and acid to visualize the bacteria. They are considered aerobic, intracellular,
obligate pathogen and have no natural reservoir outside humans. MTB are slowgrowing mycobacteria, which are more virulent, have a doubling time of 15- 20 hours
and usually produce visible colonies on a solid medium in 10-28 days31. The thick waxy
cell wall of mycobacterium protects the microbicidal mechanism of macrophages and
plays an important role in host-pathogen interaction.

7

1.3.1 Pathogenesis
Pathogenesis of MTB is a highly studied field, largely owing to the interesting strategies
that the pathogen uses to evade immune recognition, thereby preventing its elimination
from the host.

In most instances,

MTB enters the lungs via inhalation,
reaches the alveolar space and
comes in contact with mononuclear
phagocytic cells such as alveolar
macrophages and dendritic cells.
The

bacteria

are

then

phagocytosed, which is the process
by which bacteria is recognized,
Figure 1.6. Phagocytosis involves 4 main steps: 1.
Pathogen recognition 2. Development of early phagosome 3.
Phagolysosome maturation 4. Pathogen degradation. Created
with BioRender.com. Adapted from Carranza et al. (2019),
Several Routes to the Same Destination: Inhibition of
Phagosome-Lysosome Fusion by Mycobacterium
Tuberculosis; N Am J Med Sci;
doi.org/10.1016/j.amjms.2018.12.003.

engulfed and destroyed (Figure
1.6)32,33. Phagocytosis is one of the
responses

of

the

host,

which

deploys a

combination of innate

and adaptive immune systems34 to eliminate MTB.
The process begins by recognition of pathogen-associated molecular patterns (PAMP)
such as LAM through specialized receptors such as (TLR)- 2, C-type lectin receptors,
complement receptor type 3 (CR3) and mannose receptor (CD206) expressed on the
cell surface in the host. Once recognized, signaling pathways induce actin filament
8

polymerization, which allows the cell membrane to elongate and form pseudopods that
surround the MTB cell. Then the membrane seals around the engulfed MTB, and forms
an early phagosome. The final step in the destruction process takes place in
phagolysosome, which is formed by the fusion of phagosome and lysosome. Once MTB
is internalized, a localized pro-inflammatory response occurs that leads to the
recruitment of other cells from nearby blood vessels leading to the formation of
granuloma. The granuloma is characteristic of TB disease and consists of a kernel of
infected macrophages surrounded by foamy giant cells35, forming an escape capsule for
the long-term survival and persistence of MTB. This encapsulation defines the latent
stage of TB. Caseation of the granuloma under conditions where the host immune
system is compromised, results in the dissemination of the contained MTB – causing
active disease. Consequently, if bacteria are destroyed in the phagolysosome, the
degraded antigens are then presented to T cells, resulting in the activation of the
adaptive immune response.
MTB exhibits remarkable abilities to evade host immunity, and block host-mediated
phagocytosis to ensure pathogen survival, using several different strategies where
ManLAM plays a crucial role in helping MTB evade host immune mechanisms as
discussed later in LAM section.

1.4 Mycobacterial cell wall
The cell wall of mycobacteria plays a crucial role in MTB physiology, and comprises of
the hallmark feature of mycobacteria- their abundance of unique in lipids

36

. The cell

wall consists of the periplasm, a peptidoglycan layer, and the outer membrane37. The
9

outer membrane contains mycolic acids, various glycolipids and phthiocerol
dimycocerosates. All these mycobacterial cell wall lipid components are vital for
interaction with the host and its immune system. The lipids and lipoglycans also play an
important role in MTB growth, survival and virulence38–41.
1.4.1 Mycolic acid
Mycolic acids (MAs) are the main component of the cell wall of mycobacteria and
important for regulating the permeability, viability and virulence of MTB. They are also
responsible for the acid-fast characteristic of MTB. These unique lipids are composed of

Figure 1.5. The structure of the Mycobacterium tuberculosis cell wall. This figure shows a
schematic representation of the major components of the cell wall and their distributions. Figure
created with BioRender.com. Adapted from: Vilchèze, C. Mycobacterial Cell Wall: A Source of
Successful Targets for Old and New Drugs. Appl. Sci. 2020, 10, 2278.
doi.org/10.3390/app10072278
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meromycolate chains of up to 62 carbons with numerous modifications. MTB has 3
different structural classes of MAs namely, alpha-, methoxy- and keto-Mas42, with the
most abundant form being α -MA (>70%), and methoxy- and keto-MAs being minor
components (10 to 15%)43. MA is synthesized in the cytoplasm and transferred to the
cell envelope via formation of trehalose monomycolate. The acids occur interlaced with
trehalose-containing glycolipids and phthiocerol dimycoserates in the outer membrane
of MTB. The internal layers of the cell wall of MTB consist mostly of arabinogalactan
and peptidoglycans, as well as phosphatidyl-myo-inositol mannosides (PIMs), such as
lipoarabinomannan (LAM) and lipomannan (LM) (Figure1.5)29. Many of these
components provide vital functions for the cell, such as the polysaccharide,
peptidoglycan, which provides rigidity, integrity, and shape to the cell44. The tensile
strength and stability are achieved by the interlaced pattern of peptidoglycan, which
consists of alternating N-acetylglucosamine and muramic acid residues which are linked
by β (1→4) bonds45. The molecule may also be anchored to an arabinogalactan
complex via N-glycosylated- muramic acid residues46. Linear galactan and highly
branched arabinans form the arabinogalactan, where arabinan anchors the mycolic acid
forming the mycolyl-arabinogalactan-peptidoglycan (mAGP) complex. As mentioned
earlier, the mycobacterial phospholipids are derivatives of phosphatidic acid and include
phosphatidylglycerol, diphosphatidylglycerol, phosphatidylethanolamine and PIMs.
These PIMs constitute major components of plasma membrane, and form the lipid base
of LAM and LM30. Mannosylated- LAM (Man- LAM), LM, and PIMs all share a
conserved mannosyl- phosphatidyl-myo-inositol (MPI) domain that likely secures the
structures into the plasma membrane47. LAM is a critical virulence factor and plays an
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important role in host pathogenesis which makes it an ideal candidate for early
diagnostics and therapeutics, and is a major focus of this dissertation – hence
discussed below in some detail.
1.4.2 Lipoarabinomannan
LAM is a critical cell wall lipoglycan originally isolated from a human infected with MTB
in 193948–50. Present day understanding of LAM structure comes from the pioneering
work by Hunter, Chatterjee, Brennan and coworkers51,52 that, together with others
identified the antigen as an amphipathic molecule released from metabolically active or
degrading bacterial cells53. This lipoglycan is comprised of three primary domains,
including a glycophosphatidyl anchor and D-mannan with a D-arabinan core. The size
and branching pattern of arabinan and mannan vary by strain, and differently modulate
the human immune response. Depending on the capping motif, LAM can be classified
into 3 types: a) Man-LAM is comprised of mannosyl caps, and is associated with slowgrowing mycobacteria such as MTB, M. leprae, M. bovis. b) Phosphoinositol- capped
LAM (PILAM) is characterized by the absence of a manno-oligosaccharide cap, and is
found in non-pathogenic species such as M. smegmatis. c) AraLAM has an arabinan
cap devoid of both mannose or phosphoinositol, and is found in M. chelonae52,54. The
degree of mannose capping in ManLAM varies among different MTB strains, with 70%
capping observed among the most virulent ones52. MTB H37Rv and M. bovis BCG both
are known to have seven caps per molecule55.
Despite much research, little is known about the orientation of LAM in the cell wall.
Chatterjee and Khoo48 described three possible hypotheses in 1997 (1) LAM is attached
12

through lipids to the cell wall plasma membrane and the arabinose or mannose capped
arabinose units are exposed outside, (2) LAM is integrated by its PI-anchor into the
external leaflet of a suggested outer-membrane analogue in mycobacteria, (3) LAM is a
secreted molecule which has no permanent position in the cell wall. In 2012, Mukundan
et al.56 described three possible spatial models for LAM on a lipid bilayer: (1) LAM in a
vertical orientation with its lipidic potion inserted into the membrane, (2) a flat position
laying on top of the membrane, (3) and lying on its edge. Even in present day, it is clear
that more studies are required to fully elucidate the structure and orientation of LAM in
association with MTB and lipid architectures as LAM plays an important role in MTB
pathogenesis. According to the first three-dimensional model of ManLAM, described by
Mukundan et al., LAM is 14 nm long, and consists of 2139 atoms with a molecular
weight around 16,100 Da56. Detailed understanding of LAM structure, presentation and
orientation in cell wall, interaction with key molecules and how it plays a role in disease
pathogenesis are key factors to develop much-needed diagnostics and therapeutics for
MTB.
Role of ManLAM in host pathogenesis: LAM is an important virulence factor released by
MTB during an active infection, and is recognized by the innate immune system via
pattern recognition receptors such as Toll-like Receptor 2 (TLR-2). Beyond LAM, TLR-2
is activated by a large variety of conserved microbial components such as lipoproteins,
lipoteichoic acid from gram-positive bacteria and peptidoglycan57. The receptor can
exist as a heterodimer with either TLR1 or TLR6 which have been shown to discriminate
between acylation states of lipoproteins58–60. TLR2/1 complex preferentially recognizes
triacylated

lipoproteins

whereas

TLR2/6
13

preferentially

recognizes

diacylated

lipoproteins57,58. In any case, the interaction of LAM with TLR2 stimulates cytokine and
chemokine signaling in host macrophages. More details of the association of LAM with

Figure 1.7. Disruption of MTB- TLR signaling pathway. Created with BioRender.com. Adapted
from Koul et al. (2004), Interplay between mycobacteria and host signaling pathways. Nat. Rev.
Microbiol.; doi:10.1038/nrmicro840. Abbreviations: MTB- Mycobacterium tuberculosis, TLR- Toll- like
receptor, DC-SIGN- Dendritic cell- specific intracellular adhesion molecule-grabbing non-integrin,
14
ITAM- tyrosine- containing activation motif, IRAK- interlukin-1
receptor-associated kinase, TRAF-6TNF- receptor-associated factor 6, IKK- inhibitor of κB kinase.

lipoproteins and the impact of presentation on the resultant stimulation of
cytokines/chemokines are discussed in chapter 9.
ManLAM also alters the host apoptotic pathways by inhibiting the increase in cytosolic
Ca2+ concentration61. Ca2+ ions can promote apoptosis by increasing the permeability of
mitochondrial membranes, stimulating the release of pro-apoptotic elements62–64. This is
one of the ways by which ManLAM helps MTB in immune evasion.
Another MTB-Man LAM immune evasion strategy is by modulation of DC-SIGN
(Dendritic cell-specific intracellular adhesion molecule- grabbing non- integrin) signaling
pathway. DC-SIGN is a C-type lectin receptor found on the surface of macrophages and
dendritic cells. When MTB enters the host, it binds to TLRs and results in activation of
NF-κB (Figure 1.8) through MyD88 signaling pathway leading to the production of
immunostimulatory cytokines that activate T cells and mediate the killing of MTB

65

.

However, in case of the suppressed immune system in the host, Man-LAM binds to DCSIGN and inhibits TLR signaling. This blocks the maturation of macrophages and
dendritic cells that are attracted to the site of infection which causes suppressed T-cell
activation and prevents appropriate immune response66.
In conclusion, MTB is well adapted to the hostile environment of macrophages and
other immune cells and uses various strategies for survival within host immune cells.
Though our understanding of host-pathogen interaction is still incomplete, it is known
that MTB disrupts host signaling machinery for intracellular survival. Further studies in
the field of omics including proteomics, transcriptomics, lipidomics and metabolomics
are needed to elucidate the exact mechanism by which MTB downregulates various
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signaling pathways. In addition, further understanding of the association of amphiphilic
LAM with lipoproteins and its impact on immune signaling will provide insight into new
improved diagnostic as well as therapeutic targets.
1.4.3 Diagnostics
The challenges associated with diagnosis of TB have been discussed in detail in
chapters 3 and 4 of this manuscript. Table 1.1 provides a summary description of the
various methods for the diagnosis of TB, which are currently endorsed by the WHO.
There is a critical need for non-sputum-based diagnostic tests for TB, especially those
that can be used at the point of need, quickly and easily67. In this context, the detection
of biomarkers such as LAM has garnered great attraction as a target for diagnostics
development.48,68–70. Detection of LAM in several clinical matrices such as urine, sputum
and serum has been evaluated, and several platforms have been developed to detect
the biomarker (Table 1.2). However, the sensitivity and specificity of LAM tests
developed so far do not meet WHO criteria for point-of-care diagnostic.
So far, urine remains the most evaluated matrix for LAM assay development and use.
Yet, with the disseminated and paucibacillary disease, and in individuals with HIV coinfection, blood may be a more reliable sample for LAM detection. The detection of LAM
in blood, however, has been a challenge – and this difficulty is likely associated with the
amphiphilic biochemistry of the molecule. ManLAM in aqueous solution has been shown
to self-aggregate to form homogenous, regular spherical structures of around 30 nm
and 200 nm of which 30 nm constitutes >99.5% of mass. This supramolecular
organization has been attributed to hydrophobic interactions between acyl components
16

Table1.1. TB diagnostic tests in use and endorsed by WHO
Intended
Method
Products
and/or typical
Main strengths
use

Main weaknesses

Smear microscopy
for acid- fast bacilli

Light and lightemitting diode
microscopy

Rapid point of
care test for
diagnosis and
treatment
monitoring

Requires moderate
training, minimal
infrastructure,
minimal equipment

Low sensitivity, requires
adequate sputum
sample

Culture on solid
and liquid media

Commercial liquid
culture systems
and rapid
speciation
Culture- based
phenotypic DST
using 1% critical
proportion in LJ,
7H10, 7H11 and
MGIT media

TB case
detection and as
prerequisite to
drug
susceptibility
testing

Good sensitivity,
liquid culture has
better sensitivity
than solid media

Slow time to growth
(results take 6-8
weeks), higher
contamination rate in
some settings

Chest radiograph

N/A

Pulmonary TB
case detection

Indications and use
not restricted to TB

Tuberculin skin
test

Many
commercialized
reagents

Detection of
MTB

Extensive practical
and published
experience

Detection of
MTB

Highly specific for
MTB

Interferon-γ
release assays

Molecular
detection of TB
and drug
resistance (nucleic
acid amplification
test)

Biomarker based
assays

T.SPOT.TB,
Oxford Immunotec,
UK
QuantiFERON-TB
gold plus, Qiagen,
USA
1.Xpert MTB/RIF
and Xpert Ultra,
Cepheid, USA
2.Line probe
assays, Hain
Lifescience,
Germany
and Nipro, Japan
3.Line probe
assays, Hain
Lifescience,
Germany
4.TB LAMP, Eiken,
Japan
5.Truenat MTB,
MTB Plus and
MTB-RIF Dx
assays, Molbio
Diagnostics, India
Alere Determine
TB-LAM

Low sensitivity and
specificity, requires
trained interpreter
Sensitivity decreases
with increasing
immunocompromised;
cross reaction with BCG
vaccine
Requires moderate
training and equipment,
imperfect sensitivity
especially for
immunocompromised
persons

TB case
detection and
drug
susceptibility
testing

Good sensitivity,
highly specific for
MTB, less time to
results

Xpert ultra cartridges
have short shelf life,
sensitivity decreases in
immunocompromised,
requires expensive
equipment, line probe
assays have high
contamination risk due
to open tube format,
requires sputum as
sample

TB detection in
HIV infected
individuals

Easy to use
sample, easy to
read results, less
time consuming

Low sensitivity in HIV
negative individuals
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of the molecule. A more detailed understanding of LAM supramolecular structure comes
from various biophysical approaches used by Riviere and colleagues, who estimated
that there are about 452 ManLAM molecules per micelle71. These properties impact the
orientation and stability of LAM in aqueous blood as well. Indeed, our team has
demonstrated that amphiphilic LAM associates with host carriers, including high- and
low- density lipoproteins (HDL and LDL)). HDL and LDL are composed of a core
nanodisc lipidated structure that associates with the lipid moieties of LAM from MTB72.
However, the interaction of LAM with host lipoproteins interferes with traditional
methods for detecting these bacterial biomarkers directly in patient blood73.
Immunoassays designed to target proteins display limited sensitivity when applied to
amphiphiles in aqueous blood73 due to the aforementioned host-pathogen interactions
that

sequester

the

biomarker56,72,74.

Our

team

developed

two

novel

assay

methodologies that account for the amphiphilicity of LAM to achieve their ultra-sensitive
detection in serum (discussed in detail in chapter 6). The first assay, termed
membrane insertion utilizes the passive interaction between an amphiphilic LAM and a
lipid bilayer to capture the biomarker directly on the biosensor surface for interrogation
with a labeled antibody. The second assay, termed lipoprotein capture exploits the
interaction between LAM and host carrier lipoproteins in blood and thus requires prior
knowledge of PAMP-lipoprotein association. In this second approach, an antibody
targeting the lipoprotein carrier is used to capture a host-biomarker complex to the
biosensor surface followed by interrogation with a labeled antibody targeting the
biomarker of interest. Lipoprotein capture has been validated for the detection of LAM
from MTB in patient serum and discussed in chapter 6 of this manuscript72. Rest of this
18

manuscript describes in detail the challenges associated with diagnostics, evaluation
and validation of lipoprotein capture and membrane insertion in adults and pediatric
population, in vitro THP-1 cell studies to understand the impact of LAM- lipoprotein
association on immune signaling and future directions.

Table1.2. Review of studies using different biomarkers and methods for detection of TB
Sample
Sensitivity %
Specificity%
Biomarker(s)
Index test type
Reference
Type
(95% CI)
(95% CI)

Urine

LAM

ELISA & Lateral Flow
Assay (LFA)

Urine

LAM

ELISA & LFA

Urine

LAM

ELISA

Urine

LAM

LFA

Urine

LAM

FujiLAM, Alere
Determine LAM,
electochemiluminescen
ce (EcILAM)

Urine

LAM

Urine

LAM

Urine

LAM

Urine,
Serum

LAM, ESAT6

Electochemiluminescen
ce (EcILAM) assay

Urine

LAM

EcILAM assay

One- sided
immunoassay
Immunomacroarray
assay (Nanocage with
a copper complex dye)
Determine TB LAM

ELISA- HIV positive0 (0-14.3) HIV
negative- 3 (0.410.5)
LFA:
HIV positive- 65.2
(42.7-83.6) HIV
negative- 42.4 (30.355.2)
ELISA- HIV positive70 (35-93) HIV
negative- 13 (0-53)
LFA: HIV positive- 50
(19-81) HIV
negative- 0 (0-37)
Compared to
microbiology/clinical83 Compared to
microbiology- 33
43 (10-82)
AlereLAM- 11 (6-18)
FujiLAM- 53 (44-62)
EclLAM- 67 (57-75)

ELISA- HIV
positive- 95.2
(88.1-98.7) HIV
negative- 95.9
(93.3-97.7)
LFA: HIV positive56.6 (45.3-67.5)
HIV negative- 61.7
(56.5-66.7)
ELISA, LFA- 97
(85-100)
Compared to
microbiology/clinic
al- 85 Compared
to microbiology- 60
91 (84-95)
AlereLAM- 92 (8895)
FujiLAM99 (97-100)
EclLAM- 98 (9699)

75

76

77

78

79

90

73.50

80

95

80

81

23 (17-29)
Urine- LAM- 93,
ESAT-6- 65
Serum- LAM- 55,
ESAT-6- 46
93 (80-97)

93 (90-96)

82

97

83

97 (85-100)

84
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Sample
Type

Biomarker(
s)

Urine

LAM

Urine

LAM

Serum

LAM

Urine,
Serum

LAM

Urine

LAM

Urine

LAM

Urine

LAM

Index test type
Magentic
immunoassay
Determine TB
LAM
Surface enhanced
Raman scattering
based
immunoassay
ELISA

Sensitivity
% (95% CI)

Specificity%
(95% CI)

82

100

85

12-45

80-100

86

87.50

100

87

Serum- 33
(68-100)
Urine- 40 (1668)

92 (64-100)

88

59 (52-66)

96 (91-99)

89

51

88

90
91

Reference

66 (57-74)

66 (57-74)

LAM

Clearview TB
ELISA
ELISA
Determine TB
LAM
Clearview TB
ELISA
ELISA

Urine- 6-21
Sputum- 86
91

Urine- 95-100
Sputum- 15
100

Urine

LAM

ELISA

93 (68-100)

95 (83-99)

94

Urine

LAM

80

99

95

Urine

LAM

95

100

96

Urine

LAM

44 (36-52)

89 (81-94)

97

Urine

LAM

38

100

98

Urine

LAM

46 (40-51)

89 (86-91)

99

Urine

LAM

Determine TB
LAM

Overall-37
HIV positive60

98

100

Urine

LAM

Clearview TB
ELISA

15-70

NR

101

Urine

LAM

ELISA

74

89

102

Urine

LAM

LAM Strip test

56-64

95-98

103

Urine

LAM

82

NR

104

Urine

LAM

Sputum

Urine,
Sputum
Sputum

LAM

Chemogen LAM
ELISA
Single molecule
fluoroscence
assay
Chemogen LAM
ELISA
Chemogen LAM
ELISA
Clearview TB
ELISA

92
93

6-20

83-89

105

MPT64

Determine TB
LAM
Chemogen LAM
ELISA
ELISA

86.9 (79-92)

92 (90-94)

106

PBMCs

IL-2

ELISPOT

100

81
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Whole
blood

ESAT-6, CFP10

ELISA

85 (75-96)

60 (40-80)

107

PBMCs

Antibody in
lymphocyte
secreting
assay

ELISA

91

87

108
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Sample
Type

Biomarker(
s)

Index test type

Sensitivity
% (95% CI)

Specificity%
(95% CI)
Validation
cohort83.6(74.6–92.7)
IGRA- 83.3 (72.292.6) Xpert
MTB/RIF assay100 (100- 100)

Whole
blood

51-gene
mRNA
signature

Microarray

Validation
cohort82.9 (68.6–
94.3)
IGRA- 60.0
(33.3-86.67)
Xpert
MTB/RIF
assay- 54.3
(37.1- 68.6)

PBMCs

MTB-specific
CD4+ CD27+
T-cells

ICS/Flow
cytometry

83 (59– 96)

97(89–99)

Milliplex human
cytokine/chemokin
e kits with
analyses
conducted on a
Luminex 200
analyzer

ESAT-6 (IFN𝜸- 90.9, IP10- 95.5,
TNF-⍺- 95.5,
IL-1ra- 81.8,
IL-2- 95.5, IL13- 77.3,
MIP-1β- 90.9)
CFP-10 (IFN𝜸- 81.8, IP10- 86.4,
TNF-⍺- 86.4,
IL-1ra- 77.3,
IL-2- 90.9, IL13- 63.6,
MIP-1β- 77.3)
PPD (IFN-𝜸95.5, IP-1095.5, TNF-⍺95.5, IL-1ra50, IL-2- 100,
IL-13- 77.3,
MIP-1β- 81.8)

ESAT-6 (IFN-𝜸97.3, IP-10- 96.0,
TNF-⍺- 88.0, IL1ra- 69.3, IL-297.3, IL-13- 89.3,
MIP-1β- 70.7)
CFP-10 (IFN-𝜸89.3, IP-10- 93.3,
TNF-⍺- 85.3, IL1ra- 78.7, IL-294.7, IL-13- 86.7,
MIP-1β- 68)
PPD (IFN-𝜸97.3, IP-10- 81.3,
TNF-⍺- 84.0, IL1ra- 46.7, IL-296.0, IL-13- 69.3,
MIP-1β- 60.0)

Diagnostic gene
list comparison to
published gene
list for pediatric
dataset - 48- 93,
Treatment
response- 40-80

TB vs healthy- 97
Latent TB- 85
Other diseases79

Plasma

Cytokines

Whole
blood

71 genes

ribonucleic acid
sequencing

Diagnostic
gene list
comparison to
published
gene list for
pediatric
dataset -38100,
Treatment
response- 7080

Whole
blood

3 genes
(GBP5,
DUSP3, and
KLF2)

Studies with
microarray-based
whole genome
expression
profiles

TB vs
healthy- 93
Latent TB- 88
Other
diseases- 82
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Reference

109

110

111

112

113

Sample
Type

Biomarker(s)

Index test type

Sensitivity
% (95% CI)

Specificity%
(95% CI)
TB vs Latent
TB- ACOT786, AMPH52, CHRM262, GLDC- 79,
HBD- 93,
PIGC- 76,
S100P- 76,
SNX17- 65,
STYXL1- 65,
TAS2R46- 72
TB vs healthyACOT7- 76,
AMPH- 76,
CHRM2- 46,
GLDC- 73,
HBD- 78,
PIGC- 89,
S100P- 35,
SNX17- 86,
STYXL1- 30,
TAS2R46- 84

Whole
blood

116 gene
signature set

Microarray

TB vs Latent
TB- ACOT767, AMPH56, CHRM256, GLDC67, HBD- 67,
PIGC- 55,
S100P- 89,
SNX17- 56,
STYXL1- 56,
TAS2R46- 67

PBMCs
isolated
from whole
blood

CRP, Ferritin,
Mycobacterial
antibody secreting
cell assay
(MASC)

ELISA

MASC-78,
Ferritin- 89,
CRP- 67

MASC-86,
Ferritin- 75,
CRP-83

IFN-a2- 52.6
(39.0-66.0),
IL-1Ra-98.2
(90.6-99.9),
sCD40L- 93.0
(83.0-98.0),
VEGF- 61.4
(47.6-74.0),
MCP-3- 98.3
(90.6-99.9)

Reference

114

115

Whole
blood

12 host markers

Luminex platform

IFN-a2- 89.5
(66.9-98.7),
IL-1Ra-26.3
(9.1-51.2),
sCD40L- 42.1
(20.3-66.5),
VEGF- 83.3
(58.6-96.4),
MCP-3- 26.3
(9.1-51.2)

Whole
blood

Interferon gamma
inducible protein
10 (IP-10)

ELISA

NR

NR

117

ELISA

QFN-G-IT
and TSPOT.TB91.7, IP-1066.7

NR

118

Whole
blood

IP-10

116

119

Whole
blood

IP-10

Microsphere based
assay on luminex
platform

NR
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NR

Sample
Type

Whole
blood

Peripheral
blood

Whole
blood

Whole
blood and
urine

Whole
blood

Biomarker(s)

Index test type

Sensitivity
% (95% CI)

Specificity%
(95% CI)

18 cytokines

Cytometric bead
array- T helper 13plex assay and a
custom 5-plex assay
(LEGENDplexTM,
BioLegend) and
analysed using a 2laser flow cytometer
(FAC- SCaliburTM,
Becton Dickinson).

NR

NR

120

21 cytokines

Milliplexe Human 10
Cytokine Kit
(Millipore, Billerica,
MA, USA).
phycoerythrin
fluorescence
measured using BioPlex 200 System

NR

NR

121

Cytokines

IP-10

IFN-𝜸

Bioplex Pro Human
Cytokine Group 1
assay (Bio-Rad
Laboratories,
Hercules, CA, U.S.)

ELISA

ELISA

IFN-𝜸- 79
(66.1-88.6),
IL-1ra- 80.7
(68.1-90), IL2- 75.4 (62.285.9), IL-1380.7 (68.190), IP-1080.7 (68.190), MIP-1β70.2 (56.781.6), TNF-⍺30.9 (19.144.8), IL-2,
IL-13, IP-1084.2 (72.192.5)
HIV
negative- IP10 blood- 79,
IP-10 urine53, QFT-IT53, TST- 61
HIV positiveIP-10 blood100, IP-10
urine- 54,
QFT-IT- 17,
TST- 23
TST- 88.2
(79.4-94.2),
QFT-IT 89.6(79.795.7), T
SPOT- 88.5
(80.4-94.1)

23

IFN-𝜸- 83.8
(76.5-89.6),
IL-1ra- 68.4
(59.9-76.1),
IL-2- 99.3 (96100), IL-1393.4 (87.897), IP-10- 86
(79.1-91.4),
MIP-1β- 67.7
(59.1- 75.4),
TNF-⍺- 88.2
(81.6-93.1),
IL-2, IL-13, IP10- 82.4
(74.9-88.4)
HIV negativeIP-10 blood53, IP-10
urine- 66,
QFT-IT- 83,
TST- 82 HIV
positive- IP10 blood- 17,
IP-10 urine61, QFT-IT82, TST- 94
TST- 86.3
(83.9-88.6),
QFT-IT 95.4(93.896.6), T
SPOT- 96.8
(94.2-98.5)

Reference

122

123

124

Sample
Type

Whole
blood

Whole
blood

Peripheral
venous
blood

Serum

Serum

Biomarker(s)

Index test type

Sensitivity
% (95% CI)

Specificity%
(95% CI)

13 cytokines

Luminex or ELISA,
Chemiluminiscence
immunoassay for
ferritin and 25 (OH)D

IP-10, IFN-γ,
ferritin, and
25(OH)D93.2

IP-10, IFN-γ,
ferritin, and
25(OH)D- 90

198 genes

dual-color-ReverseTranscriptaseMultiplex-Ligationdependent-ProbeAmplification (dcRTMLPA)

7 and 10
transcript
signature91.7 (71.598.5)

7 transcript
signature80.8 (60.092.7), 10
transcript
signature88.5 (68.796.9)

Cytokines

Bio-Plex multiplex
ELISA cytokine
assay system,
Luminex

NR

NR

Metabolic
signatures

1H nuclear magnetic
resonance (NMR)
spectroscopy and
mass spectrometry
(MS)

1H NMR - 69
(56-73), MS67 (60-71)

1H NMR - 83
(73-93), MS86 (75-93)

119 antigens

Multiplex baed based
luminex assay to
meaasure IgG
antibody

60

60

1H NMR
spectroscopy

L-valine,
pyruvic acid
and betaine
Training set85.7 (66.495.3)
Independent
validation
cohort- 82.4
(55.8-95.3)

L-valine,
pyruvic acid
and betaine
Training set94.6 (80.599.1)
Independent
validation
cohort- 83.9
(65.5-93.9)

NR

NR

131

NR

NR

132

Plasma

17 plasma
metabolites

Peripheral
blood

Transcriptional
and translational
biomarkers

Whole
blood

45 genes and 10
cytokines

Whole
blood

29 miRNA

Microarray, RT-PCR

TB vs
Healthy 95.8

TB vs Healthy
- 100

Plasma

20 circulating
immune markers

Multiplex ELISA
using Luminex

NR

NR

Dual colour Reverse
TranscriptaseMultiplex
Ligationdependent
Probe Amplification
Dual-color ReverseTranscriptase
Multiple Ligationdependent ProbeAmplification and
bioplex assay for
cytokines
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Reference

125

126

127

128

129

130

133

134

Chapter 2.
Goals and Overview of this Work
TB affected 10 million people in 2019, with nearly 1.4 million deaths3, a statistic that can
be greatly controlled if reliable diagnostics and therapeutics were available. The current
gold standard for TB diagnosis is microbiological culture, which can take up to 6-8
weeks to result and therefore, not conducive to timely treatment135. Several additional
diagnostics have been approved for use in adults, as discussed in Section diagnostics,
chapter 1 of this manuscript. Co-morbidities such as HIV not only influence the
likelihood of presenting with active disease, but also the outcome of the diagnostic
results. 136.
Current diagnostic assays for TB largely use sputum as the sample of choice, making
them ineffective in individuals with extra-pulmonary and disseminated forms of the
disease. Biomarker assessments use urine samples, but the poor sensitivity of these
assays limits their use only to certain subsets of infected individuals. Thus, there is a
clear need for better diagnostic tests for TB. Many a time, a combination of these
diagnostics is required for confirmation of disease, which is a challenge concerning
implementing countermeasures promptly.
This challenge is especially grave in pediatric populations where the manifestation of
the disease can be very different than in adults as discussed in chapter 3 of this
manuscript in detail137. Children can manifest extra-pulmonary and disseminated forms
of the disease. In addition, the disease is often paucibacillary in children, which makes
extrapolation of culture and microscopic outcomes unreliable.
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Based on the complex presentation of the disease and current diagnostic tests, the
WHO has identified the need for a non-sputum, biomarker-based diagnostic test for
TB67. Direct detection of these pathogen biomarkers in infected patients can allow for a
rapid, sensitive and reliable method of diagnosis for TB, and is a concept that has been
studied by our group and other investigators94,138–140. LAM is one such biomarker that
has garnered lot of attention recently and the use of this antigen as a biomarker and its
biochemistry and molecular biology has been discussed in chapter 1. LAM detection in
urine has been studied by many researchers, but has shown consistently poor
sensitivity in HIV-negative individuals139,141,142. The detection of LAM in blood, however,
has been a challenge – and this difficulty is likely associated with the amphiphilic
biochemistry of the molecule. Yet, with the disseminated and paucibacillary disease,
and in individuals with HIV co-infection, blood may be a more reliable sample for LAM
detection. The guiding hypothesis of this work is that the sequestration of LAM in
immune complexes/lipoprotein carriers is responsible for the difficulty in
detection of the amphiphilic antigen in blood, and also impacts immune induction
in patients. To test this hypothesis, the following three specific aims were investigated
(Figure 2.1).
Aim 1. Detection of LAM in serum using the Lipoprotein Capture and Membrane
Insertion Assay, with subsequent validation in adult TB patient samples.
Aim 2. Validate feasibility of LAM in serum as a diagnostic biomarker for pediatric TB
disease
Aim 3. Understand the impact of LAM interaction with lipoproteins such as HDL/LDL on
TLR2-mediated cytokine production
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The primary goal of this work was to develop and integrate a blood-based assay
for detection of LAM in adult and pediatric TB patients. While a seemingly simple goal,
the underlying complexities of the disease made this task quite challenging. The
research conducted to test the hypothesis and investigate each aim is outlined as
individual chapters throughout the manuscript and is summarized below.

The work presented in Chapter 3, was published as a book chapter in the book
Diagnosis and management of tuberculosis. This work was researched by me as
primary author, Kiersten Lenz and Harshini Mukundan. In this chapter, we reviewed the
challenges associated with diagnosis of pediatric TB due to differential disease
presentation in children, WHO goals for controlling pediatric TB, as well as current
27

diagnostic tools available to diagnose TB in children. We also described the addition of
complexity to disease detection due to presence of HIV.
Chapter 4 reviews current technology used for diagnosis of TB, and presents the value
of incorporating lipidomics, transcriptomics and proteomics approaches for disease
diagnosis. The work was published in the International Journal of Molecular Sciences.
The chapter was researched by me as primary author, Alexis A Bitzer, Loreen R.
Stromberg and Harshini Mukundan. The chapter describes in detail genomics,
transcriptomics, proteomics, lipidomics and metabolomics techniques including studies
used to study biomarkers for diagnosis of TB – and expands on the value of a multiomic approach towards developing comprehensive diagnostics that can address the
spectrum of TB disease.

Chapter 5 describes the difficulties associated with detection and measurement of
amphiphilic biomarkers, including LAM, and the various techniques and methods that
are used to detect them. We address the significance of amphiphiles associated with
the disease as well as their suitability for use as diagnostic target. This review was
published in Biosensors with Jessica Z.Kubicek-Sutherland as first author. Dung M. Vu,
Heather M. Mendez and I assisted with the review, under guidance of Harshini
Mukundan. The use of varied detection approaches including mass spectrometry, NMRbased sensor, optical, mechanical and electrochemical biosensors for amphiphiles, are
discussed in great detail. The waveguide-based biosensor used for detection of LAM in
this research work is also discussed.
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Details, optimization and clinical validation of lipoprotein capture and membrane
insertion assays are described in chapter 6, which has been accepted for publication in
PLOS One. As the primary author of this manuscript, my role was to optimize the
lipoprotein capture and membrane insertion assays for the detection of LAM in serum. I
also performed the clinical validation of both assays in serum from adult TB patients
from Uganda. The antibody characterization for lipoprotein capture was done by
Ramamurthi Sakamuri using Enzyme-linked immunosorbent assay (ELISA). The
antibodies were generously provided by Emmanuel Moreau at the Foundation of
Innovative New Diagnostics (FIND). Loreen R. Stromberg played a critical role in
training me on biosensor platform used for this work. Priya Dighe and Dung M. Vu
assisted with conducting initial assays. Lipoprotein capture and membrane insertion
assays were developed by Harshini Mukundan and her team at LANL, including Basil
Swanson who helped conceive the initial approach with her. The clinical study was in
collaboration with Susan E. Dorman, then at Johns Hopkins University (recently
transitioned to Medical University of South Carolina) who provided clinical specimens
and her expertise in analyzing the work. Harshini Mukundan served as primary
investigator and helped with experimental design, insight, troubleshooting, data analysis
and manuscript editing. Laura Lilley and Nicolas Hengartner assisted with the statistical
analysis for amphiphile assays.
The purpose of this work was to explore feasibility of detection of LAM in patient serum
using two tailored assays-lipoprotein capture and membrane insertion. All assays were
performed on a waveguide-based biosensor developed at Los Alamos National
Laboratory. The assays targeted amphiphilic LAM associated with carrier moieties, or
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liberated using a sample processing method. Using lipoprotein capture assay, we were
able to detect LAM in most of the clinical samples, and no LAM was detected in healthy
controls. To further explore the reason for missed LAM detection in some clinical
samples, we hypothesized that the positive HIV status of patients might alter lipoprotein
levels and thus LAM detection. Therefore, we measured lipoprotein levels in HIV
positive and negative serum samples and found out that HIV positive patients have
significantly less HDL concentrations compared to HIV negative. These findings showed
that an assay strategy independent of lipoprotein levels might result in increased LAM
detection Therefore, to evaluate serum LAM levels without dependence on host
lipoprotein concentrations, we adapted sample processing method to liberate LAM from
associated host lipoprotein assemblies followed by direct detection of the pathogen
biomarker using the membrane insertion approach. The latter approach improved the
sensitivity of LAM detection in serum, and improved the sensitivity of LAM detection by
10-fold. This study validated membrane insertion with sample processing method as a
reliable method for detection of LAM in serum from TB patients. It also led to critical
questions about further implications of LAM/host lipoprotein associations for diagnostic
assay performance and TB pathogenesis.
The validation of membrane insertion assay for detection of LAM in serum from
pediatric patients is presented in Chapter 7. After successfully detecting LAM in adults,
as described in chapter 6, we asked the question if similar approach was feasible for
diagnosis of TB in pediatric patients. The work is under preparation for publication. I
performed all the clinical assays using membrane insertion method. The study was in
collaboration with Dr. D.J. Perkins at the University of New Mexico, who provided serum

30

samples from a clinical site in Siaya, Kenya. Harshini Mukundan is the principal
investigator, provided project design, supervision, experimental oversight and data
interpretation.
In this study, we demonstrated the direct detection of LAM in pediatric serum for the
first time using membrane insertion assay. The study validated membrane insertion as a
reliable method for detection of LAM in serum from pediatric TB patients.
The work in Chapter 8 describes the functional assessment of microfluidic device
allowing improved biomarker retention compared to benchtop method of sample
processing. The manuscript is published in scientific reports. The idea originated from
work in chapter 5 where membrane insertion using sample processing proved to be
more sensitive for the detection of LAM. Thus, we attempted to develop a strategy to
easily and effectively perform the required sample processing at the point of need.
Kiersten Lenz leads the development and design of the microfluidic chip and is the
primary author on this manuscript. As the second author on the manuscript, I validated
the device using membrane insertion to detect LAM. Jing Chen, Dylan Purcell, Omar
Ishak assisted with device design. Harshini Mukundan was the principal investigator,
and provided project vision, supervision, experimental oversight and data interpretation.
Pulak Nath was the fabrication laboratory lead, and responsible for the microfluidics
work. Other authors were Aaron Anderson, Jessica Kubicek-Sutherland, Jennifer Harris,
Leyla Akhadov helped with concept development, experimentation and manuscript
review. The outcome of the study was that we were able to achieve excellent retention
of LAM using the microfluidic chip compared to traditional benchtop methods. The
device can be broadly used for the separation of serum from blood at the point of need,
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and is compatible with both hydrophilic and hydrophobic biomarkers secreted by other
pathogens. Kiersten Lenz is working further on validation of the device for the extraction
of lipids from blood.
The research described in chapters 6 and 7 led us to our final aim - to understand the
impact of LAM interaction with lipoproteins on TLR-2 induced cytokine expression to
refine and improve LAM detection strategies. The outcome of this work is discussed in
Chapter 9, and a manuscript is under preparation. I developed the TLR-2 and knockout cell system, and performed the majority of experiments. Dr. Jessica Kubicek
Sutherland guided design of experiments, and trained me on the new techniques and
instruments used for this work. Kiersten Lenz and Katja Klosterman are other authors
on the manuscript who helped with experiments. Harshini Mukundan is the principal
investigator who provided project direction, supervision, experimental oversight and
data interpretation.
All the assays performed for detection of LAM in chapter 6 and 7 were done on a lipid
bilayer system on the LANL waveguide biosensor platform. Although complex bilayers
provide a more stable system and molecular insight into detection of amphiphiles, they
do not signify the entire intricacy of cell membranes. Therefore, we studied LAM
interaction with lipoproteins using human cell lines under different physiological
conditions. Our hypothesis was that cytokine expression due to LAM-lipoprotein
interactions would be different based on the presentation of the amphiphile - in serum
versus buffer. These outcomes cast further insight into the impact of amphiphile carrier
associations on innate immunity, and define optimal conditions for performing
physiologically relevant cell studies. Further studies will continue to explore the use of
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nanodisc (synthetic lipoproteins) in cell-based systems to sequester amphiphilic
biomarkers and improve diagnostic and therapeutic strategies.
Though each chapter focuses on a very specific aspect of this dissertation work, taken
as a whole, it represents a comprehensive approach to developing and optimizing
blood-based strategies for detection of LAM, facilitating improved TB diagnosis. We
present a vigilant optimization and validation of lipoprotein capture and membrane
insertion assays in serum from adult and pediatric TB patients. The assays are platform
and antigen ambivalent, and can be easily transitioned to other detection platforms and
for diagnosis of other infectious and non-infectious pathogens that secrete amphiphilic
biomarkers. The work is concluded with future directions at the end (Chapter 10).
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3.1 Overview and statement of problem
Tuberculosis (TB) is a chronic bacterial disease caused by Mycobacterium tuberculosis
(Mtb). About one third of the world’s population is infected with Mtb, of which only 510% develop clinical symptoms and progress to an active disease state. The rest of the
population are carriers of the disease, a condition referred to as latent TB infection
(LTBI). The transition from latent carriers to active disease can be influenced by many
factors such as HIV co-infection, age, co-morbidities such as malaria and other factors,
and poses a problem for reliable diagnosis of TB20.
TB is a major public health concern in all age groups, but presents a bigger
challenge in pediatric populations, primarily owing to the lack of reliable diagnostics.
Young children (<3-4 years of age) are most commonly exposed to Mtb infection from
adults in the family. Some of the factors that increase risk of exposure are age, physical
structure of the child’s house, and sleeping practices. The chance of infection differs
with age: there is a 20-30% risk in children aged 1-2 years, 5% risk in children aged 3-5
years, 2% risk among children 5-10 years, and 5% risk among children older than 10
years.143 The burden of TB is much higher in developing countries due to various
factors including poverty, malnutrition, HIV, HIV-TB co-infection, and increased drug
resistance. TB reporting gaps are the most profound among younger children, as 55%
of children estimated to have the disease are not reported to national monitoring and
surveillance programs, as compared to a rate of 35% in adults. This reporting disparity
amongst children varies with age: 69% of cases are unreported in children younger than
5 years of age, and 40% of cases are unreported in children 5-14 years19. Because of
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the disease progression and risks to children, more focus needs to be placed on
understanding, diagnosing, and treating pediatric TB.
There are three major challenges associated with presentation of TB disease in
pediatrics, which complicate diagnostics and therapeutic intervention:
1. Pediatric TB is paucibacillary – i.e. clinical samples and isolates from infected
children contain few bacteria, making culture and isolation of the causative agent
challenging27. For this reason, pediatric TB is considered a minor contributor to the
spread of infection in a population. However, young children have a high risk of
disease progression following infection, and are more likely to develop severe or
disseminated disease. Indeed, in some of the higher burden regions, children
account for more than 20% of TB cases144.
2. Pediatric TB is also often disseminated. As with adults, disseminated TB is much
more difficult to treat and control, because of the uncharacteristic presentation and
unclear treatment regimens. This same challenge also extends to children
presenting with drug-resistant forms of the disease, because the dosage and
regimens for treatment in children have not been well established. Dodd et al.
reported that of the estimated 850,000 children diagnosed with TB in 2014, about
7% were isoniazid resistant, 3% were multidrug resistant (MDR), and 4.7% of MDR
cases were extreme drug resistant (XDR). It has been demonstrated that more
children are infected with drug resistant TB than are actually diagnosed145. Thus,
drug resistant TB presents an significant challenge in children, especially those living
in the vicinity of adults with similar variants of the pathogen, because it is difficult to
diagnose, track, and treat in this population.
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3. TB can manifest itself in pulmonary and extra pulmonary forms, of which extra
pulmonary TB (EPTB) is more difficult to diagnose, especially in pediatric
populations. Pulmonary TB (PTB) commonly presents as a cough that lasts greater
than 4 weeks, dyspnea, asthenia, chest pain, hemoptysis, persistent evening fever,
night sweats, and weight loss. In children, these symptoms can be easily mistaken
for infections associated with other respiratory, and present with similar clinical and
radiological findings, making it more difficult to diagnose the disease in this
population. EPTB presents an even greater challenge. The disease can be
disseminated, or it can present in the genitourinary, gastrointestinal, cerebral,
lymphatic, or skeletal systems25.
Together, these factors complicate our ability to identify and control pediatric TB.
The goal of this chapter is to summarize the problems, challenges, promising future
avenues, and future needs for combating the problem of pediatric tuberculosis, with
specific emphasis on diagnosis of the condition.
3.2 Challenges
The inability to diagnose TB poses the biggest challenge to management of the disease
in children. Early symptoms of TB are very similar to other childhood diseases, including
viral and bacterial infections, pneumonia, and other respiratory diseases. As mentioned
earlier, TB presents in paucibacillary form in children146. Sputum culture, which is the
gold standard diagnostic for adults, remains negative in ~70% of pediatric cases
because of the low bacterial load in this population144. This problem is further
confounded by the fact that many children present with disseminated disease, thereby
producing no sputum. And even in those with pulmonary disease, young children are
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unable to expectorate sputum, making it a difficult approach for reliable diagnosis in this
population. These factors and the differential pathology of the disease impact diagnosis
by traditional culture-based methods, sputum microscopy, and newer approaches such
as Gene Xpert based detection. Indeed, the percentage of children with active TB that
were missed by confirmatory tests are 40% missed by culture, 50% by gene Xpert, and
77% by microscopy147. Therefore, the diagnosis of childhood TB is currently based on
history, clinical symptoms, the Tuberculin skin test (TST), and chest radiography26, each
of which is associated with high rate of failure and unreliability. The consequent
alarming percentage of missed diagnoses points to an urgent need for a rapid and
sensitive point-of-care diagnostic for tuberculosis in children.
3.3 WHO goals for pediatric TB (2018)
Throughout the world, TB remains the leading cause of pediatric mortality from a single
infectious agent. In 2017, 1 million children younger than 15 years of age (10% of total
TB cases) developed TB, of which 52% were less than 5 years of age. 80% of TBrelated pediatric deaths were among children 5 years old or younger, and 17% of those
were co-infected with HIV. 15% (233,000) of the pediatric TB-related deaths were
among children that had poor access to diagnosis and treatment. There were about
150-400 cases per 100,000 people in high-burden, low income countries, as compared
to only about 10 cases per 100,000 in high income countries. This disparity highlights
the need to increase access to proper diagnosis and treatment in low income regions,
which would help prevent many of the TB-related deaths in children. Because of these
reasons, the World Health Organization (WHO) is on a mission to reduce the absolute
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number of TB deaths by 90% and incidence rate by 80% by the year 2030 (as
compared to 2015)148.
The WHO report clearly identifies the need for an effective diagnostic in pediatric
populations in order to achieve this goal. According to the WHO, successful diagnosis
and treatment of TB can prevent millions of deaths each year. In order to develop a
successful diagnostic, understanding the reasons for under-diagnosis are critical.
Today, under-diagnosis of TB in pediatric and adult populations can be due to various
factors such as poor access to healthcare, lack of symptoms, healthcare providers
failing to test for TB, in addition to the poor sensitivity and specificity of the diagnostic
itself. These factors are all compounded in pediatric populations owing to the differential
presentation of the disease. Further, most of the gaps in detection and treatment were
observed in African regions, where HIV-TB coinfection rate is significantly high, and in
resource-poor regions of the world (e.g., parts of India and China)149. To close the gap
between detection and treatment, a new WHO initiative called “Find. Treat. All.” was
established in 2018. The goal of this initiative is to detect and treat 40 million people,
including 3.5 million children, from 2018-2022. Such initiatives and the WHO report
establish the clear need for new and effective diagnostics for pediatric TB.
3.4 Current TB diagnostic tools
Approaches to diagnose Mtb infection can be broadly divided into two categories:
1. Detection of the human immune response to Mtb infection (e.g.; detection of
antibodies and activated T cells); and
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2. Direct detection of Mtb and Mtb Signatures (e.g.; microscopy, culture, antigen and
nucleic acid detection assays)
Several diagnostics have been developed under each of these categories for the
diagnosis of TB infection, and many have been adapted or evaluated in pediatric
populations. A complete review of all of them is beyond the scope of this chapter.
Thus, we will primarily focus on non-nucleic acid-based diagnostics for pediatric TB
in this manuscript.
Assays for the detection of the human immune response to Mtb infection:
Tuberculin skin test (TST) - One of the earliest diagnostic assays that was
developed for the diagnosis of TB infection is the Tuberculin skin test (TST). The
technique involves the application of tuberculin/purified protein derivative to the skin,
and is also known as the Mantoux test, Mendel- Mantoux test, Heaf test, or Pirquet
test. The antigen is injected intradermally and the human immune response to the
pathogen-specific antigens is assessed by measuring the diameter of the
inflammatory response on the skin. If the diameter of induration is greater than 10
mm within two days after injection, the result is considered positive for TB exposure.
Thus, the results are subjective, qualitative, and require two visits to the physician
for final diagnosis150. TST cannot discriminate exposure from infection, and is
currently only prescribed for the diagnosis of LTBI. Another disadvantage of the TST
is poor specificity in individuals with prior exposure to non-tuberculous Mycobacteria
(NTM), or those who have been vaccinated with Bacillus Calmette-Guerin (BCG),
both of which can result in false positive outcomes. TST may also have low
sensitivity in younger children and those with advanced TB, immunity, or
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malnutrition.151 The sensitivity of this test is reported to be 63-75% in
immunocompetent TB-suspected individuals, 44-56% in malnourished individuals,
and 36-69% in HIV-infected individuals147,152.
Depending on the antigen preparation and methods used, there is significant
disparity in the efficacy and use of the TST. This also depends on the population in
question, and health care infrastructure therein. A Gambian study showed that TST
is slightly more sensitive than enzyme linked immune absorbent spot (ELISpot,
which measures release of IFN γ, a host immune biomarker, see below for further
information) in children exposed to Mtb, and it is not confounded by prior BCG
vaccination153. On the other hand, a study performed in the UK showed that ELISpot
had a higher sensitivity when compared to TST in children exposed to a confirmed
TB case in school154. . Similarly, a study in children with a history of exposure to TB
showed that a variant of the ELISpot assay, focused on measuring IFN γ release,
named T.SPOT, resulted in a test sensitivity of 50%, and was no better than TST
(80%) in culture-confirmed cases. Thus, TST cannot be used to exclude active
disease155. However, another study performed in Australia showed higher specificity
of QGIT compared to TST and a high discordance between both tests156. It is noted
that both IGRAs (see below) and TST measure the host immune response to the
pathogen, and hence, can be influenced by infection with similar organisms, or
previous infection with the pathogen in question.
Interferon gamma release assays (IGRAs)– Originally developed by Oxford
Immunotec, UK, Qiagen, USA, the IGRA is based on the release of interferon γ (IFN
γ) when T cells of individuals are exposed to Mtb. This release of IFN γ can be
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measured quantitatively in vitro, which makes the assay less subjective as
compared to TST. This technique has currently been approved by the WHO for
diagnosis of LTBI. Mtb antigens such as the Culture Filtrate Protein 10 (CFP10) and
Early Secretory Antigenic Target 6 (ESAT6), proteins encoded by genes within the
Region of Difference 1 (RD1) of Mtb genome, elicit interferon γ response in the
human host, via activation of innate immune receptors. The BCG vaccine strain of
Mtb, and some non-mycobacterial species, do not contain these two antigens.
Hence, even though they are based on host recognition mechanisms, IGRAs have
been shown to have better sensitivity and specificity than the TST, and can
differentiate between BCG vaccination and infection, unlike TST in a variety of
studies150. Some of the commercially available IGRAs include QuantiFERON-TB
Gold (QFT-G), QuantiFERON-TB Gold in-tube (QFT-G-IT) and T-SPOT TB (TSPOT)150, which vary in the mode of detection (lateral flow assays, ELISA-based,
and other). However, there exist some studies which question the superior
performance of IGRAs over TST. For instance, Kampmann et al. showed that TST
had better sensitivity than IGRA (QFG-IT and T-SPOT.TB) in predicting definite TB
cases, but showed similar performance of both IGRA tests in LTBI cases. Further,
TST and T-SPOT.TB had reduced sensitivity in EPTB compared to PTB, whereas
QFG-IT demonstrated similar performance in both157.
IGRAs have been evaluated for diagnostic efficacy in pediatrics. Connell et al.
showed similar concordance (93%) between both IGRAs in LTBI children158. Bianchi
et al. showed a good agreement between positive QFG-IT and active disease, and
an intermediate agreement between IGRA and TST151. A meta-analysis done by
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Laurenti et al. showed no difference in sensitivity between TST, QFT-IT, and TSPOT.TB among immunocompetent children, but found that the specificity of QFT-IT
and T-SPOT.TB was much greater in this population when compared to TST124.
Other reviews support the observation that IGRAs demonstrate higher specificity
over TST, but suggest that their sensitivity is in fact lower (66% pooled sensitivity
from 20 different studies) than TST159. ELISpot assays have been shown to
demonstrate a sensitivity of 83% in all TB cases, and ~75% in individuals with HIV
co-infection and/or malnutrition152. Most recently, Lehman et al. performed an
analysis of the use of IGRA in children, as compared to TST. They found that IGRA
testing has greater specificity compared to TST in children > 5 years of age, and
recommended it to be the test of choice for diagnosing TB in this age group.
However, in younger children (< 5 years of age) , both TST and IGRAs were shown
to have similar sensitivity. In all of these studies, a negative IGRA does not rule out
TB, particularly in children < 1 year of age and those with central-nervous system
affliction, suggesting that better and more reliable methods are required for pediatric
disease, especially EPTB.
On the whole, these findings suggest that IGRAs are a valuable platform for the
diagnosis of TB. In theory, because IGRAs measure host immune recognition of Mtb
antigens, they should be effective in PTB as well as EPTB. However, the efficacy of
this method in EPTB and pediatric populations has not been well established160.
IGRAs are more expensive compared to TST, but have the advantages of being free
from human errors, and they only require one visit to a clinic67,152,161.
Assays for direct detection of Mtb and Mtb Signatures
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Sputum smear microscopy – The acid-fast nature of Mtb provides for a simple
staining based microscopic identification in people presenting with PTB162–165. This is
the primary method to diagnose TB in low- and middle-income countries. Both light
and light emitting diode microscopes have been endorsed by the WHO for diagnosis
and treatment monitoring of TB using this method. The technique is simple, rapid,
and inexpensive, with high specificity in high burden TB areas and the sensitivity is
moderate in PTB patients162–166.
There are several challenges in the use of this technique for the reliable diagnosis of
TB. For one, the WHO requires at least two (but preferably three) sputum specimens
to be collected from each patient suspected of having PTB. The results depend on
the skill of a microscopist, and are impacted by the overall health of the patient and
ability to expectorate sputum, complicating results and therapeutic intervention.
Since sputum microscopy requires the actual presence of bacteria in the chest
expectorate, the method cannot be applied to patients with EPTB167–169. Even in
cases

of

PTB,

collecting

adequate

sputum

samples

from

children

and

immunocompromised individuals presents another challenge170. Only 15% of
children diagnosed with TB have a positive smear from either sputum or from gastric
aspirate171. The sensitivity of the method is reported to be between 12-22% in
immunocompetent TB-suspected individuals, while the specificity is 100%147,172. One
challenge in the application of the method for diagnostics in pediatric populations is
the paucibacillary nature of the disease, which complicates the ability to acquire
three repeated positive smears from a single patient. Further, the sensitivity of
microscopy for induced sputum as compared to culture range from 20-57% in
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children173, making it unreliable for diagnosis. A sputum sample is extremely
infectious; handling and processing of the sample for microscopic characterization
increases the risks associated with this method.
Culture-based methods - Culture is the current gold standard TB diagnostic in
adults, but even this method fails quite often in children because of the differential
manifestation of the disease. Mtb can be cultured, albeit requiring a longer time
compared to most common bacterial pathogens, and the requirement of laboratory
infrastructure and trained personnel complicates the process as well. The two
culture-based diagnostic systems approved by the WHO are 1) the liquid culture
system with rapid speciation, and culture-based phenotypic drug sensitivity testing
(DST) using 1% critical proportion in LJ,7H10,7H11 (culture media) and 2) the
mycobacterial growth indicator tube (MGIT) media. Of the two, MGIT provides a
significantly faster diagnosis when compared to conventional solid culture, but has
the disadvantage of a high cost148. A lower cost alternative to these methods is
microscopic observation drug susceptibility (MODS), which has also been shown to
be more sensitive in pediatric populations148 when compared to conventional
modalities, and allows for the simultaneous assessment of drug resistance. The
main disadvantage of culture-based methods is they may take up to 12 weeks for
the test results to come back due to the slow reproduction rate of Mtb. The ability to
culture the pathogen in clinical samples varies with various factors such as age, HIV
status, disease progression, and clinical presentation148.
Whereas culture is well established in adults, there is a scarcity of data in children.
The paucibacillary nature of pediatric TB results in reduced sensitivity of culture in
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children174. Only 40% of children diagnosed with TB receive a positive culture test
result175. The sensitivity ranges from 44-60% in immunocompetent TB-suspected
individuals, while specificity is 100%147,172. A study in Vietnam showed a sensitivity
of 81.3% for MODS and 88.6% for liquid culture.176 As with smear microscopy,
negative culture results cannot be used to rule out TB in children177, due to the
complications associated with presentation of the disease. However, when positive,
culture can be useful to distinguish between non-mycobacterial and mycobacterial
disease in HIV-TB coinfection177. With the PTB and EPTB presentation of the
disease, and the paucibacillary nature of pediatric TB, culture cannot be used to
exclude the disease when negative, but is definitely confirmatory when positive. The
choice of the sample, and the concentration of the bacteria for growth are critical
considerations in the use of culture.
Rapid molecular tests - Xpert Mtb/RIF assay (Cepheid, USA) is the only rapid
molecular test currently recommended by the WHO for pediatric TB today, and can
provide results within 2 hours of sample collection. Current policy recommends it be
used as an initial diagnostic test in children suspected of having MDR-TB or HIVassociated TB. The WHO acknowledges the inability to get microbiological
confirmation in children, and allows for the use of data from adults to guide this
recommendation in children. The test can simultaneously detect TB and resistance
to Rifampicin, by detecting a DNA sequence specific to Mtb through polymerase
chain reaction. Steingart et al. showed a sensitivity of 65.1-75.9% for children178. In
order to increase accessibility to rapid molecular testing for TB, Cepheid developed
the Edge platform, which is a single-module instrument that connects to a tablet,
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facilitating storage and transfer of data. This allows for the instrument to function in
more decentralized settings, at the same level as microscopy, as it includes an
auxiliary battery.
The WHO meeting report shows that the next-generation Xpert Mtb/RIF Ultra
cartridge will offer enhanced sensitivity as compared to current Xpert Mtb/RIF
cartridge in detecting Mtb in paucibacillary specimens, including smear-negative
culture-positive specimens (e.g. those from people living with HIV), extrapulmonary
specimens (notably cerebrospinal fluid), and specimens from children148. The
sensitivity is 49% in immunocompetent TB-suspected individuals, while specificity is
100%147. However, the Ultra cartridge has the disadvantage of a short shelf life,
which makes it difficult to use in low-resource countries. Yet, Xpert offers the most
promise for the application of molecular diagnostic technologies for the diagnosis of
pediatric TB, and variant manifestations of the disease.
Detection of Lipoarabinomannan, an Mtb Biomarker– Lipoarabinomannan (LAM) is
one of the most studied Mtb biomarkers179,180. LAM is secreted by Mtb, and is a
conserved lipoglycan involved in virulence. The biomarker is known to activate Tolllike receptor 2 mediated innate immune pathways during Mtb infection181.
Investigators have demonstrated the secretion of LAM in urine and its presence in
blood94,182. Detection of LAM in multiple patient samples, as described below, offers
a promising strategy for the diagnosis of TB.
LAM in urine - Detection of LAM in urine has allowed for the development of point-ofcare tests for TB. However, most of these tests present with low sensitivity and
hence, are not suitable for use as general screening tests for TB. However, the
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sensitivity for the diagnosis of TB among individuals coinfected with HIV, especially
among patients with low CD4 counts, is significantly elevated and these assays are
therefore being widely used in this population. The urine LAM strip-test
(Determine®-TB Alere, USA) is currently recommended by the WHO in HIV-positive
adults with CD4 counts less than or equal to 100 cells/µL with signs and symptoms
of TB. Since 2015, new evidence has emerged that might justify the use of the test
in a broader group of people living with HIV19. LAM detection in urine has the
advantage that it allows for simple, non invasive, sample collection, is associated
with low cost, less bench time, and does not require highly trained personnel. A
WHO update on LAM assays reported a pooled sensitivity of 47% and pooled
specificity of 82% among various studies performed in children with HIV183.
LAM in blood - LAM produced by Mtb at the site of infection quickly enters the blood
stream. However, LAM is amphiphilic, as are other bacterial pathogen associated
molecular patterns (PAMPs) that activate immune recognition, and is unstable in
aqueous blood52,184. Because of this biochemistry, LAM seeks to associate with host
membranes or carrier complexes for biochemical stability. In blood, host lipoproteins
such as high- and low-density lipoprotein (HDL, LDL) sequester LAM, resulting in
modulation of the inflammatory response72,73,185,186. Understanding this hostpathogen biology, Mukundan et al. have developed a novel lipoprotein capture
assay using a biosensor platform developed at Los Alamos National Laboratory to
directly and quantitatively detect LAM in blood72. The fact that LAM is expressed,
albeit hidden in lipoproteins, in the blood of patients with active TB, and that this
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expression occurs irrespective of whether the patient has pulmonary or
disseminated disease makes it a promising target for diagnosis of pediatric TB186,187.
3.4.1 The lack of gold standard diagnostic and implications
One of the major challenges in diagnosing childhood pulmonary TB is the lack of a
reliable gold-standard diagnostic, which leads to significant under or over treatment
of children with suspected disease135,170,188–190. Culture is considered the gold
standard in adults, but has been shown to be imperfect in detecting childhood
TB170,188. Less than 15% of pediatric cases are sputum smear positive, and culture
detects around 30-40%, due to reasons outlined earlier in this chapter. Therefore,
childhood TB is diagnosed based on a triad of close contact with a TB patient,
positive TST, and abnormal chest radiograph170, which results in significant
misdiagnosis and under diagnosis, both of which have societal and individual
implications.
Evaluation of new diagnostic tools for the detection of childhood TB is difficult
due to the absence of accurate comparative matrices and reference assays147. One
of the key factors that can be considered when evaluating new diagnostics is the
duration and proximity of suspected case of pediatric TB to confirmed cases – i.e.
transmission cohort studies. Some studies have emphasized the significance of
exposure to confirmed TB cases, as positive results increased with increased
exposure153,154.
3.5 Pediatric TB in context of HIV
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TB is the most common opportunistic infection and leading cause of death in people
with HIV, including children. The immunocompromised status of HIV positive
individuals may allow for the activation of TB in latent carriers, increase risk and
susceptibility in non-carriers, and enhance unconventional disease presentation and
possibility of disseminated disease, all of which challenge conventional diagnostic
approaches. Children with a low CD4 count have a five-fold risk of contracting TB as
compared to those with mild immunosuppression191. The risk of infection by drugresistant TB also increases with HIV coinfection192. HIV-TB coinfected patients are
37% more likely to develop resistance to at least one drug, versus 19% of patients
with TB only193. HIV-TB coinfection has been reported to be over 50% in some high
burden African settings194. Globally, 11% of HIV-positive TB patients died during
treatment, and the possible reason for poor outcome is late detection of HIVassociated TB, as well as delayed start of treatment. Whereas most of this data is
accrued on adult populations, the ramifications apply to children – if only more
significantly than to adults. Therefore, the WHO has recommended treatment for
latent TB infection in HIV individuals and children under 5 years, who are living in
households with individuals/family members with bacteriologically confirmed TB. The
2018 WHO report recommended the use of GeneXpert assays and lateral flow urine
LAM assays in HIV clinics to help ensure early diagnosis and reduced mortality195.
The relationship between TB and HIV coinfection, and the implications of this
association on disease manifestation, need to be considered in making treatment
decisions.
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3.6 Research needed on pediatric TB
The WHO has developed a roadmap to end TB in children and adolescents, with the
goal of developing new diagnostic approaches for systematic TB detection in
vulnerable children and to develop child-friendly point of care tests with requisite
accuracy by the year 2023. According to the WHO 2018 report, a major
technological breakthrough is required by 2025 so that TB incidence rate can fall to
much lower levels, and the spread of the disease can be curtailed. There is a
significant dearth in the investment and development in new diagnostics, which has
delayed such breakthroughs and effective control of disease spread. Consequently,
there is an urgent need for a new diagnostic that can minimize barriers to healthcare
access, ensure quality testing in difficult to diagnose groups, is affordable to use,
and has low maintenance costs, especially in pediatric populations. Early diagnostic
tests, which are usable at the point of care, and can accurately diagnose PTB and
EPTB in children with/without HIV co-infection can provide that much required
breakthrough and allow for the realization of the WHO goals for global TB control.
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4.1 Abstract
Tuberculosis (TB) is a major public health concern for all ages. However, the disease
presents a larger challenge in pediatric populations, partially owing to the lack of
reliable diagnostic standards for the early identification of infection. Currently, there are
no biomarkers that have been clinically validated for use in pediatric TB diagnosis.
Identification and validation of biomarkers could provide critical information on
prognosis of disease, and response to treatment. In this review, we discuss how the
“omics” approach has influenced biomarker discovery and the advancement of a next
generation rapid point-of-care diagnostic for TB, with special emphasis on pediatric
disease. Limitations of current published studies and the barriers to their
implementation into the field will be thoroughly reviewed within this article in hopes of
highlighting future avenues and needs for combating the problem of pediatric
tuberculosis.
Keywords: pediatric tuberculosis; diagnostics; omics; biomarkers; lipoarabinomannan

4.2 Introduction
Tuberculosis (TB) is one of the most common infectious diseases worldwide and
continues to pose a substantial threat to pediatric health196. According to the World
Health Organization (WHO), roughly 10 million individuals were infected with TB in
53

2019, which resulted in ~1.2 million deaths. Children (<15 years) account for
approximately 14% of all TB deaths, and 11% of all TB cases. Of these cases, only 35%
of all pediatric TB cases are accurately diagnosed, leading to a delay or lack of
treatment197. Within this pediatric population, 69% of cases in children under the age of
5, and 40% of cases in children 5–14 years of age remain unreported and undiagnosed,
partially accounting for the high infection and mortality rates in this population19. Thus,
the availability of reliable empirical diagnostics will greatly facilitate improved treatment
and survival in children with pediatric TB. However, such diagnostics are currently
nonexistent for pediatric TB infection.
A key contributing factor in our inability to effectively diagnose and treat pediatric
TB, is the continued lack of understanding of host-pathogen interactions and disease
manifestation in this population. The exact immune mechanisms of underlying TB
disease in children are unclear, but some pathways have been elucidated. TB is caused
by the bacterium Mycobacterium tuberculosis (MTB). In pulmonary manifestation of the
disease, the bacteria enter the body via inhalation and colonize terminal alveoli of the
lungs after crossing many physical barriers198. MTB then activates the host immune
response, causing macrophages and lymphocytes to migrate to the infection site. Here,
the immune cells begin granuloma formation where MTB can persist in a latent stage for
an extended time. Changes in host immune status can cause latent infection to become
active at any time199. Thus, it is the dynamic balance between bacterial pathogenicity
and the host immune system that determines the clinical presentation of TB disease.
This balance is influenced by several factors including the infectious dose, virulence and
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persistence of the pathogen, host health and co-morbidities (HIV/AIDS, diabetes, and
others), and the interplay between the innate and acquired immune system200–204.
According to the WHO, successful diagnosis and prompt treatment of TB could
prevent millions of deaths each year [2]. However, pediatric TB is not effectively
diagnosed by strategies developed for adult infection. Less than 15% of pediatric cases
are sputum smear positive, and only 30%–40% of all cases are confirmed by culture205.
The high failure rate of existing diagnostic tests in pediatrics is largely due to the
differential presentation of disease in this population.
For one, the incomplete maturation of the immune system in pediatrics has been
shown to be a contributing factor in disease manifestation and progression206. Children
aged 1–2 years present with a 20%–30% risk of disease activation, whereas the risk
decreases to 5% between ages 3–5, and can potentially further decrease to 2% between
5–10 years of age143. Additionally, the developing immune system of children can result in
a varied response depending on the stage of disease manifestation, which consequently
leads to increased risk of active TB with different disease outcomes206. Secondly,
childhood TB is often disseminated making it harder to detect via traditional sputumbased diagnostics144. Additionally, young children are often unable to expectorate
sputum, making the reliance on sputum-based diagnostics difficult for this population78.
Moreover, pediatric clinical isolates contain fewer bacteria (paucibacillary), making
culture and isolation even more challenging. These factors contribute to the challenge of
diagnosis of pediatric TB, and render adult diagnostic tests ineffective when applied to
children. For instance, while bacterial culture from blood or sputum sample from a
presumptive positive patient is the current gold standard TB diagnostic in adults, the
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method has reportedly low sensitivity when used in children207. As a result of the above
mentioned factors, a reliable diagnostic for pediatric TB has proved challenging and
remains an elusive goal135,170,188–190. The following section provides a comprehensive
assessment of current diagnostic methods with Figure 4.1 providing a comparison of
current approaches for diagnosis of pediatric TB with an “omics” future.

Figure 4.1. Pediatric tuberculosis (TB) diagnostics—today and tomorrow. The figure outlines
the diagnostic choices and decisions that are made when a child is presumed positive for TB
disease today, while highlighting that these choices and challenges may be entirely alleviated
with the realization of empirical diagnostics as facilitated by one of the many potential omics
strategies discussed in this review. To create the cumulative figure, images 379758506 by
katy_k20 and 394943974 by janista were obtained from DepositPhotos and used under the
standard license agreement. Additional images were downloaded from BioRender.com and
used under licensed agreement.
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4.3 Current Diagnostics for Pediatric TB
TB can manifest in the latent form in many individuals, and only activates in some
patients based on various influencing conditions. Depending on the design, approach,
and sensitivity of an assay, a method can be approved for either diagnosis of latent or
active forms of the disease in pediatric or adult populations. For instance, the tuberculin
skin test (TST) has historically been used worldwide and is currently recommended by
WHO for diagnosis of latent TB infection in adult and pediatric populations197. In this test
format, the tuberculin/purified protein derivative is injected intradermally and the
diameter of the inflammatory response on skin is measured. A diameter of greater than
10 mm within two days is considered positive for TB exposure25. TST cannot
discriminate between latent and active infection, requires two visits to clinic, and is
based on subjective interpretation of the spot size150. Despite approval for use in
children, TST suffers from lower sensitivity in this population, along with poor specificity
in individuals exposed to non-tuberculous Mycobacteria or prior bacille Calmette-Guerin
BCG vaccination151.
Another test that has been endorsed by WHO for diagnosis of latent TB infection is
the interferon gamma release assay (IGRA). This method is based on the quantitative
measurement of interferon gamma (IFN γ) released upon activation of innate immune
receptors when exposed to MTB antigens, in whole blood. The MTB antigens used
includes culture filtrate protein 10, early secretory antigenic target 6, and proteins
encoded by genes within the region of difference 1 of the MTB genome156. The
sensitivity and specificity of IGRA is better than TST, and can differentiate between
BCG vaccination and MTB exposure161. The assay concept has been commercialized
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by multiple companies, and available IGRAs include QuantiFERON-TB Gold (QFT-G),
QuantiFERON-TB Gold in-tube (QFT-G-IT), and T-SPOT TB (T-SPOT), which vary in
the mode of detection (such as lateral flow assays, enzyme-linked immunosorbent
assays (ELISA), and ELISpot). The need to draw blood and immediately perform the
test is a limiting factor, especially in resource limited areas.
An inexpensive and simple method commonly used to diagnose active pulmonary
TB in low and middle income countries is the sputum smear, which uses microscopic
identification of stained MTB in infected samples162–165. WHO has endorsed both light
microscopy-based and light emitting diode microscope-based formats of this assay
modality for use in both adult and pediatric TB patients. This technique is simple, rapid,
and inexpensive, with moderate sensitivity in adults with pulmonary TB162–166. However,
a drawback of the method is that two sputum specimens are necessary, which are
difficult to obtain in all patients, but especially from children208. Thus, the value of
sputum microscopy for effective diagnosis of pediatric infections is very limited.
Culture is the gold standard for the diagnosis of active TB infection. However, the
technique is time-consuming, due to the slow growth rate of MTB. There are two
culture-based diagnostic systems approved by the WHO: (1) the liquid culture system
with rapid speciation, and culture-based phenotypic drug sensitivity testing (DST) using
highly specialized culture media and (2) the mycobacterial growth indicator tube (MGIT).
Of the two, MGIT provides higher yield of MTB and significantly faster diagnosis when
compared to conventional solid culture, but has the disadvantage of a high cost148.
However, the paucibacillary and disseminated nature of pediatric TB results in reduced
reliability of culture as a gold standard in children75. Because of these pediatric TB

58

disease states, culture cannot be used to exclude the disease when negative, but is
definitely confirmatory when positive. The choice of sample, and the concentration of
bacteria for growth are critical considerations in the use of culture as a confirmatory
diagnostic. Thus, while culture is considered the gold standard for TB diagnosis in
adults, the technique often produces unreliable results in detecting childhood TB170,188.
The Gene-Xpert MTB/resistance to rifampicin (RIF) assay (Cepheid® USA) was
developed to detect DNA sequences specific to MTB, using polymerase chain reaction
(PCR). This test has been recommended by the WHO to improve adult and pediatric
case detection and identification, and can provide results within 2 h of sample
collection148,209. Current policy recommends it be used as an initial diagnostic test in
children suspected of having multi-drug resistant TB or HIV-associated TB197. However,
the sensitivity of this assay suffers when bacterial burden is low in samples, as is
common in pediatric and HIV positive populations178. Furthermore, the assay relies on
sputum as a sample, which is a limitation in children, given their inability to expectorate.
Detection of the biomarker lipoarabinomannan (LAM) is a highly promising strategy
for pediatric TB because of the non-reliance on sputum as the diagnostic sample67. As a
result, the MTB cell wall antigen-LAM has gained attention over time. WHO has
recommended the use of the lateral flow urine LAM (LF-LAM) assay (DetermineTM TB
LAM Ag, Abbott) for detection of active TB in severe HIV positive cases. LF-LAM assay
involves application of a 60 µL unprocessed urine sample on the test device and results
are read visually within 30 min142. Another commonly used method to detect LAM in
urine are immunoassays, such as ELISA. Here, the capture antibody is used in a multiwell plate, followed by addition of sample and a detection antibody75,77,210. However, LAM
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detection is not yet approved for use in diagnosis of HIV negative pediatric TB, likely
because of the lower sensitivity of current diagnostic strategies. Researchers are working
on the evaluation of the use of ultra-sensitive sensors in order to circumvent this
problem56,72,83,137,211,212. The use of samples such as urine and blood favors application of
this approach to children, and individuals with disseminated infection.
While there are promising developments, there are currently no reliable diagnostics
for pediatric TB. The percentage of children with active TB that were incorrectly
diagnosed by current diagnostic tests, as outlined above, are 40% by culture, 77% by
microscopy, and 50% by gene Xpert147. The poor reliability of current pediatric
diagnostics have caused the diagnosis of childhood TB to be based almost entirely on
medical history, clinical symptoms, TST results, and chest radiography213, and the WHO
has a prescribed process for syndromic diagnostics. Therefore, there is an urgent need
for development of diagnostics using non-sputum based, reliable biomarkers for
detection of tuberculosis in children137.
Approaches targeting diagnostics development for pediatric TB can broadly be
classified into three major categories: (1) detection of antigens or other biomarkers
produced by the pathogen, (2) measurement of host immune response to MTB antigens
(both humoral and cellular), and (3) unbiased “omics” approaches utilizing genomics,
transcriptomics, proteomics, lipidomics, and metabolomics characterization. The use of
pathogen signatures and host biomarkers for TB diagnostics have been broadly
discussed elsewhere, and is briefly summarized above. This manuscript explores the
third approach, using “omics”, for diagnosis of pediatric TB and how this can be applied
to pediatric TB diagnosis.
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4.4 The Role of “Omics” in TB Diagnostic Development
Empirical diagnostics can potentially traverse the challenges associated with various
presentations and manifestations of TB disease in children, as well as address the
varied manifestations of TB disease in adults (disseminated, extra-pulmonary, drugresistant, and latent)214. Molecular signatures to facilitate such diagnostics can belong to
any of the “omic” categories of relevance and the use of omics as a tool for biomarker
discovery has advanced greatly over the past decade, facilitating such development. As
depicted in Figure 4.2, a well-rounded omics approach for investigating TB pathology
includes genomics, transcriptomics, proteomics, metabolomics, and lipidomics. Such a
high throughput approach can provide researchers with an unbiased multi-dimensional
understanding of disease progression and outcomes, to better develop an allencompassing diagnostic test.
In comparison to current diagnostics, the average response times for the various
omics technologies discussed in this manuscript vary greatly at this point in
development. For instance, a technically naive health care worker can accomplish
running an Alere LAM assay at the point of need, within 30 min for a low cost. However,
running a genomics panel on patient sputum samples is far more expensive (hundreds
of dollars, depending on the method), and may require pathogen concentration via
culture. This is technically intensive and time consuming and requires extensive
bioinformatics capabilities, which in turn require skilled capabilities and complex
laboratory infrastructure. Whereas, the Alere immunoassay interrogates for one single
biomarker of interest, genomic arrays can provide a pan-diagnostic approach for
discriminative diagnosis of infection. Further, genomic technologies are advancing with
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respect to ease of use and operation at unprecedented rates, and, in fact, have defied
Moore’s law215. Field forward sequencing capabilities that can be used quickly and in an
automated version at the point of need are rapidly emerging216. Many culture-free
sequencing capabilities are also emerging, decreasing the time to result, especially
when combined with deployable and easy to use informatics pipelines217. Similar to
genomics, proteomic and metabolomic arrays are also time consuming, labor intensive,
and expensive in their current form. However, this is also changing rapidly, albeit not as
quickly as evidenced with genomics. Service centers providing proteomic microarray
development and validation are emerging, and despite the research required and
custom development involved, are now available for ~$100 per sample218. Thus, all of
these omics-based methods hold more promise for the future, because of their holistic
nature, flexibility, and agility to being applied to a variety of human health challenges.
These properties are especially relevant to pediatric TB, where the reliability of current
diagnostics is very poor. A novel omics future promises a superior, more reliable
strategy for pediatric TB diagnosis. Currently, there are various researchers working on
the development of deployable and easy to use informatics pipelines for proteomics,
genomics, and other omics strategies219–222.
An omics approach would expand our knowledge of diagnostic biomarkers and
could also facilitate better understanding of MTB pathogenesis and drug resistance
mechanisms to aid in the development of suitable therapeutics and vaccine candidates.
An example of this would be using proteomics to measure cellular activity to provide
deeper insight into pathogen or host cellular processes during different stages of
infection223. Additionally, whole genome sequencing (WGS) can be used to identify
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signatures of drug resistance in the pathogen before or during drug therapy to provide a
customized pharmaceutical regimen to improve treatment efficacy224. With the evolution
of machine learning and artificial intelligence based computational capabilities, an
“omics” approach can be utilized in many ways to identify host or pathogen signature
patterns for diagnostics and targets for therapeutics.
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Figure 4.2. Representative cases for an “omics-based” approach to build a comprehensive
understanding of the pathology of both adult and pediatric TB. There are still many omics-based
114,128,131,133,225–238
approaches to be further investigated, especially for pediatric TB
.

Genomics

WGS of MTB presents an exciting opportunity with respect to improved strategies for
diagnosis of TB, irrespective of disease state. Recent advances in genomics have
allowed for the use of WGS in order to discriminate between reinfection versus relapse
of TB infection. Unlike serological techniques, WGS as a diagnostic tool can confirm the
presence of current MTB infection [79]. While most WGS-based work has required prior
culture of the pathogen, there have been two recent studies using WGS as a
confirmatory diagnostic test by sequencing MTB genomes directly from uncultured
sputum samples239. This is of great relevance in the progress towards using this
technique as a diagnostic strategy. However, it is important to note that MTB DNA was
also detected in samples that were culture and smear negative. Therefore, DNA-based
genomic detection cannot distinguish between active and cleared infections where
residual DNA may be present from dead bacteria233.
One critical advantage of WGS-based diagnosis of TB infection is the ability to
identify, and appropriately treat mixed MTB infections (up to 50% in certain TB endemic
regions), which are defined as disease caused by more than one distinct MTB
strain240,241. Existing platforms have consistently demonstrated lower sensitivity in mixed
infections, suggesting that WGS may fill a major gap in this arena. For instance, the
Xpert assay for rifampicin resistance on mixed infections has a lower sensitivity of
(80%), compared to 93% on homogenous infections241. A second advantage of WGS is
the data on its application towards the determination of drug resistance. Sequencing
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data consistently agrees with conventional DST, and is associated with shorter
turnaround times, especially when done from early cultures224. The same reasons that
make WGS suitable for tackling these challenging problems, also make it an excellent
candidate for tracking multiple TB presentations in pediatric populations. However, most
often, WGS requires culture prior to sequencing, which can delay diagnosis, and
complicate application in paucibacillary pediatric cases. More studies such as the ones
noted above need to be performed on non-sputum samples to explore culture-free WGS
strategies. In addition to diagnostics, DNA microarray chips have been explored for the
rapid detection of MTB resistance to different therapeutics. One such study collected
sputum samples from 42 patients with TB and determined a 92.8% susceptibility and
93.8% specificity for the identification of resistance to the antimycobacterial drug,
rifampicin242. A similar study assessed 176 clinical isolates on an array with 12 pairs of
primers, and 60 nucleotide polymorphisms of 9 different MTB genes, and compared the
results to culture-based DSTs, GenoType MTBDRplus, and MTBDRsl tests. It was
found that the array was able to detect for resistance to isoniazid with a sensitivity of
100% and a specificity of 96.7%, whereas for rifampicin it was observed to be 99.4%
and 96.7%, respectively. These outcomes present excellent suitability for reliable use in
a clinical setting for the identification and monitoring of resistant strains. Development of
such methods could have a large impact not only on diagnosis of MTB, but also on
disease prognosis243.
Aside from diagnostics, genomics has proved to be a powerful tool for
understanding the molecular epidemiology of TB, mechanism of drug resistance, and
for unraveling protein and structural information. Analysis of WGS information is also
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useful for epidemiological characterization and tracing transmission239,244,245, and the
genetic sequence data provides a code for protein structure. The TB Structural
Genomics Consortium is an organization dedicated to determining protein structures for
MTB proteins on a genome wide scale. Large scale structural determination could help
researchers design smarter drugs to combat disease234.
Transcriptomics
Compared to genomics, transcriptomics is more readily adaptable for rapid
diagnostic development. Analysis of host coding RNA can be used to investigate gene
expression patterns throughout the course of the disease, and potentially with varied
manifestations, making them ideal targets for investigation of pediatric TB diagnostics.
Non-coding RNA, which does not encode for any protein, is frequently linked to
regulatory functions, which may be altered during different disease states. A recent
study identified 15 non-coding micro RNA (miRNA) as a signature for TB disease235. In
this study, researchers compared the miRNA profiles from different genetic
backgrounds, adult patients with active pulmonary and extra-pulmonary infections,
TB/HIV co-infections, and latent TB. Using miRNA as a marker was found to have an
overall sensitivity of 86% and a 79% specificity for diagnosis of active TB infection in these
varied populations. Using RNA sequencing of whole blood samples, researchers examined
the use of small non-coding RNA population such as miRNA, PIWI-interacting RNA
(piRNA), small nucleolar RNA (snoRNA), and small nuclear RNA (snRNA) as host
biomarkers for active and latent MTB in a systematic manner246,247. From this approach,
one miRNA and two piRNAs were identified as potential biomarkers for latent MTB248,
but further studies are required for their validation in such an application.
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There have also been several transcriptomic studies in pediatric populations with
TB in the last 10 years109,112–114,126,131,133. However, the broader implications of these
results towards the development of a pediatric diagnostic are limited by the lack of
diversity in population sampling. Host circulating miRNA profiles from whole blood in a
pediatric TB population, were analyzed by Zhou et al. who demonstrated that a
combination of eight miRNA signatures provided a 95.8% sensitivity and 100%
specificity for the discrimination of children infected with TB versus uninfected healthy
controls133. Using the GeneChip Human Exon 1.0 ST Arrays (Affymetrix), a 116 gene
signature set from whole blood was identified in 27 Warao Amerindian children (9 active
TB, 9 latent TB, and 9 healthy controls)114, again suggesting that a transcriptomic profile
assessment can provide a reliable strategy for diagnosis of pediatric TB. The
researchers further validated the ten genes in an independent cohort of 54 children by
using quantitative real time polymerase chain reaction (qRT-PCR), and found that five
out of ten genes were sufficient to achieve 78% sensitivity and 100% specificity in this
population249. Additionally, a recent study with Indian children explored transcriptomic
profiles from peripheral blood in various stages of disease presentation, and identified
12 transcriptional immune biomarkers that could differentiate between infected and
asymptomatic children131. Whereas a comprehensive and well-characterized pathogen
transcriptomic study is required in order to benchmark relevant signatures, the early
developments in this field show promise for the application of these signatures for
pediatric TB diagnosis.
A modified approach to transcriptomic diagnosis is to track changes in host cells,
rather than the pathogen. For example, by focusing on transcripts from whole blood
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samples of patients infected with TB, researchers identified a profile of 86 host
transcripts which can potentially distinguish TB infections from others, and an additional
393 which further characterize the infection as active or latent236. Similar studies in
pediatric cohorts would help further understanding of TB-host interaction, and also
facilitate differentiation of latent and active disease, thereby advancing diagnostic
applications. Transcriptional signatures are independent of bacterial load, which
strengthens the argument for using this technique for diagnosing low burden cases such
as in paucibacillary disease, as evidenced in children.
Proteomics
Proteomics profiling has been used to measure cellular activity, and can provide a deep
insight into cellular processes in complex clinical backgrounds. Understanding the wide
array of proteins expressed by both MTB and the host in response to MTB infection
could shed light on pathways responsible for pathogenesis and persistence250,251. Such
proteomic studies could target the pathogen-specific proteome, or host signatures in
response to MTB infection, both of which have been attempted extensively, and
examples from which are discussed below252,253.
The function of about one-quarter of the MTB coding genome and the precise activity
and protein networks of most of the associated proteins remain poorly understood.
Protein mass spectrometry and functional proteomics have provided new insights into
making this information more accessible to diagnostics development. Early proteomic
studies used two-dimensional gel electrophoresis (2D-GE) to analyze proteins from
bacterial fractions and culture supernatants of MTB [59]. However, the low resolution of
this method limited the analysis to only a few hundred proteins254–256, which is insufficient
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to provide a clear assessment of the signature array. The use of liquid chromatographytandem mass spectrometry (LC-MS/MS) shotgun proteomic methods in both targeted
and non-targeted studies has allowed for the expansion of this capability to several
thousand proteins at a given time237,257. More advanced MS techniques, such as
selected reaction monitoring, have allowed for the quantification of ~80% of the MTB
proteome, and do not require cell fractionation or separation237. In addition to MS,
proteome microarrays have also been used to profile thousands of protein interactions
in a single experiment258,259. Proteomic arrays have enabled researchers to define an
immunoproteome for MTB. Until recently much of biomarker discovery has relied on
traditional methods for separation and identification, however, as alternative methods
are being constantly described the field has grown. To date there are three proteomewide screening approaches that have been employed for the identification of candidate
antigens for CD4+ T cell responses to MTB. All three studies found that a relatively
small percentage of the proteome was responsible for the majority of the immune
response253,260,261.
In addition to an immunoproteome, a proteomic microarray approach has been
used to screen 4262 MTB antigens from 40 adult TB patients which allowed for the
identification of 152 MTB antigens that were differentially elevated among patients with
active versus latent disease238. Yet another study used a two-way proteome microarray
approach to screen 84 potential host MTB interactors in infected adults, developing a
signature repository that can be further used to understand MTB pathogenesis225. Deng
et al. identified 14 adult serum biomarkers to differentiate between patients with active
disease and those that have recovered from TB infection, facilitating monitoring of
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treatment outcomes226. In addition to presenting the proteome library, the investigators
were also able to begin to explore the use of such microarrays in determining protein–
protein interactions, biomarker discovery, and differentiating between individuals with
active disease and those that had recovered from TB infection, demonstrating the
potential usefulness of such platforms for real-world applications.
From a longitudinal cohort of 6,363 MTB positive, HIV-negative adolescents of ages
between 12–18 years in South Africa, host protein signatures associated with MTB were
systematically assessed. In this study, the cohort was followed for 2 years and
investigators reported that 46 individuals developed microbiologically confirmed MTB
disease, while 106 non-progressors were identified. As such, 3000 human host proteins
from plasma were quantified, of which 361 were found to demonstrate significant
difference in abundance between individuals with microbiologically confirmed TB and
non-progressors. From these 361 proteins, a 5-protein signature, TB risk model 5
(TRM5), was further sub-selected for use in discriminatory diagnostics. A second 3protein pair (3PR) was further added to this sub-selection in order to improve the
efficacy of the diagnostic platform. However, neither the TRM5 or 3PR achieved the
minimum criteria for an incipient TB test as defined by the Foundation for Innovative
New Diagnostics (FIND) or WHO, and, therefore, additional work is still needed to
improve these signature-based protein assays262. Additionally, a subset of proteins that
are exported, termed the exportome, could be potential source of additional disease
biomarkers. Efforts to identify exported proteins have been typically limited to in vitro
work. However, recently an in vivo method has been described and termed EXIT
(exported in vivo technology) for the discovery of MTB exported proteins, as
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demonstrated in murine infection models. Over 500 proteins were revealed to be
exported, several of which were induced in vivo. Proteins discovered by this technique
should be further explored as potential biomarkers for adult and pediatric MTB disease
markers263.
In a third study, researchers identified an eight-protein host signature which had
ramifications for the diagnosis of TB disease. In this study, three separate cohorts were
enrolled for a total of 640 individuals. The initial cohort of individuals was used for the
screening of protein biomarkers of TB, the second to establish and test the predicted
model, and the third for biomarker validation. The initial round of screening involved a
microarray comprised of 16 non-overlapping arrays to measure 640 human proteins.
Sixteen proteins of interest were then further analyzed in a second array. Using a series
of mathematical models, a diagnostic model was built using an eight-protein signature.
In the second test cohort the signature had an 83% specificity and a 76% sensitivity.
The third cohort, in which the signature was validated, the specificity and sensitivity was
84% and 75%, respectively. While this study was done with adults, a similar study could
be designed for pediatric MTB to develop a pediatric specific model264.
Proteomic profiles can allow for the diagnosis of pediatric TB, and despite the
disease’s varied manifestations, several researchers have begun to specifically explore
that possibility. For instance, a quantitative proteomics approach using LC-MS/MS was
employed to characterize plasma from 72 children in different test groups (active TB,
inflammatory disease control, and healthy control) at a Beijing Children’s Hospital. The
study identified 49 proteins in pediatric cases that were differentially expressed between
active and latent TB227. One study characterized the plasma proteins in children at
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different MTB infection stages (active TB and LTBI), and identified four proteins—
XRCC4, PCF11, SEMA4A, and ATP11A—to be signatures of active TB disease using
proteomics227. Given the differential presentation of pediatric TB disease, it is likely that
a combinatorial approach exploring varied biomarker signature profiles may provide a
greater reliability of identification rather than a single factor approach265.
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Lipidomics
Lipids are an essential player in biological processes, both within the host and the
pathogen. MTB is known to have one of the most complex lipid envelopes in nature, which
forms the barrier between the pathogen and the host, and a substantial lipid biosynthesis
capacity within their genome31. The multilayered cell wall contains both an inner
phospholipid bilayer as well as an outer lipid layer consisting of mycolic acid. Lipids from
both layers have strong potential to be used as a biomarker for diagnosis.
With considerable advances in mass spectrometry over the past decade, the field of
lipidomics has advanced MTB research. The large-scale characterization and
quantification of lipids has led to the development of MycoMass, a database for
mycobacterial lipids228. The database currently contains 58 lipid types. More than 40 of
these mycobacterial lipids lack any similarity to other eukaryotic or Gram-negative
organisms, making them unique signatures for diagnostics development and therapeutic
targeting. The unique Mycobacterial lipidome is, thus, a signature repository that
requires further characterization266. When comparing the lipid profile from normally
grown MTB with dormant and reactivated bacteria, analysis revealed a total of 4187
significant features with 2480 features found to have significant variation during the
transition from normoxial growth to dormancy. Across the three different stages a total
of 74 fatty acyls showed significant variations. Findings such as these could play roles
in the discovery of biomarkers for various different stages of MTB267.
Mycolic acids (MAs) are a main component of the cell wall of mycobacteria. The cell
wall of mycobacterium provides protection against a host immune response by
mediating macrophage trafficking events, and by helping the bacterium to grow within
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host macrophages268–270. MTB has three different structural classes of MAs namely,
alpha-, methoxy-, and keto-MAs42, with the most abundant form being α-MA (>70%),
and methoxy- and keto-MAs being minor components (10% to 15%)43. MA-classes play
a crucial role in virulence and are present in high concentrations in the bacterial cell
wall. While they are unique to Mycobacteria, these lipids differ considerably between
different Mycobacterial species/strains, a factor which could be helpful for differential
diagnosis. For example, the detection of all three forms of MAs in bacterial extracts and
gamma irradiated whole bacteria, using surface enhanced Raman spectroscopy271.
While some studies have used a surface plasmon resonance (SPR) technique to detect
serum antibodies to MAs, the method has not been validated clinically272. Using a
biosensor platform to detect antibodies against MAs from patient serum improved MA
detection (sensitivity 91.3% in TB and HIV positive patients) compared to ELISA273.
Other techniques used to detect MAs are LC-MS and high-performance liquid
chromatography, which are both expensive and require advanced user training to
operate and interpret data, making them difficult to use in resource-poor settings271,274.
MAs were detected in adult TB sputum by Shui et al. The study demonstrated a
sensitivity of 94% and specificity of 93% in discriminating between TB cases and
controls229. The authors speculated that the method “might offer advantages in
specialized situations such as pediatric cases (where sputum volume is very limited)”,
although clinical validation of this has yet to be performed. Lipidomic and metabolomic
analysis of MAs in samples such as urine and serum in pediatric and adult patients is
needed to establish the effectiveness of this lipidic signature as a potential diagnostic
biomarker275.
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Other prominent mycobacterial cell wall components include lipoglycans such as
trehalose dimycolate (TDM), phosphatidyl-myo-inositol mannosides (PIM), LAM, and
lipomannan (LM)48–50. Animal studies have shown that lipids on mycobacterial surface
interfere in their interaction with phagocytes, thereby influencing pathogenesis276.
However, not much is known about the molecular mechanism with exception of key
lipoglycans, LAM and LM276,277.
LAM is an amphipathic molecule released from metabolically active or degrading
bacterial cells resulting in the activation of host immune response51–53. In 2001,
Hamasur et al. discovered that LAM was detectable in the urine several hours after
intra-peritoneal injection of crude MTB cell wall extract into mice94. The observation
provided researchers with an opportunity to evaluate LAM as a biomarker for the
development of non-invasive94,182 point-of-care tests for TB. As a result, a lateral flow
urine LAM assay is currently available (Determine™ TB LAM Ag, Abbott
Biotechnologies), with a sensitivity of 45% and specificity of 92% in HIV positive
patients278 and is recommended by the WHO only for use in HIV-positive adults with
CD4 counts less than or equal to 100 cells·µL−1 presenting with symptoms of TB142. The
guidelines for use of urine LF-LAM assay are similar in children, based on data from
adults142. Previous work from our team demonstrated the detection of urinary LAM at a
maximal concentration of 350 pM in individuals without HIV co-infection using a sandwich
immunoassay on an ultra-sensitive waveguide based optical biosensor56. The
conclusions of this work are supported by a recent study using an improved
chemiluminescence readout, with sensitivity and specificity of 93% and 97%,
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respectively83. These findings show that a more sensitive assay format is required in
immunocompetent individuals.
Despite advances in LAM diagnostics testing for adults, data on pediatric testing is
still scarce. A WHO update on urine LAM assays reported a pooled sensitivity of 47%,
and a pooled specificity of 82% among various studies performed in children with
HIV158, which is also reflected in independent assessments of both lateral flow and
ELISA formats of detection75,76,78. These studies show that LAM measurement is more
reliable in immunocompromised children, and that measured concentrations of the
antigen decrease with anti-TB treatment76, which suggests potential for this biomarker
to be used as a prognostic indicator. Longitudinal studies demonstrating antigen
concentrations as a function of disease progression and treatment must be performed in
order to validate this hypothesis, as previously demonstrated for the measurement of
lipomannan in M. bovis infection279–282.
Previous work from our group has demonstrated that LAM is associated with highdensity lipoproteins (HDL) in host blood72. This association should be considered when
developing diagnostics, as with membrane insertion and lipoprotein capture
methodologies74,211,279,283–285,

because

traditional

strategies

for

measuring

the

monomeric antigen are likely to be unsuccessful in this conformation. To date there are
only a few studies showing detection of LAM in blood from adults83,182,212 and none in a
pediatric population.
Lipidic profiles of mycobacteria are unique—and targeting these differential
biomarkers can definitely provide a unique strategy for the diagnosis of active disease.
It is important to develop capabilities for the characterization and measurement of
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pathogen and host lipids, and further improve our understanding of pathogen lipid
profiles in order to advance this field of science. Furthermore, the genes and enzymes
that regulate these specific lipids can be identified and pave a way to integrate other
omics approaches, such as metabolomics.
Metabolomics
Metabolomics can be used to study changes in host metabolism and associated
processes in response to TB infection. A recent study in children from the United
Kingdom and Gambia demonstrated alterations in host metabolism using 1H NMR
spectroscopy and MS, to provide a signature repertoire for diagnostic applications. 1H
NMR data was analyzed to discriminate between children with TB, and those infected
with other diseases, and demonstrated a sensitivity and specificity of 69% and 83%,
respectively, for the diagnosis of TB. MS characterization of metabolic profiles had
similar results with a sensitivity and specificity of 67% and 86%, respectively128. The
study also showed raised levels of ceramide, a type of sphingolipid found in high
concentration in cell membranes. Ceramides have been shown to contribute to
maturation of the phagosome in macrophages infected with MTB, causing increased
killing of pathogenic MTB286, and can serve as unique metabolic signatures of
pathogenesis. Similar alterations in metabolic markers have been seen in adult
studies230–232. Thus, metabolomics studies can provide some useful insights into
understanding pediatric immune response mechanisms to MTB. However, large scale
and controlled studies are required for the identification of metabolomic processes and
signatures that can be used for diagnostic applications. Yet, the change in host
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metabolome in response to TB infection can likely provide useful information for
pediatric TB diagnosis and understanding of pathogenesis.

4.5 Conclusions
Pediatric TB is a devastating problem worldwide with no reliable diagnostic tests to
differentiate between latent and active TB cases or help guide treatment to success.
Current pediatric diagnostics are typically based on difficult-to-collect sputum samples,
are time consuming, and associated with lower sensitivity. Further, current diagnostic
tests do not address the varied challenges of differential presentation of TB disease in
children when compared to adults. Some of the current approaches can potentially be
refined and re-aligned for pediatric applications. For instance, assay modalities with
enhanced sensitivity or blood-based detection methods can greatly improve the use of
LAM as a diagnostic marker for pediatric TB disease. However, there is a distinctive
need for a broader search for empirical signatures, validated strategies, comprehensive
and reproducible assessments, and clinical studies that target pediatric presentation of
TB. Due to incredible complexity of TB pathology in various populations, using an
“omics-based” approach can facilitate the identification of suites of biological signatures
necessary for developing a universal TB diagnostic test. While many “omics” studies
have been done in adult populations, these results only provide a road map for building
further understanding of pediatric TB pathology. Additional investigation of how TB
stages differ and progress to active disease in a pediatric population would aid
development of an all-encompassing specific and sensitive diagnostic test.
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5.1 Abstract
Rapid diagnosis is crucial to effectively treating any disease. Biological markers, or
biomarkers, have been widely used to diagnose a variety of infectious and noninfectious diseases. The detection of biomarkers in patient samples can also provide
valuable information regarding progression and prognosis. Interestingly, many such
biomarkers are composed of lipids, and are amphiphilic in biochemistry, which leads
them to be often sequestered by host carriers. Such sequestration enhances the
difficulty of developing sensitive and accurate sensors for these targets. Many of the
physiologically relevant molecules involved in pathogenesis and disease are indeed
amphiphilic. This chemical property is likely essential for their biological function, but
also makes them challenging to detect and quantify in vitro. In order to understand
pathogenesis and disease progression while developing effective diagnostics, it is
important to account for the biochemistry of lipid and amphiphilic biomarkers when
creating novel techniques for the quantitative measurement of these targets. Here, we
review techniques and methods used to detect lipid and amphiphilic biomarkers
associated with disease, as well as their feasibility for use as diagnostic targets,
highlighting the significance of their biochemical properties in the design and execution
of laboratory and diagnostic strategies. The biochemistry of biological molecules is
clearly relevant to their physiological function, and calling out the need for
consideration of this feature in their study, and use as vaccine, diagnostic and
therapeutic targets is the overarching motivation for this review.
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5.2 Introduction
The utility of a diagnostic is measured by its ability to provide rapid and reliable
information to guide treatment. The past century has seen a rise in molecular diagnostic
strategies for measuring disease-specific signatures in patient samples (e.g. blood,
urine, tissue and others) using a variety of biosensor technology. A biosensor utilizes a
biological component or biocatalyst to detect the presence of an analyte and a
transducer to create a quantifiable signal from this interaction. For a biosensor to be
used feasibly in a clinical setting, it must be highly specific for the target analyte,
accurate in patient samples, rapid and reliable, and resistant to non-specific interactions
in clinical samples. In addition, for some applications, especially in resource-poor
conditions, it is also desirable for the sensor to be cost-effective and easy-to-use287. In
order to avoid false positive (signal in the absence of analyte) and false negative
(analyte present without signal) signals, the biocatalyst and transducer must be carefully
considered for each target analyte.
Identifying target analytes and their presentation in a host during disease is of
crucial importance for the success of such molecular diagnostic technologies.
Biomarkers are indicators of biological processes and disease-specific biomarkers are
of great clinical value for diagnostics. Understanding the interactions between the
biomarker and its host is key to developing assays for the detection of such analytes in
clinical samples. Because of the ease of purification and detection, proteins and nucleic
acids have been extensively used as diagnostic targets. Traditionally, nucleic acids and
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proteins have been targeted as biomarkers for the diagnosis and detection of disease,
primarily because of the availability of a variety of sensitive and tailored methods for the
detection of these biochemical signatures. However, another category of biomolecules
that play important roles in a variety of cellular processes, and can therefore serve as
indicators of disease and analytes for biosensors are lipids and amphiphiles288. Besides
membrane formation, lipids also play a crucial role in cell signaling (steroids) and
energy storage. The brain is composed of 40-81% lipid, with the myelin sheath being
78-81% lipidic in biochemistry289. Many of the bacterial virulence factors recognized by
the human innate immune response, such as lipopolysaccharide (LPS) and lipoteichoic
acid (LTA), are amphiphilic lipoglycans290–296. The structure of lipids is far more diverse
than that of proteins, nucleic acids or carbohydrates, allowing for highly specific
biomarkers for a variety of diseases. However, all lipids contain at least one
hydrocarbon chain that is insoluble in water making them difficult to detect in aqueous
solutions such as blood, which has largely limited their application as diagnostic targets.
Indeed, currently, rapid detection of lipidated targets is largely achieved via methods
that were originally designed for proteins. Here, we review advancements in methods
for detection of lipid and amphiphilic biomarkers associated with both infectious and
non-infectious diseases describing the advantages and limitations of each approach in
clinical diagnostics (Table 5.1).
Table5. 1. Advantages and limitations of sensors as clinical diagnostic tools for detecting lipid and
amphiphilic biomarkers.
Method
Advantages
Limitations
Mass spectrometry

Sensitive

Expensive
Sample preparation can be
extensive

Specific
Works in patient
samples

Requires highly trained personnel
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Requires laboratory infrastructure
NMR-based sensors

Rapid

Low sensitivity

Reproducible
Works in patient
samples

Low specificity
Sample preparation can be
extensive
Requires highly trained personnel
Requires laboratory infrastructure

Optical biosensors
SPR-based sensors

Rapid

Low sensitivity in patient samples

Specific
Interferometry-based
sensors

Low-cost

Low specificity in patient samples

Sensitive
Waveguide-based sensors

Short shelf-life of labeled
reagents

Rapid
Reproducible
Sensitive

Electrochemical biosensors
Mechanical biosensors

Specific
Works in patient
samples
Rapid

Low sensitivity in patient samples

Reproducible

Low specificity in patient samples

Rapid

Low sensitivity in patient samples
Low specificity in patient samples
Reproducibility

5.3 Methods for Detecting Lipid and Amphiphilic Biomarkers
Storage and processing of patient samples
Sample collection and preparation is a critical consideration for the detection any
biomarker297, but lipidic targets warrant further attention298. Common lab methods such
as freeze/thaw and chemical extractions can have a profound effect on the viability of
amphiphilic biomarkers299,300. Further, depending on the sample, lipid and amphiphilic
biomarkers are often sequestered by host factors, further reducing their availability for
direct detection72. Therefore, any biosensor designed to detect amphiphilic biomarkers
must account for their unique biochemical properties.
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Mass spectrometry

Lipidomics requires a thorough characterization of the structure and the function of
lipids within a living system. The study of amphiphilic biomarkers, as described here, is
a composite of lipidomics, but involves the consideration of the hydrophilic components
of the biomarker in addition to the hydrophobic lipids. Since its inception in the early 20th
century, mass spectrometry (MS) has played a significant role in characterization of
lipids301–303, and this has been extensively reviewed. Here, we will focus on the adaptive
application of MS to amphiphilic biomarkers.
MS ionizes lipids and sorts ions based on their mass-to-charge ratio. It has been
widely used to characterize lipids304–308, especially with the development of soft
ionization techniques such as electrospray ionization (ESI) and matrix-assisted laser
desorption ionization (MALDI). Lipid extraction is usually the first step for lipid analysis,
and separates the lipidic components (organic phase) from other components such as
proteins and nucleic acids (aqueous phase). Most widely used extraction methods have
been adapted from Folch309 or Bligh and Dyer310, in which a mixture of methanol,
chloroform and water are applied for phase separation. However, shotgun lipidomic
methods have also been developed which omit the chromatographic separation and
sample processing described above, and analyzes all lipid classes together, instead
using ionization additives to provide discriminative identification301. This method might
be more suitable especially for biomarker-discovery, wherein there is no prior art
regarding the biomarkers being identified/measured.
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Chromatographic

methods

such

as

gas

chromatography,

thin-layer

chromatography, high-performance liquid chromatography (HPLC), or ultra-performance
liquid chromatography (UPLC)306,311 are used for separation of lipid mixtures. HPLC
and UPLC are have broader applications in lipid analysis305,311 and can be performed in
normal phase (lipid class separation based on their different polarities and dipole
moments) or reverse phase (separates lipid according to their hydrophobicity and is
based on fatty-acyl compositions). Coupling of separation with LC methods allows lipids
to be resolved sequentially with greater ionization yields, decreased ion suppression
from major lipid classes, and increased sensitivity305,312. However, this LC step can be
bypassed, with direct infusion (shotgun lipidomics) of lipid samples, which
simultaneously analyzes the lipid species in the crude lipid extract313,314. This method
does not require a priori decisions on which lipid species to measure, is relatively
simple, high-throughput, and fast with short data acquisition times. However, a major
limitation of this method is that highly abundant lipids can compete for ionization with
the minor species, and mask detection of the latter.
MALDI-MS is based on the utilization of an ultraviolet–absorbing matrix that initially
absorbs the energy of the laser and mediates the generation of ions315,316. ESI-MS uses
a high voltage electrospray to aerosolize the lipid sample and generate ions to charge
the lipid molecule304,317. MALDI or ESI ionization can be combined with several types of
mass analyzers such as triple quadrupole, time-of-flight (TOF), ion trap, and orbitrap to
further characterize different lipid classes and species317,318. Both quadrupole and TOF
mass analyzers are commonly used and their configuration together (e.g. triple
quadrupule (QqQ), quadrupole time-of-flight (QTOF)) as tandem mass spectrometric
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instruments to break down the precursor ions into fragmented product ions, can provide
further chemical and structural resolution on the lipid species319,320. As an example, ESIMS has been successfully applied to characterize cardiolipin320. Cardiolipin, a biomarker
implicated in heart disease and cancer, is a phospholipid present in mitochrondria and
is a component of bacterial membrane321,322. The diversity of cardiolipin molecular
species is found in both the identity and position of its four fatty acyl moieties. Minkler
and Hoppel showed that reverse-phase ion pair HPLC coupled with a triple quadrupole
MS/MS linear ion trap mass spectrometer to generate MS/MS was highly effective in
characterizing cardiolipin from different species (e.g. rat liver, mouse heart, bovine
heart, dog heart)320, with the spectra facilitating deduction of the structure of cardiolipin:
the diacylglycerol phosphate region, the monoacylglycerol region, and the fatty acid
region320.
Mass spectrometry has been used by clinical laboratories to rapidly diagnose both
infectious and non-infectious diseases, detect drug toxicity, monitor treatment as well as
to discover new biomarkers323. However, clinical mass spectrometry systems such as
VITEK® MS by BioMerieux are expensive to set up and maintain and require trained
personnel to perform and analyze the tests limiting its utility as a point-of-care
diagnostic tool.
Nuclear magnetic resonance (NMR)

NMR spectroscopy is one of the most powerful analytical techniques for lipid analysis of
biological matrices (e.g., cells, tissue, and biological fluids), owing to the natural
abundance of hydrogen in such samples324–328. This method is nondestructive,
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nonselective, and provides detailed molecular information, which can be of extensive
value in analyzing amphiphilic biomarkers. Specifically, high-field proton nuclear
magnetic resonance (1H-NMR) spectroscopy is used for molecular profiling329,330,
allowing

for

identification

of

biomarkers

associated

with

diseases

such

as

tuberculosis331, cancer332,333, heart disease334; and others, identifying underlying causes
of disease335, and identifying diagnostic biomarkers and new therapeutic strategies336.
High-resolution, one-dimensional (1D) 1H NMR is reproducible and simple324,334. It has
been applied for metabolomics since the 1980s324,327, specifically, for plasma333,
serum337, urine338, and feces339. Tissues are normally examined intact328 and spectra
can be obtained rapidly (< 5 min)324 with detection limits around 1 to 10 µM at > 500
MHz327,335 MS and NMR are often used in conjunction with one another335,340. Although
NMR has decreased sensitivity in comparison to MS335,341, it has other advantages such
as being a non-destructive technique with minimal sample preparation, and providing
quantitation of molecular structures303,341. Coupling the two method yields significantly
greater sensitivity (attomole to femtomole)342.
Lipidomic NMR is associated with many challenges. A substantial number of
biomolecules in complex matrices have similar resonances, due to similar proton
chemical shift ranges327,343 resulting in considerable peak overlap327,344 and a low
signal-to-noise ratio345. Minimizing peak overlap and increasing sensitivity can be
resolved by using high resolution spectrometers (800 to 950 MHz)346. Resonance line
broadening347 attributed to the formation of micelles in an aqueous environment or
constrained molecular movement as a result of lipid aggregation into bilayers327 is
another challenge that is overcome by chemical or physical treatment of the sample327.
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The use of two-dimensional (2D) NMR348,349 can also overcome the above
challenges of 1D 1H NMR. 2D techniques such as the heteronuclear single quantum
coherence (HSQC) method are better suited for lipid profiling because of its ability to
detect resonances for both 1H nuclei and
between 1H and

13

C nuclei345, thus allowing for correlation

C chemical shifts and providing elucidation of C-H bonds within a

structure335. Although detection of
13

13

13

C is possible with HSQC, the natural abundance of

C350 is relatively low requiring prior enrichment of cells with

13

C331, 2D NMR is more

time consuming (> 1 hr/spectrum) in comparison to 1D 1H NMR (< 10 min)335,338,351.
Absolute quantitation of lipids using NMR remains a challenge352.
High resolution NMR has been shown to detect a variety of diseases directly in
human tissue and fluid samples353. Portable NMR-based biosensors have also been
developed for use as medical diagnostics354. However, portable NMR sensors suffer
from low sensitivity and specificity while high-resolution NMR tools require expensive
equipment and trained personnel to analyze results.
Biosensors

Broadly defined, biosensors recognize target molecules and produce a measurable
signal. Optical, electrochemical and mechanical biosensors (Figure 5.1) have been
adapted for the detection of lipidic and amphiphilic biomarkers, using a variety of assay
methodologies which can be categorized as a) labeled and b) label-free. Labeled
assays indirectly measure binding of an analyte to the target molecule, using a reporter
molecule (an indicator). Labeled assays have the advantage of readily multiplexing,
highly desirable in clinical applications. Label-free assays measure signal changes
89

directly associated with either target binding or cellular processes, without the need for
an external reporter. The advantages of label-free biosensors include reduced assay
complexity, cost and decreasing interference of the label on binding between ligand and
target.

Figure 5.1. Examples of biosensor techniques incorporating lipids for the detection of analytes
include (a) optical (b) electrical and (c) mechanical.

Optical biosensors detecting lipids
Optical biosensors measure binding-induced changes in light from the sensor
surface. Surface plasmon resonance (SPR) is a label-free technology that has been
used to detect the interaction of amphiphilic molecules with lipid bilayers, for ligand
screening and biomarker discovery355. In SPR sensing, a ligand is immobilized on a
gold-coated surface while an interacting molecule is injected in aqueous solution, and
the change in resonance associated with binding is measured optically using a
spectrometer. SPR has been optimized for measuring protein-protein affinities using the
BIAcore™ (GE Healthcare) system. In original iteration, SPR systems lack resolution,
cannot multiplex, and are difficult to miniaturize. However, several researchers are
working on overcoming these limitations, which may provide for more robust sensors in
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the future356. SPR is not conducive for detection of amphiphiles in biologically relevant
conditions, as required for diagnostic applications.
Interferometry, particularly Backscattering interferometry (BSI), allows for label-free
detection of both surface-bound and free-solution molecules357. In BSI, excitation of a
microfluidic channel containing the sample, as well as the channel surface, usually
made of polydimethylsulfoxide or glass, yields interference fringes. Changes in fringes
associated with binding of two molecules are measured in the backscatter region. BSI
detects interactions of amphiphiles with lipid bilayers358 directly in human serum359.
However, in complex samples, non-specific interactions and associated changes in
refractive index can prove challenging, but can be limited using suitable surface
functionalization chemistry360. BSI is inexpensive, sensitive and very versatile, making it
a promising candidate for detection of amphiphilic biomarkers in patient samples.
Ellipsometry measures the refractive index of a thin film, and has been utilized in
label-free assays where changes in refracted light are measured upon interaction of
giant lipid vesicles with a poly-L-lysine coated surface, using a biosensor based on total
internal reflection imaging ellipsometry (TIRIE)361. This sensor can detect µm size
particles such as cells, capsules and liposomes. However, the ability to detect such
particles in tissues, as well as the overall clinical utility of this system is yet to be
demonstrated.
An optical assay based on UV absorption of lipid-functionalized gold nanorods has
been used to detect the lipopeptide myristoyl-Lys-Arg-Thr-Leu-Arg, and a variety of
other lipid biomarkers, in serum362. However, the low specificity of this label-free
technique requires mass spectrometry analysis in order for multiplexing.
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In labeled assays, the target molecule is immobilized on the surface of a biosensor
and then probed with an analyte, typically an antibody, coupled to a label (fluorophore,
quantum dot, radioisotope, enzyme)363. Mukundan et al. have employed an optical
waveguide-based biosensor measuring only surface-bound fluorescent signals from
labeled antibodies for the sensitive and specific detection of lipid and amphiphilic targets
directly in clinical samples184,364,365. This system utilizes the interactions of these
biomarkers with lipid bilayers and lipoproteins to capture them directly to the waveguide
surface, followed by probing with labeled-antibodies excited by waveguide-coupled
laser light (Figure 5.2). This system has been demonstrated to effectively detect
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amphiphilic biomarkers associated with Mycobacterium tuberculosis56,72, M. bovis280,
Escherichia coli366, Salmonella Typhimurium74, influenza367, tumor markers368,369
oftentimes directly in human serum, proving potential utility as a diagnostic tool184,365.
These assays have been multiplexed for the simultaneous detection of several
biomarkers364. However, the main disadvantage of using labeled reagents is the time

Figure 5.2. Immunoassay strategies to detect lipid and amphiphilic biomarkers using (a) membrane
insertion or (b) lipoprotein capture.

and cost of the labeling process, and shelf life of the labeled ingredients370.
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Electrochemical biosensors detecting lipids

Electrochemical sensing is a label-free method where an electrode is used to
directly detect associated reactions371. Electrochemical biosensors have had the
greatest commercial success (glucose monitors) due to their low-cost, ease of use and
miniaturization properties372. Amperometric sensors measure current typically as a
result of electron transfer during the binding between a molecule, and chemically
functionalized surface, as exemplified in the detection of LPS using redox diacetylenic
vesicles on a sol-gel thin-film electrode373. Another example is the binding of cholera
toxin to a glycosphingolipid ganglioside GM1 coated gold surface, which has been
developed into a sensitive, low-cost sensor374. Potentiometric sensors measure
potential or charge accumulation and have been used to detect lipid antigens375 such as
amphiphilic cholesterol using lipid films376,377, without interference from ascorbic acid,
glucose, urea or other proteins and lipids. In addition, label-free electrochemical
biosensors have been developed for the detection of lipids such as low-density
lipoprotein (LDL) with high sensitivity and specificity378,379. These sensors have also
displayed long-term stability and high reproducibility with small sample volumes, which
make for a promising clinical tool. However, a problem with electrochemical detection of
biomarkers is specificity of detection in complex biological samples, as these platforms
are more sensitive to even small perturbations in the background, which is always a
possibility in clinical measurements.
Mechanical biosensors detecting lipids
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Mechanical biosensors provide rapid and sensitive measurements without extensive
sample processing, ideal for clinical application. The two main mechanical sensing
techniques are based on cantilever and quartz crystal microbalances (QCM), both of
which are label-free. QCM detects changes in resonance frequency on the sensor
surface from increased mass due to analyte minding372. QCM has been used to observe
the formation of supported lipid bilayers in real-time380 and lipid exchange between a
bilayer and vesicle381. The latter measures mechanical bending of a receptorfunctionalized microcantilever upon binding of the target molecule, as demonstrated for
LPS382. Another example is the measurement of the interaction between amyloid-β and
the cell membrane as an early indicator of Alzheimer's disease383. A major drawback to
cantilever sensors is that they often operate in air, rather than liquid samples, limiting
their clinical utility
5.4 Lipid Biomarkers for Infectious Diseases
Rapid diagnosis is important to halt the spread of both endemic and emerging
pathogens, as well as multi-drug resistant organisms384. Infectious diseases are caused
by bacterial, viral, fungal and parasitic organisms and are routinely diagnosed using
culture, microscopy, serology and genetic tests385, all of which are time-consuming and
performed by trained laboratory personnel. Several biosensors have been developed for
diagnosis of infectious diseases297, however all come with challenges that limit their
application in the clinic. Many biomarkers associated with infectious diseases are
amphiphiles, which are difficult to detect, especially in aqueous blood (Table 5.2).
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Biomarker

Disease

Location

Lipopolysaccharide
(LPS)

Sepsis

Blood

Urinary tract infection
Antimicrobial
resistance
Sepsis

Urine
Any sample

Tuberculosis

Urine
Blood
Blood

Lipoteichoic acid
(LTA)
Lipoarabinomannan
(LAM)
Lipomannan (LM)
OmpK36 porin
Hemozoin (HZ)

Bovine tuberculosis
Antimicrobial
resistance
Malaria

Blood

Any sample
Blood

Interacting
molecules
LBP, HDL, LDL,
holotransferrin
n.d.
n.d.

Reference

HDL, LDL, VLDL
LBP, holotransferrin
n.d.
HDL
HDL

387,391

n.d.

390

386,387
388
389

T
a
b
l
e

390

388
211

5
.
2
.

72
280

392

LBP, HDL, LDL,
VLDL, apolipoprotein
E, α-1-antitrypin
LBP: LPS-binding protein; HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very
low density lipoprotein; n.d.: not determined

S
e
l
e
c
t
l
i

pid and amphiphilic biomarkers used for the diagnosis of infectious diseases.

Sepsis
Sepsis is an infection of the bloodstream resulting in uncontrolled activation of the
immune system393. Morbidity and mortality results from organ failure, which can be
avoided with early and effective treatment, which in turn, requires rapid diagnostics394.
There are several lipid and amphiphilic biomarkers associated with sepsis. LPS (also
known as endotoxin) is a classic pathogen associated molecular pattern (PAMP) shed
by Gram-negative bacteria. LPS activates the innate immune receptor, Toll-like
Receptor 2, resulting in a cytokine cascade, which is the mechanism of endotoxic
shock395. The presence of LPS in patient blood is a clear indicator of sepsis. However,
detection of LPS in aqueous blood is complicated by the molecule’s amphiphilic
biochemistry, which drives it to associate with host carrier lipoproteins396 and other
molecules such as LPS-binding protein (LBP), high-density lipoprotein (HDL), low-
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density

lipoprotein

(LDL),

very

low-density

lipoprotein

(VLDL)

and

bactericidal/permeability-increasing protein388. Similarly, LTA is an amphiphilic cell wall
component of Gram-positive bacteria whose presence in blood also indicates sepsis.
Staphylococcus aureus LTA in human blood preferentially binds to HDL (68%), then to
LDL (28%), and minimally to very low density lipoprotein (4%)391. LBP also binds to
LTA388. These associations complicate the detection of amphiphilic LPS and LTA in
blood.
Mycobacterial infections
Lipoarabinomannan (LAM) is a biomarker for diagnosis of tuberculosis (TB)179,180,185,397.
LAM is an amphiphilic heat stable lipoglycan, which forms an integral component of the
mycobacterial cell wall179,185, and is secreted during TB infection. LAM has proved to be
an excellent diagnostic target especially in smear negative patients (HIV-positive,
pediatric population and others). Some limitations of LAM include assay cross reactivity
with common oral flora like Candida and Actinomyces that can result in lower predictive
value of detection92. LAM assays can be improved using standardized sample
processing methods and more sensitive sensor technology, as well as more specific
antibodies150. LAM is readily detected in urine (88,89), but not in blood, likely because it
associates with HDL in blood72. To this end, lipoprotein capture assays that utilize
antibodies to target HDL have been used to pull down bound LAM in serum
samples56,72,280. This method targets host pathogen interactions, can be applied to other
amphiphilic biomarkers in blood56. Pathogen biomarker based measurements can be
used in both human and animal hosts211,280. However, high cost of such technology, and
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biochemical nature of LAM are current challenges to the development of such
assays150.

Antimicrobial resistance

The global spread of antimicrobial resistance underlines the need for rapid and accurate
assays for the determination of resistant organisms prior to antibiotic treatment. A
common mechanism of antibiotics is inhibition of bacterial cell wall components, which
are lipid or amphiphilic molecules398. Modifications of membrane lipids are common
mechanisms of antimicrobial resistance in bacteria399,400 and the direct detection of such
changes would support effective treatment. In fact, targeting PAMPs that are highly
conserved, such as membrane lipids, for molecular diagnostics has a tremendous
benefit over approaches targeting more rapidly evolving aspects of bacterial physiology
(i.e. PCR). MALDI-TOF MS has been used to detect antibiotic resistance caused by
lipid alterations390. E.g.; detection of LPS alterations that reduce the molecules net
negative charge resulting in resistance to antimicrobial peptides such as colistin, and
OmpK36 porin loss in Klebsiella pneumoniae resulting in resistance to carbapenems.
However, the initial cost of setting up a clinical MALDI-TOF system is prohibitive toward
application in routine diagnostic settings.
Malaria
Hemozoin is an insoluble amphiphilic crystalline byproduct formed from the degradation
of blood by parasites such as Plasmodium falciparum, the causative agent of malaria392.
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Hemozoin is released into circulation upon erythrocyte lysis, and its presence in patient
blood is a direct indication of malarial infection401. Detection of hemozoin has mostly
been achieved using microscopy and flow cytometry in blood402. The amphiphilic nature
of hemozoin hampers its direct detection in blood due to sequestration by host immune
components401 such as apolipoprotein E and LBP392. Methods like Lipoprotein capture
can potentially be adapted for the detection of amphiphilic hemozoin in blood.
5.5 Lipid Biomarkers for Non-infectious Diseases
Non-infectious diseases including cancer and cardiovascular disorders are a result of a
malfunction

in

normal

physiological

processes.

Therefore,

identifying

specific

biomarkers for diagnosing non-infectious diseases presents a major challenge. Rather
than targeting a foreign molecule that is absent in a healthy patient, the diagnosis of
non-infectious diseases often measures irregularities in expression of host-derived
molecules403,404. Many lipid and amphiphilic molecules associated with human
metabolism can be used as biomarkers when differentially detected in diseased versus
healthy individuals (Table 5.3). Detection of such biomarkers can potentially be used to
determine prognosis, monitor recurrence, evaluate disease progression, and predict a
patient’s risk of developing a particular disease405.
Table 5.3. Select lipid and amphiphilic biomarkers used for diagnosing non-infectious diseases.
Biomarker

Disease

Location

Cholesterol

Cardiovascular
disease
Cancer
Preeclampsia
Lipotoxicity
Cardiovascular

Triglycerides

Reference

Blood

Interacting
lipoproteins
HDL, LDL

Blood
Blood

HDL, LDL
HDL, LDL

408,409

Blood
Blood

HDL, LDL
LDL, VLDL

412
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406,407

410,411

404,413,414

(TG)

Cardiolipin (CL)

disease
Cancer
Preeclampsia

Blood
Blood

LDL, VLDL
LDL, VLDL

408,409,415–420

Lipotoxicity

Blood

LDL, VLDL

412,423,424

Cardiovascular
disease
Cancer

Blood

LDL, HDL, VLDL

425

410,411,421,422

322,426

Brain tissue,
n.d.
Prostate
tissue
HDL: high-density lipoprotein; LDL: low-density lipoprotein; VLDL: very low density lipoprotein;
n.d.: not determined

Cardiovascular Diseases and Disorders

Cardiovascular diseases (CVD)427 account for 17.5 million deaths, accounting for 31%
of all deaths worldwide427. Heart attacks and strokes, mainly caused by a blockage that
prevents blood from flowing to the heart or brain account for about 80% of all CVD
deaths. In many cases, dyslipidemia, or abnormal levels of lipids in the blood, is a major
mediator of CVD428. It is typically characterized by increased levels of total cholesterol,
increased levels of low density lipoprotein cholesterol (LDL-C), increased levels of TG,
decreased levels of high density lipoprotein cholesterol (HDL-C), modified function of
lipid molecules, or a combination of some or all of these factors428–430. Cholesterol is a
major component of cell membranes, and contributes to their structural integrity and
fluidity403. Cholesterol is also a precursor of vitamin D and important steroid hormones
such as progesterones, glucocorticoids (cortisol), androgens (testosterone) and
estrogens403,431. Cholesterol homeostasis is critical to cardiovascular health. High
cholesterol can raise CVD risk407,432 by creation of sticky plaque deposits along arterial
walls, eventually blocking blood flow, causing heart attacks and strokes. LDL and HDL
are important carriers of cholesterol. Increased levels of LDL-C can cause cholesterol
buildup in arteries, resulting in their narrowing, raising cardiovascular risk433. HDL is a
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scavenger, carrying cholesterol away from the arteries and back to the liver for
breakdown406. A high TG level combined with high LDL-C and low HDL-C is linked with
fatty buildups in artery walls404,413,414.
Assessing CVD risk largely involves serum lipid profiling, focused on measuring
total cholesterol, HDL-C, LDL-C, and TG levels434, largely by use of labeled optical
immunoassay platforms. For instance, the Alere Cholestech LDX® System combines
enzymatic optical detection with solid-phase technology to rapidly and sensitively
measure total cholesterol, HDL cholesterol, triglycerides and glucose in a finger prick of
blood. Cholesterol is measured enzymatically in serum in a series of coupled reactions
that hydrolyze cholesteryl esters and oxidize the 3-OH group of cholesterol, byproducts
of which are measured colorimetrically435–437. TGs are measured enzymatically in serum
via a series of coupled reactions that produce glycerol, which is oxidized using glycerol
oxidase. H2O2, one of the reaction products, is measured colorimetrically435. In clinical
practice, the standard measure of HDL is quantification of its cholesterol content after
precipitation of apolipoprotein B (coat protein for LDL)435. Other techniques to determine
HDL-C in serum include ultracentrifugation, electrophoresis, HPLC, precipitation-based
method, direct measuring methods, and NMR435,438.
LDL-C is often determined using the “Friedewald formula” which incorporates
measured values for total cholesterol, HDL-C, and TG as: LDL-C = (total cholesterol) –
(HDL-C) – (TG/5)439. This equation assumes that the ratio of TG to cholesterol is
constant, which is not always the case. The Friedewald formula can thus underestimate
LDL-C at lower levels of LDL-C, and higher levels of TG (>400 mg/dL)440. Modifications
to the Friedewald formula have tried to address these shortcomings440. Direct LDL-C
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measurements

(e.g.

ultracentrifugation,

electrophoresis,

chemical

precipitation,

immunoseparation, and homogenous assays) are available, but standardization and
extensive validations are needed for use in clinical measurements440. For clinical
sampling, serum lipid serum profiles are determined using diagnostic test kits, and
analyzed with chemical automated continuous flow analyzers that use photometric and
colorimetric testing (Hitachi 7180/7020 Hitachi Clinical Analyzers, Randox RX Series
Clinical Chemistry Analyzers), and point-of-care devices (Alere Cholestech LDX
microfluidic device system, Professional CardioChek PA test strip system, Accutrend
Plus test strip system).
Many CVDs cannot be explained by these current standards441, as many patients
have lipid levels within the recommended range. Thus, there is a need for additional
biomarkers for early diagnosis and prevention of CVD. Several biomarkers have been
identified and are being explored for diagnostic potential. Cardiolipin is one such
biomarker, reduced concentrations and altered composition of which have been
implicated in cardiomyopathy associated with Barth Syndrome442,443. Diabetic
cardiomyopathy is characterized by altered lipid composition and mitochondrial
dysfunction443,444 and reduced cardiolipin metabolism has been implicated here as well.
Mitochondrial dysfunction due to reactive oxygen species effect has been shown to be
associated with cardiac ischemia/reperfusion306,308. Mitochondrial cardiolipin have been
proposed to undergo lipid peroxidation because of either their high content of
unsaturated fatty acids or because of their location in the mitochondria443,445. Oxidized
cardiolipin, a natural antigen that has pro-inflammatory effects, is also associated with
atherosclerosis443,446. Current methods to detect the pro-inflammatory effects and
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thrombosis induced by cardiolipin rely on determination of antibodies against oxidized
cardiolipin with commercially available standard enzyme-linked immunosorbent kits
(e.g. Orgentec Anti-Cardiolipin Screen, Germany)443,446.
Cancer
Cancer is the leading cause of death worldwide, with 8.8 million deaths in 2015427. Most
cancers are initially diagnosed either because of the appearance of signs or symptoms
of the disease, or via screening, which is not always available447. Definitive diagnosis is
by biopsy of the affected tissue. The main treatments for many cancers are surgery,
chemotherapy, and radiation therapy. The effectiveness of these treatments depends
on early diagnosis, which results in a higher chance of survivability447. Therefore, there
is a need for more research on molecular diagnostics based screening and early
detection of cancer.
Dyslipidemia has been proposed to have an association with an increased risk of
cancer, particularly breast and prostate cancers. Some studies exploring causal
associations between serum lipids and breast cancer have observed increased levels of
total cholesterol, TG, and LDL-C and decreased levels of HDL-C408,415,417,420. However
these trends are not always consistent448,449. Similar observations were made for
prostate cancer, with some studies showing an abnormal lipid trend, similar to breast
cancer149,408,409,418,419. Other studies found no correlation or opposite trends450–452. Thus,
we clearly do not have a good understanding of the pathophysiological effects of how
lipids levels contribute to cancer. Methods to detect serum lipid levels are similar to
those that are currently being applied to assessing cardiovascular disease, described in
the CVD section.
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Nobel laureate Otto Warburg claimed that cancer originated from irreversible injury
to mitochondrial respiration, the structural basis for which is still unclear453,454. A
possible hypothesis is that mitochondrial dysfunction induced by oxidative stress can
cause lipid peroxidation that contributes to the development of cancer322. One of the
culprits implicated as a candidate for lipid peroxidation is cardiolipin322. Kiebish et al.
found abnormalities in cardiolipin content or composition in several types of mouse
brain tumors, compared to normal brain322. These abnormalities were closely
associated with significant reductions in energy-generating activities322. ESI-MS showed
that the cardiolipin composition was significantly different in prostate tissue isolated from
normal individuals versus cancer patients426.
More discovery efforts need to be undertaken to understand the roles lipids play in
cancer455–458. Most of the findings suggest that there are abnormal levels of lipidsphosphatidylcholines,

phosphatidylethanolamines,

lysophosphatidylcholine,

lysophosphatidic acid, LysoPI, ceramides, cholesteryl oleate- in biological samples from
cancer patients than in normal ones455–458.
Detection of lipidated biomarkers has been explored for many cancers. For
instance, the carcinoembryonic antigen (CEA) has been implicated in a variety of
cancers such as breast, colorectal, pancreatic and others459–461. Detection of CEA is
mainly performed using targeted antibodies, and optical detection platform – labeled
immunoassays. Studies have found that serial CEA measurements can detect recurrent
colorectal cancer with ~80% sensitivity and 70% specificity, 5 months in advance of
other diagnostics! CEA has been suggested to be the most frequent indicator of
recurrence in asymptomatic patients and detection of this biomarker is the most cost104

effective test for the preclinical detection of resectable disease. CEA is most useful for
the early detection of liver metastasis in patients with diagnosed colorectal cancer. The
biomarker is also valuable as a prognostic indicator for breast cancer462. In addition to
optical colorimetric measurements, radioimmunoassays have also been used for CEA
measurement463–467. Our team has developed and validated the measurement of CEA
in serum and nipple aspirated fluid from patients with abnormal mammograms using a
fluorescence sandwich immunoassay on a waveguide-based optical biosensor platform,
demonstrating picomolar sensitivity of detection of the antigen368,369. The challenges
with CEA detection include the fact that the biomarker has been implicated with other
non-cancerous conditions such as smoking, and that the presence of the biomarker in
blood is not specific indicator of a type of cancer.
Another significant cancer biomarker family, the Carbohydrate antigens, are also
amphiphilic and belong to the mucin-class of molecules, which promote cancer cell
proliferation and inhibits anti-cancer immune responses468. Of these, CA125 is best
known as a biomarker to monitor epithelial ovarian cancer and for the differential
diagnosis of pelvic masses469,470. Serum levels of CA125 are routinely monitored in
patients with ovarian cancer as prognostic indicators of cancer recurrence. Genway
Biosystems has developed a colorimetric immunoassay for this biomarker, which is just
one of several such assays available for this target. CA15-3 (MUC1) is yet another
biomarker, which has been extensively implicated in a variety of cancers, and is
routinely used as a prognostic indicator, and a measure of cancer severity471. Again,
immunoassay methods, including radioimmunoassay methods are used for the
measurement of these antigens in serum. These assays lack sensitivity and specificity,
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and are associated with a high false-positive rate, which needs to be addressed to
increase their clinical utility. For example, Roche Laboratories has developed an
electro-chemiluminescence assay for the detection of CA15-3 in blood. These
immunoassays utilize a ruthenium-complex and tripropylamine. The chemiluminescence
reaction for the detection of the reaction complex is initiated by applying a voltage to the
sample solution resulting in a precisely controlled reaction.
Detection of exosomes has been explored for many cancers. Exosomes are small
heterogeneous extracellular vesicles (40 – 150 nm) released by most cell types in bodily
fluids such as urine, plasma, saliva and breast milk472,473. While their exact function is
still relatively unknown, the current theories are that they are involved in intracellular
communication and cellular waste disposal472,473. The lipid composition of exosomes
includes many different lipid classes as well as DNAs, RNAs and proteins.

The

exosomes are believed to contain the molecular constituents of the cell that they were
derived from. In particular, exosomes have been identified as a potential biomarker for
early detection and prognosis of cancer as they promote tumorigenesis, growth,
progression and metastasis472–475. Exosome secretion by cancer cells is considerably
up regulated compared to non-cancerous cells. RNAs (messenger RNA, microRNA,
long non-coding RNA), DNAs (mitochondrial DNA, single stranded DNA, double
stranded DNA), and proteins (small Rab family GTPases, annexins, survivin, CD9, CD
24 and CD34) are endosomal payloads that have been found to be elevated or altered
in cancer cells compared to non-cancerous cells474–476. Quantitative real-time
polymerase chain reaction, nucleic acid sequencing, antibody-based methods for
detection and quantitation (e.g. Western blot, ELISA), nanoparticle tracking, dynamic
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light scattering, flow cytometry, transmission electron microscopy have all been applied
to the detection and quantification of endosomes as well as the characterization of the
contents of the endosomes474–476.
Preeclampsia
Preeclampsia (PE) is a complex pregnancy disorder that is characterized by
hypertension and proteinuria477. PE affects 2-8% of pregnancies worldwide. It is the
most common pregnancy complication and is associated with high maternal and
perinatal mortality. PE may be life-threatening for both mother and child, increasing both
fetal and maternal morbidity and mortality478,479. In the mother, PE may cause
premature cardiovascular disease, such as chronic hypertension, ischemic heart
disease, and stroke478,479. Children birthed from preeclamptic pregnancies have an
increased risk of stroke, coronary heart disease, and metabolic syndrome478,479. While
the pathophysiology of PE remains unclear, this disorder is mediated abnormal
placentation that trigger endothelial dysfunction, resulting in vasoconstriction,
thrombosis, and end-organ ischemia477. Dyslipidemia has been shown to be associated
with an increased risk of preeclampsia411,480. Several meta-analysis studies, which
involved PE case-control studies as well as prospective cohort studies show that while
this abnormal lipid pattern may involve increased TC, TG, LDL-C and decreased HDLC, the results are not always consistent410,411,421,422. However, in many of these studies
there

seems

to

be

a

clear

consensus

of

raised

TC

levels,

resulting

in

hypertriglyceridemia410,411,421,422. It is still unclear whether hypertriglyceridemia is a risk
factor for preeclampsia or whether there is any causal association between
them411,421,422. More studies need to be done to understand the role maternal TG plays
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the pathophysiology of PE. Because PE display an abnormal serum lipid profile, many
of the bioassays and methods developed for CVD are readily applied to test for PE.
These bioassays and methods have been discussed in the CVD section. Recent mass
spectrometry based lipidomic studies have revealed several potential lipid biomarkers
associated with PE319,481. These include oxidized cholesterol, cholesteryl ester, oxidized
sphingomyelin, ceramide, glycerophosphocholine, and lysophosphatidylcholines.
Lipotoxicity
Lipotoxicity is a metabolic disorder characterized by excessive accumulation of fatty
acids within the cell and has been implicated in the development of heart failure, obesity
and diabetes482,483. Adipose tissues play a critical role in energy storage484. Adipocytes,
the primary cells forming adipose tissue, contain cytosolic lipid droplets composed of a
core of neutral lipids, including sterol esters and TGs, surrounded by a phospholipid
monolayer484–490. Lipotoxicity is the abnormal accumulation of lipid droplets in nonadipose tissues, which leads to mitochondrial dysfunction, inhibition of ATP generation,
and ultimately cell death by apoptosis483,491,492. Manifestation of lipotoxicity typically
occurs in kidney, liver, heart and skeletal muscle483. For example, a disease estimated
to affect 10 to 24% of the global population493 is the accumulation of fat within the liver
termed nonalcoholic fatty liver disease (NAFLD)494. NAFLD is characterized by
increased hepatocyte accumulation of TGs within the cytosol495 and can progress from
fatty liver accumulation to liver fibrosis and cirrhosis493,496. Serum TG and cholesterol
have been implicated as potential biomarkers for lipotoxicity and are currently detected
using serum lipid profiling as described in the CVD section412,423,424.
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5.6 Discussion

Amphiphilic and lipidic molecules are significant mediators in a variety of biological
processes associated with infectious diseases and non-infectious conditions such as
cancer and CVD. Many of the PAMPs secreted by bacteria are amphiphilic, as are a
significant proportion of biomarkers associated with neurological processes. Many
cancer signatures are also lipidated. Thus, ignoring this unique category of molecules
will only limit our understanding of host-pathogen biology and disease processes.
Because of the challenges in raising antibodies to such targets, and developing
sensitive labeled assays, many of these biomarkers are not efficiently used in the
diagnosis of disease. The biochemistry of these molecules should be considered in the
design and execution of these assays. For instance, the conformation of the amphiphilic
biomarkers changes dramatically depending on the milieu in which they are present
(Figure 5.3), and the critical micelle concentrations of these molecules. Lipidated
biomarkers adhere to plastic surfaces, decreasing sensitivity of their detection. These
characteristics also manifest themselves in physiological samples such as blood.
Amphiphilic molecules, depending on their critical micelle concentration, will either selfaggregate into micelles, or associate with carrier moieties such as HDL and LDL,
making their direct and rapid detection more challenging (Figure 5.3). Understanding
the biochemical characteristics of the amphiphilic targets and anticipating the impact of
these features in physiological systems can allow for the development of tailored,
sensitive assays for their detection.
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Figure 5.3. A comparison of the sensitivity of membrane insertion and lipoprotein capture technologies
for the measurement of amphiphilic biomarkers based on the medium of presentation (serum vs. buffer).
Biomarkers that are readily detected in (a) phosphate buffered saline (PBS) can be poorly observed in (b)
serum when utilizing a membrane insertion assay strategy, because of the uptake of these signatures by
host serum carrier molecules. This signal can be recovered if (c) lipoproteins are incorporated in the
assay format, exploiting the host pathogen interaction for maximal sensitivity of detection.
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6.1 Abstract
Lipoarabinomannan (LAM), an amphiphilic lipoglycan of the Mycobacterium tuberculosis
cell wall, is a diagnostic target for tuberculosis. Previous work from our laboratory and
others suggests that LAM is associated with host serum lipoproteins, which may in turn
have implications for diagnostic assays. Our team has developed two serum assays for
amphiphile detection: lipoprotein capture and membrane insertion. The lipoprotein
capture assay relies on capture of the host lipoproteins, exploiting the biological
association of host lipoprotein with microbial amphiphilic biomarkers to “concentrate”
LAM.

In contrast, the membrane insertion assay is independent of the association

between pathogen amphiphiles and host lipoprotein association, and directly captures
LAM based on its thermodynamic propensity for association with a supported lipid
membrane, which forms the functional surface of an optical biosensor. In this
manuscript, we explored the use of these assays for the detection of LAM in sera from
adults whose tuberculosis status had been well-characterized using conventional
microbiological tests, and endemic controls. Using the lipoprotein capture assay, LAM
signal/noise ratios were >1.0 in 29/35 (83%) individuals with culture-confirmed active
tuberculosis, 8/13 (62%) individuals with tuberculosis symptoms but no positive culture
for M. tuberculosis, and 0/6 (0%) symptom-free endemic controls. To evaluate serum
LAM levels without bias associated with potential differences in circulating host
lipoprotein concentrations between individuals, we subsequently processed available
samples to liberate LAM from associated host lipoprotein assemblies followed by direct
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detection of the pathogen biomarker using the membrane insertion approach. Using the
membrane insertion assay, signal/noise for detection of serum LAM was greater than
that observed using the lipoprotein capture method for culture-confirmed TB patients
(6/6), yet remained negative for controls (2/2). Taken together, these results suggest
that detection of serum LAM is a promising TB diagnostic approach, but that further
work is required to optimize assay performance and to decipher the implications of
LAM/host lipoprotein associations for diagnostic assay performance and TB
pathogenesis.
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6.2 Introduction
Tuberculosis (TB) is the leading cause of global mortality associated with a single
infectious disease, and is estimated to afflict 10 million people worldwide (2018),
with ~ 1.3 million deaths197. The World Health Organization has identified the need for a
non-sputum diagnostic test for TB, particularly extrapulmonary TB and pulmonary TB
associated with low bacillary burden in airways, as can occur in young children and in
individuals with HIV co-infection67.
Accordingly, several biomarkers have been explored for the empirical diagnosis of TB,
with lipoarabinomannan (LAM) arguably being the most studied70,497,498. LAM is an
amphiphilic lipoglycan component of the Mycobacterium tuberculosis (MTB) cell wall
that has in vitro immunomodulatory activity including activation of the Toll-like receptor 2
pathway284,499,500. Following the findings of Hamasur et al. that LAM was detectable in
mouse urine within one day after intra-peritoneal injection of crude MTB cell wall extract,
most clinical diagnostic work focused on detection of LAM in urine85,94,501,502. One lateral
flow urinary LAM assay is now commercially available (Alere Determine™ TB LAM Ag,
Abbott Biotechnologies). However, the sensitivity of the Alere assay is suboptimal –
ranging from 42% in HIV-negative TB patients to 53% in TB patients with advanced HIV
disease, a condition in which total mycobacterial burden can be very high and occult
renal TB can be present47,499,503. The next generation Fujifilm SILVAMP TB-LAM
(FujiLAM; Fujifilm, Tokyo, Japan), a lateral flow test incorporating high-affinity
monoclonal anti-LAM antibodies and, has 30% better sensitivity compared to Alere LAM
but needs further validation in clinical settings141. Several other LAM assay formats
including FujiLAM with enhanced sensitivity are in development85,141.
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The amphiphilic biochemistry of LAM confers instability in aqueous milieu such as
blood. Previous work from our team has shown that, in human blood, LAM associates
with host lipoproteins such as high density lipoproteins (HDL). In aqueous blood, HDL is
a stable lipidic assembly comprised of a core lipid nanodisc stabilized by coat
apolipoproteins73,141,503. While LAM has been extracted from blood of TB patients504,
direct measurement of LAM in blood or serum has proved to be more elusive, and
achieved mainly in individuals with advanced HIV disease211,504,505. We hypothesized
that sequestration of LAM in host lipoprotein assemblies may contribute to the difficulty
in detecting the antigen in blood. In parallel assessment of LAM in serum and urine from
TB patients using an electrochemiluminescence immunoassay, Broger et al. showed
substantially lower assay sensitivity in serum than in urine, but that matrix inhibition of
serum could largely be reversed by heat treatment, resulting in substantial increases in
LAM signal in tested sera83.
To evaluate the impact of serum sequestration of LAM in host lipoprotein complexes,
we measured serum LAM using two methods tailored for the detection of amphiphilic
biomarkers in aqueous matrices (Fig 6.1) – lipoprotein capture and membrane insertion.
The lipoprotein capture assay (Fig 6.1) relies on capture of host lipoproteins, exploiting
their biological association with the pathogen amphiphile to “concentrate” LAM72,506. In
contrast, the membrane insertion assay (Fig 6.1) is independent of that host
lipoprotein/LAM association, and directly captures LAM based on its thermodynamic
propensity for association with a supported lipid membrane which forms the functional
surface of a biosensor184,211,506. Although both of these assays are platform ambivalent,
we used enzyme linked immunosorbent assays (ELISA) and fluorescence
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measurements from a waveguide-based biosensor platform developed at the Los
Alamos National Laboratory for this study72,365. There are two limitations that impact the
use of conventional plate-based methods for the detection of LAM. 1) LAM is an
amphiphile and therefore, sticks to plastics and other surfaces, reducing assay
reliability, sensitivity and reproducibility. 2) In clinical samples, LAM is already
sequestered by host lipoproteins and not available in free-form72. It has to be detected
in this conformation or liberated from it to facilitate detection. In this manuscript, we
have attempted to develop methods that address both these limitations. Both the
assays are performed on a surface functionalized with lipid bilayer, and therefore
override the challenges of using plastic ELISA plates in concert with amphiphiles.
Further, we have consistently shown that the use of the waveguide platform offers at
least 10X greater sensitivity than conventional plate-based ELISA, which is an
advantage when it comes to sensitive detection of pathogen antigens in complex clinical
samples285,369.
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Figure 6.1. Overview of Lipoarabinomannan (LAM) detection strategies. When LAM is associated
with a host lipoprotein carrier such as HDL, detection can be performed using lipoprotein capture, which
requires two antibodies, as well as prior knowledge of LAM-lipoprotein carrier associations. An antibody
targeting apolipoprotein A1, the coat protein of HDL, is used to capture the nanodiscs on the assay
surface, followed by detection with a fluorescently labeled antibody targeting LAM. In the absence of
sequestration by a host lipoprotein carrier, LAM can be directly detected by membrane insertion, which
requires only one antibody. The amphiphilic antigen, LAM, is allowed to partition into a supported lipid
bilayer interface, followed by detection with a specific fluorescently labeled antibody. Graphic
representations are not drawn to scale. Figure created with BioRender.com.

In this manuscript, we evaluated the use of the above two assays- lipoprotein capture
and membrane insertion- for the direct detection of LAM in serum from carefully
characterized samples from tuberculosis patients, and endemic controls.
6.3 Methods
Clinical specimens
This study used existing stored specimens that previously had been obtained from
participants in Uganda for a study that evaluated the diagnostic accuracy of the Alere
Determine™ TB LAM Ag assay100. That diagnostic accuracy study enrolled HIV-positive
adults suspected of having active tuberculosis based on the presence of at least one of
cough, fever, night sweats, or weight loss. Individuals were excluded if they had
received more than two days of anti-tuberculosis treatment. At enrollment, each
participant provided two sputum specimens, each of which was cultured in liquid and
solid media. One mycobacterial blood culture, performed using the Myco/F LYTIC
system (Becton and Dickinson, Franklin Lakes, NJ), was performed for each participant
at enrollment. A participant was considered to have active TB if M. tuberculosis was
isolated in culture from any specimen. Neither Xpert MTB/RIF nor other nucleic acid
amplification test was performed on sputum, since those tests were not available on-site
at the time of study enrollment. At enrollment, blood was drawn into a BD Vacutainer
serum separator tube (Becton and Dickinson), and serum was subsequently withdrawn
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and immediately frozen at -80°C until used for this study. For this exploratory study, one
of the investigators (SED) selected specimens based on knowledge of participant
microbiological classification, with intent to include a representative spectrum of
participants with and without culture-confirmed TB. Samples were selected on the basis
of culture results and sent to LANL in a double blinded fashion. Additionally, we used
existing de-identified serum specimens from six Ugandan adults who did not have TB
symptoms and were not known to be HIV-positive; no additional meta-data were
available for these specimens. Samples were thawed immediately prior to use for the
studies described here. If multiple assays were performed on a single serum sample,
lipoprotein capture was performed first with the fewest possible freeze/thaw cycles to
avoid degradation of lipoprotein carriers.
Ethics
This study was approved by ethics committees of Johns Hopkins University School of
Medicine, the Joint Clinical Research Centre (Kampala, Uganda), and Los Alamos
National Laboratories. All participants provided written informed consent.
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Reagents and materials
Anti-LAM monoclonal antibody (CS40), rabbit anti-LAM polyclonal antibody, and purified
LAM (H37Rv) used in validation and optimization assays were obtained from
Biodefense and Emerging Infections Resources (BEI resources, Manassas, VA). AntiLAM monoclonal antibodies used in the reporter cocktail (see below) were a generous
gift from the Foundation of Innovative New Diagnostics (FIND, Geneva, Switzerland).
Biotinylated anti-ApoA1 antibody (ab27630) was purchased from Abcam (Cambridge,
MA). Alexa Fluor 647 conjugated streptavidin (S21374), 1-Step Ultra TMB-ELISA
Substrate Solution (34028), EZ-Link Plus Activated Peroxidase kits, Alexa Fluor 647
labelling kits, and polystyrene flat-bottom 96 well plates (Corning 9017) were purchased
from Thermo Fisher Scientific (Waltham, MA). Bovine serum albumin (BSA, A7906) and
Dulbecco’s phosphate buffered saline (PBS, D1408) were obtained from Sigma Aldrich
(St. Louis, MO). Human serum was obtained from Fischer Scientific Inc (Catalogue. No.
BP2657100). 1, 2-Dioleoyl- sn-glycero-3-phosphocholine (DOPC) and 1, 2-dioleoyl-snglycero-3-phosphoethanolamine-N- (cap biotinyl) (sodium salt) (cap Biotin) were
obtained from Avanti Polar Lipids (Alabaster, AL).

Waveguide-based optical biosensor
The waveguide-based optical biosensor was developed at Los Alamos National
Laboratory and is described in detail elsewhere365. Waveguides were custom
engineered by nGimat Inc (Norcross, GA) and the surface chemistry was performed at
Spectrum Thin Films (Hauppauge, NY). Silicone gaskets for waveguide assembly were
from Grace Bio-Labs (Bend, OR) and Secure seal spacers (9 mm diameter x 0.12 mm
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deep) were from Electron Microscopy Sciences (Hat- field, PA). Glass microscope
slides used as coverslips were purchased from Thermo Fisher Scientific (Rockford, IL).

Waveguide preparation and flow cell assembly
Single mode planar optical waveguides were used for functionalization as previously
described363. Briefly, waveguides and glass coverslips were cleaned by sequential
sonication in chloroform, ethanol and water (5 min each), followed by drying under
argon stream and exposure to UV-ozone (UVOCS Inc., Montgomeryville, PA) for 40
min. Flow cells for immunoassays were assembled using clean waveguides and cover
slips, which were bonded together with a silicone gasket containing a laser cut channel
creating a flow cell. Following assembly, the flow cell was injected with 70 µl of lipid
micelles (preparation described below) and then incubated overnight at 4 °C to facilitate
vesicle fusion and lipid bilayer stabilization.

Lipid micelle preparation
1, 2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1, 2-dioleoyl-sn-glycero-3phosphoethanolamine-N- (cap biotinyl) (sodium salt) (cap biotin) were obtained from
Avanti Polar Lipids (Alabaster, AL), resuspended in chloroform and stored at −20 °C.
Lipid micelles for use in waveguide experiments were prepared as described
previously211. Briefly, 2 mM DOPC and 1% cap biotinyl (mol/mol) were combined in a
glass tube then the chloroform was evaporated off under argon gas. Lipids were
rehydrated in PBS, incubated in the dark for 30 min at room temperature with shaking
(100 rpm) on an orbital shaker. Lipid solutions then underwent 10 rapid freeze/thaw
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cycles alternating between liquid nitrogen and room temperature water. Finally, lipids
were probe sonicated for 6 min total (1.0 sec pulse on/off, 10% amplitude) using a
Branson ultrasonic generator. Once the lipids were stabilized, the addition of biotin
allowed for the bilayer integrity to be evaluated during immunoassay experiments by
probing with 50–100 pM of a streptavidin Alexa Fluor 647 conjugate184,363.

Waveguide-based assays
All incubations occurred at room temperature. Dilutions of all reagents were made in
PBS. Flow cells were prepared as described above and the lipid bilayer was blocked for
1 hr with 2% BSA in PBS (w/v). All incubations were immediately followed by a wash
with 2 mL of 0.5% BSA in PBS (w/v) to remove any unbound constituents. Incident light
from a 635 nm laser (Diode Laser, Coherent, Auburn, CA) with power adjusted to
440−443 µW was coupled into the waveguide using a diffraction grading. The response
signal was adjusted for maximum peak intensity using a spectrometer (USB2000,
Ocean Optics, Winter Park, FL) interfaced with the instrument and an optical power
meter (Thor Labs, Newton, NJ)74.
The background signal associated with the lipid bilayer and 2% BSA block was
recorded, and then the integrity of the lipid bilayer was assessed by incubation of
50−100 pM streptavidin, AF647 conjugate (Molecular Probes, S32357) for 5 min. The
two control steps are performed in every experiment as intrinsic controls. The remaining
assay steps depended on the particular assay as described below. The antibodies used
in this assay (FIND Clones 171 and 24) were labeled with AF-647, and the optimal
combination of antibodies and their concentrations were determined using Enzyme
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Linked Immunosorbent Assays (S1 Fig., Section S1, Supplemental Information). The
incubation times for the assays were optimized in all cases by standard measurements
using LAM spiked into commercially procured human serum. The antigen titrations were
performed on the waveguide-based biosensor.
Lipoprotein capture assay. Host HDL lipoproteins are nanodiscs of lipids that are
held together by a coat protein, Apolipoprotein A1. The lipoprotein capture assay
utilized an anti-apoA1 capture antibody for the capture of HDL lipoproteins onto the
sensing surface. Following the test for lipid bilayer integrity (instrument controls), 10 nM
unlabeled streptavidin was added and incubated for 10 min to saturate the biotin
embedded in the lipid bilayer. Next, 100 nM of biotin conjugated α-apoA1 (α-HDL)
antibody was added and incubated for 45 min, allowing for the capture antibody to
adhere to the surface via biotin-streptavidin interaction. The surface is now
functionalized with the capture antibodies for the lipoprotein capture assay. Prior to
experimental measurement, however, the non-specific signal was determined by
incubation of the fluorescence reporter antibody, FIND antibody cocktail labeled with
AF647 (15nM each antibody, for 45 min), with control human serum on to the
waveguide surface. This allows for the determination of the fluorescence signal
associated with the interaction of the reporter antibody with the surface and control
serum, in the absence of the antigen (no-antigen control).
Upon completion of the control measurements above, the antigen was added, and
specific interaction between LAM and the reporter antibody cocktail was measured. To
generate standard LAM concentration curves, varying concentrations of MTB H37RV
LAM (100, 250, 500, 1000, 1500, 2500, 5000 nM) were spiked into commercially
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procured human serum, and incubated for 24 hours to allow for complete association
with lipoproteins. For clinical specimens, 200 µL of serum was used for each assay, and
directly added to the flow cell. Upon incubation, the FIND reporter cocktail was again
added, and the specific signal associated with the binding of LAM with the antibodies
was measured via the spectrometer interface.
Three sets of controls were performed (n=25 each). The instrument background
signal is an assessment of the biosensor function and bilayer integrity. No antigen
control experiments were performed using control serum, in the absence of LAM.
Specificity controls were performed using anti-LAM antibodies (FIND 171 and 24), and
measuring the signal associated with their interactions with LAM functionalized on the
biosensor surface. In all experiments, raw data were recorded as relative fluorescence
units (RFU) as a function of wavelength (nm). The specific/non-specific ratio (S/N) was
determined by taking the maximum RFU value for the specific signal, subtracting out the
RFU value for the instrument controls, specificity and no-antigen controls (henceforth
referred to as the background) and dividing this by the maximum RFU value for the nonspecific signal minus the maximum RFU value for the background [Equation (1)].

(Specific – Background)
S/N =
Equation (1)

(NS – Background)

Membrane insertion assay. For this assay, LAM is released from host lipoprotein
complexes prior to detection via a pre-established sample processing method310. Briefly
processing

was

performed

using

a

modified

single-phase

Bligh

and

Dyer

chloroform:methanol extraction. Chloroform, methanol and LAM sample (either standard
or clinical) were combined in a siliconized microfuge tube (Fisher Scientific, 02-681-320)
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at a 1:2:0.8 (v/v) ratio. The chloroform, methanol, and serum mixture was combined by
gentle pipetting using low-retention pipet tips to avoid lipid adherence to the plastic, and
then the mixture was centrifuged for 1 min at 2,000 x g to separate the proteins
(supernatant) from the lipid/amphiphilic molecules (pellet). The supernatant was
discarded and the LAM-containing pellet was resuspended in PBS by gentle pipetting.
Following a 5 sec pulse spin to settle debris that could clog the septum of the biosensor
flow cell, the LAM-containing solution was used as the biomarker sample for
immunoassays.
There is no need for a capture antibody (reduces assay time by 40 min.) in the
membrane insertion assay format, as it relies on the direct interaction of the LAM
antigen (liberated from carrier assemblies as described above) into the supported
bilayer interface. To generate standard concentration curves, LAM antigen was diluted
to the desired concentration in control human serum in high-recovery glass vials
(Thermo Scientific, Waltham, MA) C5000-995 and incubated overnight (18−24 hrs) at 4
°C to allow for association with lipoproteins in serum, as described above the lipoprotein
capture assay. The samples were serially diluted, as described above for the lipoprotein
capture assay. Each dilution was then subject to the sample processing method, and
evaluated in the assay format in order to generate the standard curve. For the clinical
samples, 50ul of each serum sample from patients and controls was subjected to the
sample processing method, and used in the assay.
For this set of assays, the three control measurements described above (instrument
controls, no-antigen control and specificity controls) were performed (n=10 each) as
well, and the concentration of the reporter antibodies was the same as used for the
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lipoprotein capture assay above (15nM for 45 min.). For the experimental
measurements, 200 uL of the processed sample was incubated in the flow cell, allowing
for association of amphiphilic biomarkers with the lipid bilayer. Then the FIND antibody
cocktail was added again, and incubated (15nM for 45 min) for assessment of the
specific signal. Raw data were recorded as relative fluorescence units (RFU) as a
function of wavelength (nm).
For both the lipoprotein capture assay and the membrane insertion assay, a S/N ratio >
1.0 was considered a positive result, and each sample measurement was repeated two
times in order to assess reproducibility. The laboratory team performing LAM assays
using participant specimens was blinded to participant group assignment and other
clinical information, and it was held by one of the team members (SED) as described
earlier.
For use of waveguide based sensor at the point of need, our team has simplified the
waveguide-based optical biosensor for field deployment, and validated assay
performance on this new portable (<10Lbs) instrument with optical components
integrated and the software for functionality on a phone-based application. For easier
use of sample processing method, we have developed and validated the first
microfluidics device which is capable of performing lipid extractions within minutes at
the point of need.

Statistical analysis
S/N ratios are presented as means ± standard deviation. Welch’s t test and Mann
Whitney U test was used to determine statistical significance. A significance level (P) of
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less than 0.05 was considered statistically significant (***P < 0.001, **P < 0.01, or *P <
0.05). Outlier analysis was performed using Chauvenet’s criterion, which identifies the
probability that a given data point reasonably contains all samples in a data set. LAM
concentration curve and all significance tests were performed using GraphPad Prism8.
Limit of detection
The limit of detection (LOD) was obtained as described in Equation (2). For a given
sample concentration, the average non-specific signal for all replicates was obtained
and added to three times the standard deviation (σ), multiplied by the sample
concentration, and divided by the average specific signal for that concentration. Sample
concentration and LOD will be in the same units, so if sample concentration is in nM
then LOD will be in nM.

(NS + 3σ)[Sample]
LOD =

Specific

Equation (2)

6.4 Results
Antibody selection and optimization:
For both the lipoprotein capture assay and the membrane insertion assay, antibodies
were selected and concentrations determined by Enzyme Linked Immunosorbent
Assays (ELISAs) (S1 Fig., Section S1). Briefly, antibodies were chosen based on
sensitivity and specificity for LAM detection, and a combination of two different
monoclonal antibody clones (24 and 171) yielded best outcomes for LAM detection in
serum samples. These two antibodies were used as a cocktail at 15 nM each for both
the membrane insertion and lipoprotein assay formats.
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Optimization of the lipoprotein capture assay: Fig 6.2a shows a representative
spectral measurement on the waveguide-based biosensor211,365 for the measurement of
LAM (1.5 µM) spiked and incubated overnight in control human serum. RFU is plotted

Figure 6.2. Assay optimization for the detection of LAM in human serum by lipoprotein capture assay.
Measurement of LAM by lipoprotein capture assay, as a function of concentration. (a) Representative
spectral measurement of LAM (1.5 mM) incubated overnight at 4 °C in control human serum, with the
specific signal (Relative Fluorescence Units, RFU) from the detection α-LAM antibody (15 nM) as a
function of emission wavelength (nm). The background and non-specific signals are measured before the
addition of LAM. (b) Lipoprotein capture assay was performed for the detection of LAM spiked into control
serum at various concentrations and incubated overnight to allow incorporation of the amphiphile into
carrier assemblies. Results are plotted as RFU as measured on the waveguide-based optical biosensor,
at increasing concentrations of LAM. All values given in (b) are the mean ± standard deviation derived
from at least two independent determinations (n = 2). Statistical significance was determined by Welch’s t
test using Graph pad Prism 8.

as a function of emission wavelength (nm), as measured on the spectrometer interface
associated with the instrument. LAM concentration curve (Fig 6.2b) shows a sigmoidal
fit with a R2 value of 0.999 and limit of detection- 69nM, which corresponds to a
concentration of 1900 ng/mL LAM.

Optimization of the membrane insertion assay: Fig 6.3a shows a representative
spectral measurement for LAM (0.5 uM, RFU), using the membrane insertion assay
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following extraction from spiked serum. The LAM concentration curve (Fig 6.3b) using
this method shows a sigmoidal fit with a R2 value of 0.998 and limit of detection- 3.3nM,
which corresponds to a concentration of 114 ng/mL.

Figure 6.3. Measurement of LAM by membrane insertion assay, as a function of concentration. (a)
Representative spectral measurement of LAM (.5 mM) incubated overnight at 4 °C in control human
serum, with the specific signal (Relative Fluorescence Units, RFU) from the detection α-LAM antibody (15
nM) as a function of emission wavelength (nm). The background and non-specific signals are measured
before the addition of LAM. (b) Membrane insertion assay was performed for the detection of LAM spiked
into control serum at various concentrations and incubated overnight to allow incorporation of the
amphiphile into carrier assemblies. Sample processing was done to remove lipoproteins. Results are
plotted as RFU as measured on the waveguide-based optical biosensor, at increasing concentrations of
LAM. All values given in (b) are the mean ± standard deviation derived from at least two independent
determinations (n = 2). Statistical significance was determined by Welch’s t test using Graph pad Prism 8.

Detection of LAM in clinical samples:
Using the lipoprotein capture assay, LAM signal/noise ratio (S/N) was > 1.0 in 29/35
(83%) culture-confirmed TB patients, 8/13 (62%) individuals with TB symptoms but no
positive cultures, and 0/6 (0%) healthy controls (Fig 6.4). Mean S/N ± SD values were
3.8 ± 4.7, 1.9 ± 1.4, and 0.6 ± .20, respectively (Table 6.1).
To further understand the LAM lipoprotein capture assay performance, we stratified
culture-confirmed TB patients by specimen source (sputum and/or blood) of positive
MTB culture(s). Surprisingly, there was no association between MTB detected in blood
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culture, and LAM detected in serum. Serum LAM S/N was >1.0 in 10/12 (83%) cultureconfirmed TB patients with MTB in blood cultures vs. 19/23 (83%) culture-confirmed TB
patients whose blood culture was negative for MTB (relative risk 1.01, 95% CI 0.68,
1.28). Median (IQR) LAM S/N was 2.2 vs 1.3 among culture-confirmed TB patients with
vs. without MTB in blood cultures (Table 1).

Table 6.1. Signal to noise ratios, by clinical group, for the lipoprotein capture assay

S/N
Clinical Group

Median

% with SNR >1.0 (n/n)

S/N Mean (SD)
(IQR)

Culture-confirmed TB (HIV-positive)
Sputum

culture-MTB,

blood

83 (29/35)

2.2 (2.6)

3.8 (4.7)

100 (9/9)

2.2 (6.2)

5.0 (6.4)

33 (1/3)

0.9 (5.7)

2.8 (2.7)

83 (19/23)

2.5 (2.5)

3.5 (4.0)

62 (8/13)

1.3 (0.4)

1.9 (1.4)

0 (0/6)

0.6 (2.3)

0.6 (.20)

culture

MTB
Sputum culture negative, blood culture
MTB
Sputum culture MTB, blood culture
negative
TB

symptoms

but

all

cultures

negative
Controls
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Abbreviations: TB, tuberculosis; MTB, Mycobacterium tuberculosis; S/N, signal to noise ratio; SNR,
signal to noise ratio; IQR, inter quartile range; SD, standard deviation

Figure 6.4. Direct detection of LAM in patient serum samples. Detection of LAM in clinical serum
samples using the lipoprotein capture assay. Data are presented as the Signal/Noise (S/N) ratio with a
value above 1.0 indicating a positive result. The measured S/N in sera from 54 patients from 3 different
categories (see legend) is plotted. Results of urine testing using the Determine™ TB LAM Ag assay at the
time of enrollment into the clinical study: patients 1-20 were positive, patients 21-48 were negative, and
healthy controls 49-54 were not tested.

We hypothesized that, if host HDL concentration impacted the outcome of the
lipoprotein capture assay, then use of a LAM assay approach that was independent of
host lipoproteins – membrane insertion- might increase assay analytical sensitivity. Fig
6.5a shows the comparison of the two methods for detection of LAM in a serum sample
spiked with 500 nM of LAM, with all other parameters held constant. Specific signal was
significantly greater (x10) using the membrane insertion assay as compared to the
lipoprotein capture assay (p value= 0.04, R2= 0.99).
Subsequently we performed the membrane insertion and lipoprotein capture assay in
parallel for the same eight clinical samples with sufficient volume for comparative testing
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(Fig 6.5b). For serum from culture-confirmed TB patients, the S/N was uniformly higher
for the membrane insertion assay than for the lipoprotein capture assay; no specific
signal was detected in healthy control sera by either assay.

Figure 6.5. Comparison of Lipoprotein capture and Membrane Insertion. (a) Representative
measurement of LAM (0.5 µM), by lipoprotein capture (black bars) and membrane insertion assay (grey
bars), incubated overnight at 4 °C in control human serum, with the specific signal (RFU) from the
detection of α-LAM antibody (15 nM). Values are the mean ± standard deviation derived from at least two
independent determinations (n = 2). Statistical significance was determined by Welch’s t test (*P < 0.05).
(b) Comparison of LAM detection signal by lipoprotein capture (black bars) and membrane insertion
assay (grey bars) in patient serum samples. Data are presented as the S/N ratio with a value over 1
indicating a positive result. Samples 14, 3, 4, 27, 22 and 24 are positive for LAM by either blood or
sputum culture methods, whereas samples 52, 53 are healthy controls.

6.5 Discussion
In this exploratory study, we compared and contrasted the use of two tailored methods
for the detection of amphiphilic biomarkers in aqueous samples – lipoprotein capture
and membrane insertion – for the measurement of serum LAM.
Both these methods were able to directly measure LAM in serum, with a demonstrated
enhancement of sensitivity using the membrane insertion method.
In our initial evaluation in serum from adults whose TB status had been rigorously
characterized by conventional mycobacteriology testing, we observed a clear difference
between culture-confirmed TB cases and adult controls with regard to both proportion
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with detectable LAM signal and LAM S/Ns. This finding demonstrates the applicability of
these two tailored methods for serum amphiphilic LAM detection.
Clinically, there were two unexpected findings. Our working hypothesis – that serum
LAM was associated with presence of MTB in blood cultures – was not supported by the
lipoprotein capture assay data, as serum LAM was detected in the majority of cultureconfirmed TB patients whose blood cultures were negative for MTB, and further, was
not detected in the few patients whose blood cultures were positive for MTB. This
outcome can be either because of an absence of serum LAM, or simply be associated
with a failure to pull-down host lipoprotein/ failure to detect LAM due to LAM epitopes
being hidden by the lipoprotein matrix.
In order to evaluate these two possibilities, we used a membrane insertion assay that is
independent of host serum lipoproteins. Compared to lipoprotein capture, the
membrane insertion assay resulted in higher S/N in all tested TB patients, but the
magnitude of the difference varied from patient to patient. In all, our results indicate
clearly that an assay modality that is independent of variable host factors (membrane
insertion) is more sensitive than one that is dependent on them (lipoprotein capture).
The enhanced sensitivity of membrane insertion compared to lipoprotein capture is
based on the optimization assays and the 8 clinical samples. The increased sensitivity
of the membrane insertion assay over lipoprotein capture assay, even in spiked
samples, indicates some of the LAM associated with lipoproteins is not readily detected.
Indeed, a variety of factors can impact host lipoprotein concentrations, including
HIV/AIDS507,508. Because of insufficient volume of clinical samples, we were not able to
quantitate lipoprotein concentrations to formally establish an association between serum
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concentrations of these host lipoproteins and LAM S/N in TB patients, and this is a
weakness of our study.

HIV is associated with quantitative and qualitative lipid

abnormalities including low levels of HDL, disordered HDL metabolism, and reduced
Apo A levels509–511. It is intriguing to speculate that HIV effects on host lipoproteins
might influence host handling of MTB LAM, thereby impacting TB disease
pathophysiology in addition to impacting performance of our lipoprotein capture assay.
A better understanding of the mechanisms and kinetics of LAM sequestration and
clearance could have important implications for understanding tuberculosis and
inflammation more broadly.
The second unexpected finding was that serum LAM was detectable (using the
lipoprotein capture assay and threshold S/N > 1.0) in over half of TB symptomatic
individuals whose sputum and blood cultures all were negative for MTB. There are two
possible explanations for this: 1) These are false positive results, and detected signal in
the absence of LAM; or 2) MTB LAM was present in serum, but sputum and blood
cultures were falsely negative. Our existing data cannot tease apart these possibilities.
However, we note that all of these individuals were enrolled with suspected TB disease,
and that our assay did not have any false positive measurements in the control group
(0/6). Further, the recognized sensitivity limitations of mycobacterial culture as a gold
standard as well as the recognition that “TB” is nonbinary and represents a spectrum of
conditions including incipient and subclinical TB, support further investigation of serum
LAM as a biomarker21,512.
There are important limitations of our exploratory study. The sample size was small, and
adult controls all were HIV-negative whereas individuals with TB symptoms all were
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HIV-positive. Second, as noted above, serum specimen volumes precluded
performance of both LAM detection methods and HDL quantitation on all specimens,
and therefore we were not able to comprehensively characterize the associations
between serum LAM, host lipoproteins, and HIV serostatus. We hope to address these
limitations in future clinical evaluations that are curated to address out needs.
In conclusion, we present two tailored assay strategies for the direct detection of
amphiphilic serum LAM. Our findings highlight the role that host pathogen interactions
play in pathogen amphiphile presentation and the need to account for these interactions
in the design of diagnostic assays. Our findings also raise the intriguing possibility that
serum LAM might be an informative TB biomarker of incipient or subclinical TB.
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7.1 Abstract
Tuberculosis (TB) in children remains underdiagnosed and underreported. Pediatric TB
is paucibacillary and often disseminated, making traditional culture and sputum-based
diagnosis ineffective. There are no gold standards for the diagnosis of TB in children,
and there is an urgent need for effective detection methods to address this problem.
Our team has utilized the mechanism of host-pathogen interactions between
amphiphilic lipoarabinomannan (LAM), a biomarker released by Mycobacterium
tuberculosis, with host lipoproteins in blood to develop a method for the direct detection
of infection. Herein, we apply this assay format, membrane insertion, for the rapid
diagnosis of pediatric TB using the ultra-sensitive waveguide-based optical biosensor
developed at the Los Alamos National Laboratory. Our two-step approach involves a
rapid sample processing step to liberate LAM from serum lipoproteins, followed by its
detection on the biosensor by membrane insertion. Herein, we evaluate the
measurement of serum LAM in 24 TB positive patients and age-matched controls using
this approach. LAM signal-to-noise ratios were > 1.0 in 12/12 (100%) of children
classified as TB positive by WHO clinical criteria, and 0/12 (0%) in symptom-free agematched controls. To our knowledge, this is the first study demonstrating the direct
measurement of LAM in serum from infected children. Additionally, this work provides
preliminary evidence that the detection of LAM can be used to track disease
progression. Further testing and qualification of these findings is required; however,
these early findings offer promise for the ability of this approach to provide diagnostic
solutions for pediatric TB.
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7.2 Introduction
According to the World Health Organization (WHO), there were 1.2 million new cases of
childhood tuberculosis (TB) and 233,000 TB-related deaths in 20193. However, globally,
only about 35% of all pediatric TB cases are accurately diagnosed, leading to
underestimation of incidence and mortality, as evidenced by several studies78,197,513,514.
Further, the mortality and morbidity associated with pediatric TB is particularly high
among children co-infected with HIV515.
Lack of reliable diagnostics for pediatric TB clearly contributes to the exacerbation of the
severity of this problem. Microbiological confirmation of pulmonary TB is challenging, as
it is difficult for young children to expectorate sputum, the sample needed for
diagnosis135. In a study by Zar et al., only 25% of children (62/250) suspected of having
pulmonary TB were positive by either smear microscopy (29/62) or culture (58/62)171,
which is consistent with the confirmation rates reported by other studies in the
literature516. Even when sputum can be induced, smear microscopy is rarely positive in
children due to the paucibacillary nature of the disease171,517,518. M. tuberculosis, which
causes TB disease, is a Gram-indeterminate pathogen with a very high lipid content,
making it difficult to culture and characterize in the laboratory. Mycobacterial culture,
which has positivity rates of up to 30% and takes 6-8 weeks before results are available,
is often required for confirmation of disease, thereby delaying the treatment
decisions75,171,518–521. Therefore, the only accepted criteria for the diagnosis of pediatric
TB are clinical symptoms reported by the WHO. Joel et al. demonstrated the efficacy of
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this method, and their correlation with actual TB disease in a large pediatric study of
1394 patients522.
Based on challenges associated with current TB diagnostics, the WHO has called out
the need for biomarker-based tests to diagnose TB. GeneXpert MTB/RIF, which
measures pathogen load in sputum samples via polymerase chain reaction (PCR), has
been endorsed by the WHO for pulmonary TB diagnosis in children523. However, young
children develop disseminated TB more often than adults do, making the reliance on a
sputum-based approach challenging. Biomarker detection in urine or blood samples,
which can be of value in individuals with extrapulmonary TB, would therefore be more
useful than diagnostics based on sputum samples75.
Lipoarabinomannan (LAM), an immunogenic glycoprotein component of the
mycobacterial cell wall, is a biomarker that has been extensively researched for the
diagnosis of TB49,94,102,182 and a lateral flow urine LAM assay (Determine™ TB LAM Ag,
Abbott Biotechnologies) is currently recommended by for use in HIV-positive adults with
CD4 counts less than or equal to 100 cells·µL−1 that have symptoms of TB142. The test
has a reported sensitivity of 45% and specificity of 92% in adult HIV-positive patients278.
The increased use of LAM as a biomarker for diagnosis of TB in adults has led to the
exploration of its potential use in pediatrics83,182,212. Studies in pediatric populations
using lateral flow and immunoassay methodologies show a pooled sensitivity of 47%,
and a pooled specificity of 82%75–78,517,524. Based on the above findings, the WHO has
published guidelines for the use of LAM as a diagnostic biomarker in children75,78,142,525.
However, there is a clear need to improve the sensitivity of this assay in this population.
Recently, Nicol et al evaluated the FujiLAM SILVAMP TB LAM assay (Fuji LAM assay)
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in urine samples from pediatric patients, and it showed a similar sensitivity to Alere LAM
immunoassays (42% vs 50%) . However, the sensitivity of the Fuji LAM assay was
significantly higher in both HIV-positive (60%) and malnourished children (62%). The
specificity of Fuji LAM was also much higher compared to Alere LAM (92% vs 66%)526.
Studies have also demonstrated that LAM concentrations decrease with anti-TB
treatment76, which suggests potential for this biomarker to be used as a prognostic
indicator.
LAM is an amphiphilic lipoglycan, and previous work from our team has shown that it
associates with human high- and low- density lipoproteins (HDL and LDL) in infected
individuals. Thus, serum lipoproteins serve as carriers for lipidic and amphiphilic
pathogen signatures such as LAM, and this interaction interferes with traditional
methods for detecting the biomarker directly in aqueous matrices such as blood. Based
on this understanding, we developed a rapid and gentle sample processing method to
liberate the antigen from host lipoproteins. The antigen can then be directly detected
using a tailored method for amphiphile detection called membrane insertion (Figure
7.1)73,211,368,527–530. This approach has been previously validated successfully for the
detection of LAM in HIV-positive adults531. In this manuscript, we evaluated the ability of
this tailored membrane insertion assay to detect LAM in serum from pediatric TB
patients, with and without HIV, and age-matched controls. To our knowledge, this is the
first preliminary study evaluating the detection of LAM in serum for pediatric TB
diagnosis.
Whereas the detection assay is compatible with any immunoassay sensor, we have
used an ultra-sensitive waveguide-based optical biosensor that was engineered at the
142

Los Alamos National Laboratory for the work presented in this
manuscript73,284,364,365,527,529.

Figure 7.1. Overview of TB diagnostic pathways and LAM detection strategies. In current practice, a
child suspected to be infected with TB is assessed on the basis of clinical symptoms and chest X-ray, and
classified as either positive or negative. Further assessment of pulmonary vs. extrapulmonary TB is also
made. For presumed pulmonary TB patients, sputum is analyzed by one of three methods: GeneXpert,
microscopy, or culture. But, if sputum is unavailable, blood and urine sample is obtained, for culture and
LAM detection, respectively. Membrane insertion assay (described in text, schematic representation in
grey), presented in this manuscript, can be used as a reliable alternative for LAM detection from blood in
individuals with both pulmonary and extrapulmonary TB. Graphic representations not drawn to scale.
Created using Biorender.com.
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7.3 Results
Optimization of the membrane insertion assay

Figure 7.2. Optimization of detection of LAM in human serum by membrane insertion on the
waveguide based optical biosensor. (a) Representative spectral measurement of LAM (500nM) in
control human serum (grey curve), with the specific signal (Relative Fluorescence Units, RFU) from
the detection of α-LAM antibody (15 nM) as a function of emission wavelength (nm). Background
(blue) and non-specific signal (black) are shown. (b) Detection of LAM (100nM) in various conditions spiked into buffer (black), c serum (pre-processing) (blue), serum (post processing) (light grey) and
serum (delipidated) (dark grey). Results are plotted as RFU measured on the waveguide-based
optical biosensor, as a function of experimental condition. All values given in (b) are the mean ±
standard deviation derived from at least two independent determinations (n = 2). P value<.05.
Statistical significance was determined by one way ANOVA using Graph pad Prism 9.

Figure 2a shows a representative spectral measurement for LAM (500nM), using
the membrane insertion assay following extraction from spiked serum using our sample
processing method. Relative fluorescence units (RFU) was plotted as a function of
emission wavelength (nm), as measured on the spectrometer interface associated with
the instrument. Background (measurement of intrinsic impurities in the waveguide itself,
3RFU, blue), non-specific background (interaction of anti-LAM antibody with serum, in
the absence of LAM antigen, 5 RFU, black), and specific signal (signal associated with
the interaction of the fluorescently labeled antibody cocktail with serum LAM, 1565 RFU,
blue) are measured in every experiment. The signal/noise ratio (S/N) for the
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representative spectrum in Figure 7.2 a is 781 and was determined by taking the
maximum RFU value for the specific signal, subtracting out the corresponding value for
the instrument controls, specificity, and no-antigen controls (henceforth referred to as
the background) and dividing this by the maximum value for the non-specific (NS) signal
minus the maximum signal intensity measured for the background [Equation (1)].

Equation (1)

Figure 7.2b assesses the efficacy of our sample processing method in extracting LAM
sequestered by serum lipoproteins. 100nM of LAM spiked into PBS (not sequestered by
host carriers) was used as positive control, and a S/N of 554 was measured by
membrane insertion under these conditions. 100nM LAM was spiked into serum to
mimic its presentation in host blood, and under this condition, the S/N measured
decreases significantly to 89, and a signal intensity of 127 RFU was measured
compared to 606 RFU in the positive control. This lost signal intensity is partially
recovered when serum containing LAM (100 nM) is subject to sample processing.
Under this condition, a signal intensity of 411 RFU and a S/N of 397 is observed. This is
comparable to the signal intensity observed in delipidated serum (serum lacking host
lipoproteins such as HDL and LDL), with a signal intensity to 406 RFU, corresponding to
a S/N of 394. This demonstrates that the sample processing method is capable of
recovering all the LAM associated with serum lipoprotein carriers.
Detection of LAM in pediatric serum samples
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Table 7.1 collates the patient clinical and demographic information for 12 pediatric
patients and 12 age-matched controls evaluated in this preliminary feasibility study. The
average age of children in both groups was 9.5 years, with 9/12 males, 3/12 females in
TB positive group and 5/12 males, 7/12 females in TB negative group. Children in the
TB positive group had co-morbidities such as HIV (4/12), malnutrition (4/12), malaria
(5/12), sepsis or anemia (7/12), whereas none of the children in the healthy group had
HIV or malnutrition. However, 4/12 children in the healthy group had malaria, and 3/12
had sepsis/anemia.
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Figure 7.3a shows the S/N calculated in pediatric serum samples for the
measurement of LAM by membrane insertion, with a value of 1 or greater indicating a
positive outcome. Among children who had confirmed TB on the bassis of the WHO
clinical criteria the S/N for LAM measurement was > 1.0 in 12/12 (100%). None of the
healthy controls ( 0/12 (0%)) we positive for LAM measurement using this method.
Mean S/N ± SD values were 15.6 ± 21 and 0.5 ± 0.2, respectively. The median was 8.0
and 0.5, respectively (Table 1). Thus, comparison of our assay results with WHO-based
clinical criteria for diagnosis of TB yielded 100% corroboration with disease status,
irrespective of co-morbidities.
Longitudinal serum samples were available from two patients, and we evaluated the
LAM signal at both these time points, as shown in figure 7.3b and c. Both patients
were classified as TB-negative by WHO clinical criteria when they visited the clinic for
the first time, for their annual health assessment, otherwise referred to as the “wellchild” visit. Interestingly, these two children returned for clinical assessment months
later, and were then classified as TB-positive by WHO clinical criteria. Patient 1 (14
years old) came to the clinic with fever, night sweats, and had an abnormal chest X-ray
during the second visit, which was 3 months after the first, and was diagnosed as
positive for pulmonary TB and sepsis. Membrane insertion showed a higher LAM signal
on the second visit (Figure 7.3b) (S/N= 7.0, black bar), compared to the first visit (S/N=
4.7, grey bar). Patient 2 (7 years old) returned to the clinic 2 months after the first visit,
and presented with an abnormal chest X-ray, and was diagnosed with pulmonary TB
and malaria. Patient 2 also had a household member who was diagnosed with TB and
was subsequently initiated on TB treatment. Membrane insertion showed a positive
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signal on the second visit (Figure 7.3c) (S/N= 1.7, black), compared to the first visit
(S/N= 0.80, grey) (Figure 7.3b). These longitudinal measurements further support the
feasibility of using serum LAM measurements for diagnosis of pediatric TB.

Figure 7.3. Direct detection of LAM in pediatric serum samples. Detection of LAM in clinical sera
using membrane insertion. Data are presented as log(Signal/Noise (S/N)) ratio, with a value above
1.0 indicating a positive result. a) S/N measured in 24 pediatric patients. Black bars indicate TB
positive, and grey bars indicate healthy children. b) and c) Longitudinal variability in LAM signal in
patients between visits (n=2). Grey bars represent first visit, and black, second. The cross-bar
indicates the period between the two sample collections.

7.4 Discussion
In this exploratory study, we assessed the feasibility of a tailored method for the
detection of amphiphilic biomarkers in aqueous serum- membrane insertion – for the
measurement of LAM in serum from children suspected of pediatric TB. Of the 24
individuals tested in this early assessment, we observed 100% corroboration with
disease status. All twelve patients with TB disease (diagnosed by WHO clinical criteria)
had co-morbidities such as HIV, malaria, anemia, malnutrition, and sepsis. This
demonstrates that LAM can be detected in pediatric serum using this approach
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irrespective of presence of co-morbidities, garnering support for further investigation of
this method as a diagnostic for pediatric TB.
We had longitudinal samples for two (2/24) individuals enrolled in this study. Both of
them had provided samples during their annual well-visit, and then subsequently
returned to the clinic following presentation of respiratory symptoms.
Interestingly, patient 1 tested positive for LAM during both the first and second visits,
with a greater signal intensity evidenced during the second visit. This raises the
possibility that the individual was already TB-positive but did not present with symptoms
and was not diagnosed using the clinical criteria. It also suggests that LAM can be
detected early in disease progression, allowing for timely diagnosis to guide treatment.
This observation requires further evaluation and validation in a longer longitudinal
cohort.
Patient 2 was negative during the well visit, and presented with a positive LAM
signature during the second visit. This individual also had a TB positive household
contact, which correlates with previous literature that the risk of secondary TB is greater
among young children than in adults with a positive household contact532–534.
With the lack of reliable gold standard diagnostics for pediatric TB, we compared our
assay outcomes against the WHO’s clinical method of diagnosis – which is the method
used for clinical decision making in Siaya, Kenya. In future, we hope to study a larger
pediatric cohort and compare the performance of membrane insertion against other
diagnostic methods such as lateral flow assays for urinary LAM measurement,
mycobacterial culture, and GeneXpert (Cepheid, USA). None of these methods has
currently been accepted as the confirmatory diagnostic for pediatric TB, and has
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limitations when applied to this population, as discussed previously 75,78. The relative
performance of these methods in children presenting with TB disease can offer further
insights into pathophysiology and disease manifestation.
In conclusion, we present a tailored assay strategy – membrane insertion- which offers
promise direct detection of amphiphilic serum LAM in pediatric populations, as
evaluated in a small clinical cohort. Our findings highlight the importance of the
amphiphilic biochemistry of LAM and the need to account for this property in the design
of diagnostic assays, and warrant the need for follow on evaluations of novel biomarker
based methods for pediatric TB.
7.5 Methods
Materials- Bovine serum albumin (BSA, A7906) and Dulbecco’s phosphate buffered
saline (PBS, D1408) were obtained from Sigma Aldrich (St. Louis, MO). Control human
serum was obtained from Fischer Scientific Inc (Catalogue No. BP2657100), 1 mL
aliquots were stored at −20 °C and thawed only once prior to use. Control delipidated
human serum was obtained from Alfa Aesar (Catalogue No. BT-931), 1 mL aliquots
were stored at −20 °C and thawed only once prior to use. 1, 2-Dioleoyl- sn-glycero-3phosphocholine (DOPC) and 1, 2-dioleoyl-sn-glycero-3-phosphoethanolamine-N- (cap
biotinyl) (sodium salt) (cap Biotin) were obtained from Avanti Polar Lipids (Alabaster,
AL). Purified LAM (H37Rv) used in validation and optimization assays were obtained
from Biodefense and Emerging Infections Resources (BEI resources, Manassas, VA)
AND resuspended to 1mg/mL in sterile nanopure water. 60 µL aliquots were stored in
low retention tubes at -80 °C and thawed immediately prior to use. Anti-LAM
monoclonal antibodies used in the reporter cocktail (see below) were a generous gift
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from the Foundation of Innovative New Diagnostics (FIND, Geneva, Switzerland). Alexa
Fluor 647 conjugated streptavidin (S21374) was obtained from Thermo Fisher Scientific.
LAM antibodies were fluorescently-conjugated using Alexa Fluor® 647 (AF647)
antibody labeling kits purchased from Life Technologies (Thermo Fisher Scientific,
Grand Island, NY) according to manufacturer instructions. Antibody concentration and
degree of labeling was measured using a NanoDrop 1000 instrument (Thermo Fisher
Scientific).
Clinical specimens
Clinical samples were obtained from pediatric patients (ages 1month- 17 years)
recruited at the Siaya County Referral Hospital in western Kenya between 2016 to 2020
as part of a longitudinal study examining the pathogenesis of tuberculosis and related
co-morbidities.

Blood and sputum samples were collected. Serum samples were

isolated from venous blood and stored at –80 °C until use. Samples were thawed
immediately prior to injection in the waveguide assays. For membrane insertion assays,
50 µL of clinical serum sample was used.
Ethics
The scientific and ethical review committees of the Kenya Medical Research Institute
and the institutional review boards of the University of New Mexico and LANL approved
all protocols in this study involving human patients. All samples were collected following
written informed consent by the parents or guardians of the patient, and patients
participating in this study were treated according to the Kenyan Ministry of Health
guidelines.
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Waveguide-based optical biosensor
The waveguide-based optical biosensor was developed at Los Alamos National
Laboratory and is described in detail elsewhere

365

. Waveguides were custom

engineered by nGimat Inc (Norcross, GA) and the surface was coated with a 10 nm
SiO2 to enable functionalization at Spectrum Thin Films Inc. (Hauppauge, NY). Silicone
gaskets for waveguide assembly were from Grace Bio-Labs (Bend, OR) and Secure
seal spacers (9 mm diameter x 0.12 mm deep) were from Electron Microscopy
Sciences (Hat- field, PA). Glass microscope slides used as coverslips were purchased
from Thermo Fisher Scientific (Rockford, IL).
Waveguide preparation and flow cell assembly
Single mode planar optical waveguides were used for functionalization as previously
described 211,363,364,368. Briefly, waveguides and glass coverslips were cleaned by
sonication in chloroform, ethanol and water (5 min each). Next, waveguides and cover
slips were dried completely under argon gas and irradiated using UV-ozone (UVOCS
Inc., Montgomeryville, PA) for 40 min and stored dry until use. Flow cells for
immunoassays were assembled using clean waveguides and cover slips, which were
bonded together with a silicone gasket containing a laser cut channel creating a flow
cell. Following assembly, the flow cell was injected with 70 µl of lipid micelles
(preparation described below) and then incubated overnight at 4 °C to enable vesicle
fusion and lipid bilayer stabilization.
Lipid micelle preparation
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1, 2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1, 2-dioleoyl-sn-glycero-3phosphoethanolamine-N- (cap biotinyl) (sodium salt) (cap biotin) were obtained from
Avanti Polar Lipids (Alabaster, AL), resuspended in chloroform and stored at −20 °C.
Lipid micelles for use in waveguide experiments were prepared as described previously
211

. Briefly, 2 mM DOPC and 1% cap biotinyl (mol/mol) were combined in a glass tube

then the chloroform was evaporated off under argon gas. Lipids were rehydrated in
PBS, incubated for 30 min at room temperature with shaking (100 rpm) on an orbital
shaker. Lipid solutions then underwent 10 rapid freeze/thaw cycles alternating between
liquid nitrogen and room temperature water. Finally, lipids were probe sonicated for 6
min total (1.0 sec pulse on/off, 10% amplitude) using a Branson ultrasonic generator.
Once the lipids were stabilized, the addition of biotin allowed for the bilayer integrity to
be evaluated during immunoassay experiments by probing with 50–100 pM of a
streptavidin Alexa Fluor 647 conjugate 184,363.
Waveguide-based assays
All incubations occurred at room temperature. Dilutions of all reagents were made in
PBS. Flow cells were prepared as described above and the lipid bilayer was blocked for
1 hr with 2% BSA in PBS (w/v). All incubations were immediately followed by a wash
with 2 mL of 0.5% BSA in PBS (w/v) to remove any unbound constituents. Incident light
from a 635 nm laser (Diode Laser, Coherent, Auburn, CA) with power adjusted to
440−443 µW was coupled into the waveguide using a diffraction grading. The response
signal was adjusted for maximum peak intensity using a spectrometer (USB2000,
Ocean Optics, Winter Park, FL) interfaced with the instrument and an optical power
meter (Thor Labs, Newton, NJ) 74.
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The background signal associated with the lipid bilayer and 2% BSA block was
recorded, and then the integrity of the lipid bilayer was assessed by incubation of
50−100 pM streptavidin, AF647 conjugate (Molecular Probes, S32357) for 5 min. The
two control steps are performed in every experiment as intrinsic controls. The remaining
assay steps depended on the particular assay as described below. The antibodies used
in this assay (FIND Clones 171 and 24) were labeled with AF-647, and the optimal
combination of antibodies and their concentrations were determined using Enzyme
Linked Immunosorbent Assays as described before531. The incubation times for the
assays were optimized in all cases by standard measurements using LAM spiked into
commercially procured human serum. The antigen titrations were performed on the
waveguide-based biosensor.
Membrane insertion assay. Here, LAM is released from host lipoprotein complexes prior
to detection via a pre-established sample processing method 310. Briefly processing was
performed using a modified single-phase Bligh and Dyer chloroform:methanol
extraction. Chloroform, methanol and LAM sample (either standard or clinical) were
combined in a siliconized microfuge tube (Fisher Scientific, 02-681-320) at a 1:2:0.8
(v/v) ratio. The chloroform, methanol, and serum mixture was combined by gentle
pipetting using low-retention pipet tips to avoid lipid adherence to the plastic, and then
the mixture was centrifuged for 1 min at 2,000 x g to separate the proteins (supernatant)
from the lipid/amphiphilic molecules (pellet). The supernatant was discarded and the
LAM-containing pellet was resuspended in PBS by gentle pipetting. Following a 5 sec
pulse spin to settle debris that could clog the septum of the biosensor flow cell, the
LAM-containing solution was used as the biomarker sample for immunoassays.
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Antibody selection criteria, methods to generate standard curve and limit of detection
have been discussed previously531. Briefly, to generate standard LAM concentration
curves, varying concentrations of MTB H37RV LAM (6, 25, 50, 100, 200, 500, 1000,
1500, 2500 nM) were spiked into commercially procured human serum, and incubated
for 24 hours to allow for complete association with lipoproteins. Each dilution was then
subject to the sample processing method, and evaluated in the assay format in order to
generate the standard curve. For the clinical samples, 50ul of each serum sample from
patients and controls was subjected to the sample processing method, and used in the
assay.
Three sets of controls were performed (n=10 each). The instrument background
signal is an assessment of the biosensor function and bilayer integrity. No antigen
control experiments were performed using control serum, in the absence of LAM.
Specificity controls were performed using FIND antibody labeled with AF-647 and
measuring the signal associated with their interactions with LAM functionalized on the
biosensor surface. The concentration of the reporter antibodies was 15nM for 45 min.
For the experimental measurements, 200 uL of the processed sample was incubated in
the flow cell, allowing for association of amphiphilic biomarkers with the lipid bilayer.
Then the FIND antibody cocktail was added again, and incubated (15nM for 45 min) for
assessment of the specific signal. In all experiments, raw data were recorded as relative
fluorescence units (RFU) as a function of wavelength (nm). The specific/non-specific
ratio (S/N) was determined by taking the maximum RFU value for the specific signal,
subtracting out the RFU value for the instrument controls, specificity and no-antigen
controls (henceforth referred to as the background) and dividing this by the maximum
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RFU value for the non-specific signal minus the maximum RFU value for the
background [Equation (1)].

(Specific – Background)
S/N =
Equation (1)

(NS – Background)

A S/N ratio > 1.0 was considered a positive result. The laboratory team performing LAM
assays using participant specimens was blinded to participant group assignment and
other clinical information, and it was held by one of the team members (DJP).

Statistical analysis
S/N ratios are presented as means ± standard deviation. Welch’s t test was used to
determine statistical significance. A significance level (P) of less than 0.05 was
considered statistically significant (***P < 0.001, **P < 0.01, or *P < 0.05). Statistical
analysis was performed using GraphPad Prism9.
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8.1 Abstract
The separation of biomarkers from blood is straightforward in most molecular biology
laboratories. However, separation in resource-limited settings, allowing for the
successful removal of biomarkers for diagnostic applications, is not always possible.
The situation is further complicated by the need to separate hydrophobic signatures
such as lipids from blood. Herein, we present a microfluidic device capable of
centrifugal separation of serum from blood at the point of need with a system that is
compatible with biomarkers that are both hydrophilic and hydrophobic. The cross-flow
filtration device separates serum from blood as efficiently as traditional methods and
retains amphiphilic biomarkers in serum for detection.
8.2 Introduction
The separation of serum from whole blood is a necessary first step in many clinical
diagnostic blood tests, since serum contains important biomarkers, whether autogenic
or pathogenic, for disease diagnosis and monitoring535–537. Our focus is on the detection
of amphiphilic bacterial biomarkers that are released into the host’s blood stream rapidly
after infection72,211,283,529,538. Early detection and specific treatment of bacterial infections
is necessary to help prevent the spread of antimicrobial resistance, save lives, and
reduce the chances of outbreaks. Ideally, diagnosis will occur at the point of need and
provide rapid intervention solutions. The development of rapid, simple, automated, safe,
and inexpensive processing of blood samples can therefore benefit many diagnostic
assays.
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We are working towards a universal diagnostic strategy for all bacterial pathogens,
including the development of novel assays to quickly detect biomarkers indicative of
bacterial infection285. Our universal bacterial sensing strategy mimics innate immune
recognition in the laboratory, facilitating diagnosis of all bacterial infection from a single
clinical sample: blood. The bacterial biomarkers targeted by our assays are the same as
those targeted by our human innate immune response, and are most often lipidated
sugars (lipoglycans or glycolipids, such as lipopolysaccharide, lipoteichoic acid, and
lipoarabinomannan). Previous work from our laboratory and others has shown that the
amphiphilic biochemistry of these biomarkers causes them to be sequestered by host
lipoprotein carriers, including high- and low-density lipoproteins (HDL and
LDL)72,73,506,528. Because of this sequestration, it is necessary to liberate the amphiphilic
biomarkers from their lipoprotein carriers in order to enable sensitive measurement.
Detection can then occur via enzyme-linked immunosorbent assays (ELISA’s),
waveguide-based biosensor211,283,529 or other methods73.
The focus of the work presented in this manuscript is the separation of serum from
blood within a microfluidic device that preserves the integrity of relevant amphiphilic
biomarkers present in serum. Our current sample processing method, while reliable,
requires trained personnel and a multi-step laboratory procedure284. For use in a pointof-care setting, sample preparation should be automated in order to save time and
ensure user safety, while preserving sample quality539. The platform must be able to
process small volumes of whole blood, have a low cost of production, and offer minimal
loss of sample integrity during processing. It is also beneficial to have the ability to
integrate additional processing steps as dictated by the specific application.
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While there have been many reported microfluidic devices that separate serum from
blood, most to our knowledge have emphasized the preservation of protein and nucleic
acid signatures539–550. Lipidic and amphiphilic biomarkers present a unique challenge,
as they tend to adhere to many different surfaces, including certain plastics and dialysis
membranes.
Centrifugal microfluidics is a promising area of research for the automation of a variety
of processes, including biological assays and sample preparation551–553. The field is
especially appealing for point-of-care and deployable devices, due to the fact that
minimal instrumentation is needed, and the centrifugal force present is inherently
effective for density-based separations553. This applies to our system, as the extraction
of serum from blood is essentially a phase separation. We have applied the concepts of
centrifugal microfluidics in order to develop a cross-flow filtration scheme for the gentle
separation of serum from blood552–554.
During the process of cross-flow filtration, the sample passes tangentially across a filter,
which is achieved via the centrifugal force acting on the platform. Components smaller
than the membrane’s pores are driven through the filter as pressure increases, while
larger components pass over the membrane surface555. In contrast, dead-end filtration
can result in clumping of particles that clog the filter (Figure 8.1). Cross-flow filtration
decreases the chances of clogging, which in turn decreases the chances of red blood
cell (RBC) lysis. Lysis of RBCs is of concern, since the release of hemoglobin (a
fluorescent molecule) from the cells can interfere with fluorescence-based detection
methods556–558.
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Figure 8.1. A schematic depicting the difference between the separation of serum from blood via deadend filtration (left), which tends to cause clogging of membrane pores, and cross-flow filtration (right). Red
circles represent RBCs

Based on these observations, we chose to develop a cross-flow centrifugal microfluidic
platform for the separation of serum from whole blood that is compatible with the
biochemistry of amphiphilic biomarkers. While this is not the first time a cross-flow
filtration method has been integrated into a centrifugal microfluidic chip, it is the first to
our knowledge to specifically preserve amphiphilic molecules within serum559–561. The
design was optimized to purify serum to commercial standards, as validated by
performing cell counts on all samples. Materials used for the fabrication of the
centrifugal platform were compatible with our sample processing criteria, as confirmed
by testing samples from the device on our waveguide-based optical biosensor for the
retention of amphiphilic biomarkers of interest211,365,366,529. This development greatly
simplifies the sample processing requirements for our biosensing assays and facilitates
the transition of such technologies to the point-of-need. In addition, this method can be
applied to other detection techniques that require the separation and preservation of
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serum from whole blood, including in resource limited settings, inexpensively and
rapidly.
8.3 Working Principle
The device consists of multiple chambers stacked on top of each other, separated by a
membrane, according to the layout in Figure 8.2a and 8.2b. Four separation units are
present on the centrifugal disc (Figure 8.2c), enabling multiple simultaneous
experiments on one chip, which could be used for various assays or replicates of the
same sample. The following steps take place within each separation unit (Figure 8.2a):
Step 1: Blood is introduced into the platform though the sample inlet. The ports are
sealed, and the disc is placed on a motor to impart centrifugal force onto the sample at
a given revolutions per minute (RPM). The centrifugal force causes the blood to flow
away from the center of rotation. RBCs cluster toward the bottom of the sample
reservoir in pellet trap #1 due to their density.
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Figure 8.2. A) Edge view of one cross-flow filtration unit and separation concept; B) Top-view schematic
of one separation unit; C) One completed disc with four separation units.

Step 2: As the pressure increases in the sample reservoir, serum is able to flow through
the embedded membrane, while RBCs are largely prevented from flowing through due
to their size. A small number of RBCs may squeeze through the pores of the
membrane.
Step 3: Excess RBCs that went through the membrane are caught in pellet trap #2. As
RBCs accumulate in pellet trap #2, the serum flows up into the serum reservoir, passing
through another membrane section that serves as a secondary filtration step for RBCs.
The serum is then collected through the serum outlet.
Our initial cross-flow filtration design included only one pellet trap, but we observed that
some RBCs were able to get through the membrane. We realized we could easily
integrate another filtration step, without changing our fabrication process, by adding
another pellet trap to the design.
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8.4 Methods
Device Fabrication
The cross-flow filtration platform consists of five structural layers of plastic and one thin
plastic membrane layer. The device was fabricated using a rapid prototyping method
involving laser-based micropatterning and lamination. A pressure-sensitive adhesive
(91022, 3MTM) was used to facilitate the lamination process. Layer schematics were
drawn using SolidEdge10 2D drafting software. Alignment holes were included on all
layers for assembly on a jig. The layers were cut using a CO2 laser cutter (M360,
Universal Laser Systems) from stock cast acrylic (McMaster Carr Supply Company),
polycarbonate (McMaster Carr Supply Company), and membrane sheets (Sterlitech
Corporation). After cutting, the plastic layers were cleaned by bath sonication in water
with dish soap for 15 minutes followed by a manual wash by wiping with isopropyl
alcohol.
The membrane layers are Sterlitech Corporation’s track-etched hydrophilic
polycarbonate with 5 µm pores. The polycarbonate membrane was coated by the
manufacturers with polyvinylpyrrolidone (PVP) to ensure hydrophilicity38. The
membrane sheets are reported by the manufacturer to be between 3-24 µm thick,
making them delicate to work with562. In order to obtain reproducible separation by the
membranes, it was important to integrate suspended membranes that are flat. We have
developed a method for membrane integration, described in the Electronic
Supplementary Information (ESI), which consistently produces a surface that is free
from visible indentations or imperfections.
Device Testing and Optimization
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Device functionality was verified in a series of systematic experiments that determined
ideal RPM (from 3500-5000, tested in 500 RPM increments), time (from 2-5 min, tested
in 1 min increments), membrane type (polycarbonate and polyester; 2, 3, and 5 µm pore
sizes), and geometric design parameters (pellet trap sizes, tested in 0.5 mm height
increments) for phase separations. An example of these systematic testing schemes is
described in the ESI. In order to test different conditions, the disc was placed on the jig,
and 90 µL of whole sheep’s blood was pipetted into each inlet hole. The inlets were
designed to be the same diameter as the pipette tip in order to create a seal and
prevent leakage. A one-sided custom polycarbonate tape was aligned on top of the disc
to seal all ports and prevent the escape of fluids during processing. A microcentrifuge
(Scilogex) was used to test different RPM and time profiles. A central hole (Figure 8.2c)
was cut into the microfluidic disc to fit over the rotor, and the cap from the
microcentrifuge was securely fastened over the disc.
Blood/Serum Separation Efficiency
Serum purity, defined as the percentage of cells removed from whole blood, was
determined by using a TC20 Automated Cell Counter (Bio-Rad Laboratories, Inc.). Cell
counts from whole blood (Sheep; ThermoFisher Scientific, Inc.) were compared to
counts on serum from the microfluidic device, and purity was calculated using the
following formula563: serum purity (SP) (%) =
𝑆𝑃 =

# 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑤ℎ𝑜𝑙𝑒 𝑏𝑙𝑜𝑜𝑑 − # 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑠𝑒𝑟𝑢𝑚
∙ 100
(# 𝑜𝑓 𝑐𝑒𝑙𝑙𝑠 𝑖𝑛 𝑤ℎ𝑜𝑙𝑒 𝑏𝑙𝑜𝑜𝑑)

Cell counts were also performed on commercially-available sheep serum produced by
ultracentrifugation (ThermoFisher), and serum separated from whole blood in our lab by
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traditional benchtop methods, for comparison. Results were analyzed by a Student’s ttest for significance.
Biomarker Retention
We validated the ability of our microfluidic device to retain serum biomarkers of interest
by comparing the efficacy of the process against the benchtop method developed by
our team211,283,364,366,368,529. Because the bacterial biomarkers of interest are amphiphilic
in nature, this step also ensured that the biomarkers were retained in the sample and
not adsorbed to the plastic device materials.
Initial biomarker retention experiments were performed on the Los Alamos National
Laboratory’s waveguide-based optical biosensor, which is used for the detection of
biomarkers from Gram-negative, -positive, and -indeterminate bacteria211,366,529. The
technology is described in detail elsewhere211,365,366,368,529.
The ability to retain and subsequently detect lipoarabinomannan (LAM), the virulence
factor associated with Mycobacterium tuberculosis, was chosen as an assessment of
biomarker retention. LAM is an amphiphilic biomarker, and previous work has shown
that the antigen associates with HDL72,95. We have evaluated the benchtop sample
processing method for the extraction of carrier-associated LAM, followed by its
detection on the waveguide biosensor using a tailored method called membrane
insertion366,529. Herein, we compared benchtop and microfluidic methods by measuring
the sensitivity of detection of LAM in serum.
In order to test biomarker retention, whole blood was spiked with LAM to a
concentration of 0.05 µM and incubated overnight at 4oC. The next day, serum was
separated from blood using either the microfluidic device or by traditional benchtop
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separation, depending on the assay. For extractions using the microfluidic device, 90 µL
blood was pipetted into each inlet hole, and the disc was centrifuged at 4500 RPM for 3
minutes. This RPM and time combination was optimized as described earlier. For
traditional methods, 500 µL whole blood was pipetted into a microcentrifuge tube and
centrifuged at 4500 RPM for 3 minutes. The serum from each method of separation was
analyzed by cell counting, and sample processing was finished by benchtop methods in
both cases. 120 µL of serum was mixed by pipetting with 150 µL chloroform and 300 µL
methanol in low-retention microcentrifuge tubes. The mixture was spun at 5500 RPM for
1 minute on a microcentrifuge, and the supernatant was discarded. The pellet
containing biomarkers of interest was re-suspended in 120 µL of 1X PBS, which was
injected into the flow cell of the waveguide and incubated for 45 minutes at room
temperature. After incubation, the flow cell was washed, and the specific signal was
measured on the waveguide-based optical biosensor. Complete details for the
waveguide-based assays can be found in the ESI.

8.5 Results
Device Functionality
We found that spinning the disc at 4500 RPM for 3 minutes yielded serum with the least
amount of RBCs remaining in it. Sterlitech’s polycarbonate membrane with 5 µm pores
was the most effective at filtering out RBCs. Our design includes two pellet traps for
RBC collection (Figure 8.2). Pellet trap heights of 5 mm and 2 mm for pellet trap #1 and
#2, respectively, were found to be the most effective. A two-step filtration design was
determined to be more successful at separating serum from blood when compared to a
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one-step method, as described in the Working Principle section. Figure 8.3 shows
cross-sections of the one-step vs. two-step filtration designs and the resulting phase
separations.

Figure 8.3. Schematics of one-step (A) vs. two-step (B) cross-flow filtration, with corresponding photos of
phase separations on the microfluidic device; A) The one-step filtration method was ineffective at
separating a large fraction of blood cells from serum; B) The two-step filtration method was successful at
separating serum from blood.

Serum Purity
We compared the RBC count of serum separated on the microfluidic device to serum
separated by traditional centrifugation and to commercially-available serum. The serum
processed on our microfluidic platform had a statistically significantly lower cell count (P
= 0.0179 for microfluidics vs. benchtop; P = 0.0128 for microfluidics vs. commercial
serum). A bar graph of cell counts for whole blood compared to different methods of
separating serum is shown in Figure 8.4. Serum purity was calculated for benchtop
methods of separation and for the microfluidic separation. Both methods yielded a high
percentage of cells removed from whole blood, greater than 99.99%.
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We determined that our device is suitable for blood/serum separation, a common first
step of many sample processing methods. The serum processed on the microfluidic
device had a lower cell count than either the serum processed using the benchtop
separation method or commercially-available serum, which indicates higher serum
purity.
Biomarker Retention
We validated biomarker retention for blood separated on the microfluidic chip and
compared the results to our benchtop sample processing method. After serum from the
microfluidic device was determined to have a significantly lower cell count (Figure 8.4)

9

Figure 8.4. Average cell counts (n=3) on whole blood (6.8x10 cells/mL), serum processed on the
5
5
microfluidic device (1.27x10 cells/mL), serum processed by benchtop methods (4.45x10 cells/mL), and
5
commercially-available serum (1.9x10 cells/mL). ** indicates statistical significance.

than serum from the benchtop or commercially-available serum, we further validated the
device by testing for biomarker retention in the sample. LAM was spiked in whole blood
at 0.05 µM before separating serum from blood on the microfluidic device. Blood from
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the same aliquot was used for benchtop blood/serum separation in microcentrifuge
tubes. After separation, the serum was analyzed on our waveguide-based optical
biosensor, as described in the Experimental Section. There was no statistically
significant difference between LAM levels in serum processed on the microfluidic device
vs. by benchtop methods (P = .9392), indicating that the microfluidic device preserves
amphiphilic biomarkers present in serum as effectively as benchtop processing
methods, and the device’s materials are suitable for our application. A comparison is
shown in Figure 8.5.

Figure 8.5. Signal intensity (n=3) of LAM from whole sheep’s blood separated on the microfluidic device
vs. benchtop methods. Higher intensity indicates higher concentration of biomarker retained in the serum
sample. There was no significant difference between signals, indicating that our cross-flow filtration chip
is suitable for the separation of serum from blood and subsequent detection of amphiphilic biomarkers.
The fact that serum processed on the microfluidic disc yielded a similar signal intensity indicates that the
microfluidic device preserves amphiphilic biomarkers present in serum as effectively as benchtop
processing methods.

8.6 Discussion
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We have integrated a multi-stage cross-flow filtration system into a centrifugal
microfluidic platform to perform blood/serum separation. To our knowledge, this is the
first cross-flow based microfluidic device capable of the separation of serum from blood
with a documented ability to preserve lipidic biomarkers with the same efficiency as
benchtop processing. Serum processed on our device contained fewer RBCs when
compared to serum separated using benchtop methods and to commercially-available
serum. The serum separated on our microfluidic chip was over 99.99% pure. There was
no significant loss of signal for detection of the model biomarker of interest, LAM, when
compared to benchtop methods of separation, indicating the suitability of our device for
amphiphilic and lipidic signature retention.
This method of blood/serum separation offers several advantages. The platform
requires only 90 µL of whole blood, which reduces invasiveness and is of importance
when working with potentially dehydrated patients at the point-of-care. It is simple to
manufacture, disposable, and does not rely on pumps or valves for fluidic movement. It
does not interfere with amphiphile detection as validated on our optical biosensor, nor
does it require the dilution of blood. The chip itself is modular, as shown by the decision
to use two pellet traps instead of one. This highlights the ease with which the design
can be adapted for other phase-separation applications, without changing the
manufacturing process we developed. Finally, the platform is a promising design for the
complete automation of sample processing at the point-of-care, whether for bacterial
biomarkers or other lipidic signature.
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9.1 Introduction
Lipoarabinomannan (LAM) is a pathogen associated molecular pattern (PAMP)
that is released by Mycobacterium tuberculosis (MTB) during active infection564.
Mannose capped LAM (ManLAM), a type of LAM, is produced by pathogenic and
slow growing mycobacterial species including MTB55. It is an amphiphilic
lipoglycan component of the mycobacterial cell wall that plays an important role
in modulating key aspects of the host’s innate and adaptive immune responses
to mycobacterial infections31,565,566.
LAM has been shown to circulate as an immune complex or occurs associated
with serum lipoproteins in aqueous blood101,567. Studies from our lab have shown
that bacterial amphiphiles including lipopolysaccharide (LPS), lipoteichoic acid
(LTA), and LAM72,279,283 associate with lipoproteins such as high-, low-, and very
low-density lipoproteins (HDL, LDL, and VLDL). These carrier proteins transport
amphiphilic molecules in aqueous blood and play an important role in mediating
the protective inflammatory response on host cells.
LAM is recognized by several pattern recognition receptors (PRRs), including
Toll-like receptor 2 (TLR2) and other receptor heterodimers such as TLR2/TLR1
and TLR2/TLR6, which are mostly expressed on the surface of macrophages
and dendritic cells during early MTB infection568,569. Binding with PRRs
subsequently triggers the MyD88-dependent signaling pathway, leading to the
production of pro- and anti-inflammatory cytokines570,571. There have been
contradictory findings from a limited number of studies with respect to the
mechanism of interaction of TLR2 with mycobacterial lipoproteins such as
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ManLAM. Some studies have suggested there is a strong interaction between
TRL2 and ManLAM,564,570 while others indicate a weak association572,573. We
argue that this contradiction could be due to the differential interaction of LAM
with host lipoproteins, and that such associations should be considered in the
design of physiologically relevant in vitro experimental models.
Extensive literature exists on the interaction of LPS with serum binding proteins.
279,387,574

But the global understanding of the association of LAM with lipoproteins,

and its impact on immune signaling is still very limited, despite the fact that LAM
is currently the most researched biomarker for MTB diagnosis. Whereas an
enormous amount of effort is being put into improving the sensitivity of LAM
assays for MTB detection, the design and evaluation of these assays is limited by
our limited comprehension of the pathophysiology of the interaction of the
biomarker with host. Previous research on LPS from our lab demonstrated a
dramatic difference in cytokine profiles when the antigen was presented in media
versus serum. A stark suppression of pro-inflammatory cytokines expression was
observed in serum279. These findings indicated that the amphiphilic biochemistry
of bacterial PAMPs, and their association with host lipoproteins, impacts hostpathogen interaction and is an important feature to be considered in the design of
experiments.
The majority of cell studies with LAM have been performed in either media or
serum, without considering the impact that interaction of LAM with lipoproteins
could have on the observed response. In fact, THP-1 cells (a human monocytic
cell line) are primarily cultured in media containing 10-20 % serum for optimal cell
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growth, which can have significant effect on the interaction of LAM with the cells.
Given that serum concentrations in vivo is around 90%, a physiologically relevant
in vitro system that accurately represents the LAM-induced cytokine expression
as it occurs in infected hosts does not currently exist. Here, we explore the
impact of LAM presentation on immune stimulation in human differentiated
macrophage [THP-1 monocytes differentiated to macrophages using phorbol 12
myristate 13 acetate] cell line, as the first step towards developing a
physiologically relevant cell-based model of innate immunity. Specifically, we
investigated whether the association with lipoproteins found in serum alter the
LAM-associated pro-inflammatory cytokine profile as compared to LAM in a
system devoid of lipoproteins.

9.2 Material and methods
Materials. Human monocyte cell line THP-1 (TIB-202), was purchased from the
American Type Culture Collection (ATCC). Human THP-1 TLR2 (-/-) cell line was
custom engineered by Horizon inspired cell solutions (HD204-038). RPMI-1640
(30-2001) and fetal bovine serum (FBS) (30-2020) were from ATCC. 2mercaptoethanol (M6250) and phorbol 12 myristate 13 acetate (PMA) (P8139)
was from Sigma-Aldrich. RNeasy Mini Kit (74106), RT2 First Strand Kit (330404),
RT2 Profiler PCR Array Human Cytokines & Chemokine (PAHS150ZC6EA), RT²
SYBR Green ROX qPCR Mastermix (330529) were from Qiagen. Individual RT2
primer assays (330011 (PA-031), 330001 (PPH00701B, PPH00192F,
PPH00564C, PPH00566F, PPH00703BPPH00576C, PPH007723B,
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PPH00696C, PPH00552F, PPH00698B, PPH00694B, PPH00586A,
PPH00580C, PPH00690A, PPH00171C, PPH00568A, PPH00341F,
PPH00073G, PPH01018C, PPH21138F, PPX63340A, PPH00549C)) were
purchased from Qiagen. Human very low density lipoproteins (LP1),
Chylomicrons (SRP6304), low density lipoproteins (L7914) and high density
lipoproteins (L8039) were from Sigma. Purified Man LAM (H37Rv) used in
validation and optimization assays were obtained from Biodefense and Emerging
Infections Resources (BEI resources, Manassas, VA) AND resuspended to
1mg/mL in sterile nanopure water. 60 µL aliquots were stored in low retention
tubes at -80 °C and thawed immediately prior to use. Control human serum was
obtained from Fischer Scientific Inc (Catalogue No. BP2657100), 1 mL aliquots
were stored at −20 °C and thawed only once prior to use. Control delipidated
human serum was obtained from Alfa Aesar (Catalogue No. BT-931), 1 mL
aliquots were stored at −20 °C and thawed only once prior to use.
Cell culture. Cells were revived in T-25 flask with RPMI-1640 supplemented with
0.05 mM 2-mercaptoethanol and 20% FBS. Cells were maintained in T-75 tissue
culture flasks with RPMI-1640 supplemented with 0.05 mM 2-mercaptoethanol
and 10% FBS (growth media) and incubated in 5% CO2 at 37 °C. THP-1 cells
double every 24-48 hours and were sub cultured by addition of fresh growth
media before concentration reached 106 cells per mL.
Cell viability assay. To evaluate cytotoxicity of LAM, viability assays were
performed with THP-1 cells. 5 x 104 cells per well with LAM (10 µg/mL and 50
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µg/mL) in RPMI 1640 growth media were added in 24-well tissue culture plate
and allowed to incubate in 5% CO2 at 37 °C for 24 h. After 24 h, cytotoxicity was
assessed by incubating cell cultures with the resazurin-based PrestoBlue at 37
°C for 1 h. Measurements were taken using a SpectraMax Gemini EM plate
reader (Molecular Devices, Sunnyvale, CA) with excitation at 560 nm and
emission at 590nm. Percent cell viability was determined by dividing the relative
fluorescence units (RFU) of LAM-containing wells by the RFU of the media-only
wells. Assays were performed with at least four replicates.
THP-1 adaptation to 2.5% FBS. To assess gene expression between serum, no
serum conditions, cells were adapted to RPMI-1640 supplemented with 0.05 mM
2-mercaptoethanol and 2.5% FBS. To do so, FBS concentration in RPMI 1640
was reduced to half on every subsequent sub culture (20%, 10%, 5%, and 2.5%).
Differentiation of THP-1 cells using PMA. THP-1 cells were differentiated to
macrophages using PMA. Once cells were adapted to 2.5 % FBS in RPMI-1640,
cells were added to 20nM PMA-media (RPMI 1640 with 0.05 mM 2mercaptoethanol and 2.5 % FBS). 8 x 104 cells/mL/well were plated in a 24 well
tissue culture plate and allowed to incubate in 5 % CO2 at 37 °C for 24 h after
which cells become adherent. PMA-media was aspirated off cells after 24 h and
wells were rinsed gently 2 times with RPMI growth media (2.5%FBS). 1mL
growth media was added again and cells were allowed to differentiate for another
48-72 h in 5 % CO2 at 37 °C. Once differentiated, supernatant was discarded
and different solutions as described below were added.
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Conditions of LAM exposure to THP-1 cells. Condition 1 is when 10 µg/mL of
LAM/no LAM is presented to TLR2 (+) cells in serum. 10 µg/mL of LAM was
spiked into 20 % serum and incubated at 4 °C overnight to allow time for
association before adding to RPMI 1640 media with no serum. Condition 2 is
when LAM is presented to TLR2 (+) cells in delipidated serum. 10µg/mL of LAM
was spiked into 20 % delipidated serum and incubated at 4 °C overnight to allow
time for association before adding to RPMI 1640 media with no serum. Condition
3 is when 10 µg/mL LAM/no LAM is presented to TLR2 (+) cells in media (serum
free) with and without lipoproteins. Condition 3a is media with LAM/no LAM.
Condition 3b is LAM added to HDL (0.5 mg/mL)/no HDL in media. Condition 3c is
LAM added to LDL (1 mg/mL)/no LDL in media. Condition 3d is LAM added to
VLDL (0.15 mg/mL)/no VLDL in media. Condition 3e is LAM added to
chylomicrons (0.1 mg/mL)/no chylomicrons in media. The different lipoprotein
concentrations were based on normal physiological concentrations as mentioned
in literature575–577.
0.5 mL of solution per well was added to 24 well plate and incubated in 5 % CO2
at 37 °C for 24 hours after which supernatant was collected in low retention tubes
and stored at -80 °C. Wells were washed with PBS suitable for cell culture and
RNA extraction was done as described below.
Gene expression analysis. To evaluate changes in gene expression between
condition 1, 2 and 3, RNA was extracted from THP-1 cells after 24 h of exposure
to 10 µg/mL of LAM with and without lipoproteins (HDL/LDL/VLDL/Chylmicrons)
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in RPMI-1640 media without FBS using a RNeasy Mini Kit [Qiagen, 74106.].
Cells from at least four technical; and three biological replicates were pooled for
RNA analysis. cDNA synthesis from RNA samples was performed using the RT2
First Strand Kit [Qiagen, 330404.]. Initial gene expression analysis to screen for
select genes was performed on cDNA samples using an RT2 Profiler PCR Array
Human Cytokines & Chemokines in a 96-well plate format [Qiagen,
PAHS150ZC6EA]. Each array contained 84 different human cytokines and
chemokines, five housekeeping genes, proprietary controls to monitor genomic
DNA contamination, first-strand cDNA synthesis, and real-time PCR efficiency.
Gene expression analysis for rest of the conditions was performed on cDNA
samples using individual RT2 qPCR primer assays in a 96 well plate format
[Qiagen, details in materials section]. 18 cytokines and chemokines included on
basis of initial screen were: BMP2, CCL1, CCL2, CCL20, CCL3, CCL5, CSF2,
CSF3, CXCL1, CXCL2, CXCL5, IL15, IL16, IL18, IL1A, IL1B, CXCL8 AND TNF;
3 housekeeping genes; ACTB, HPRT1 and RPLP0 and 3 controls to monitor
genomic DNA contamination (GDC), reverse transcription control (RTC) and no
template control were ran on every 96 well plate. PCR arrays were run on
Applied Biosystems StepOnePlus thermocycler using RT2 SYBR Green ROX
qPCR Mastermix [Qiagen, 330529]. data analysis suite and Graphpad Prism 9.0.
Statistical analysis
CT values were uploaded onto the data analysis web portal at
http://www.qiagen.com/geneglobe. Samples contained controls and test groups.
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CT values were normalized based on Manual selection using ACTB, HPRT1 and
RPLP0 as reference genes.
Independent Student’s t-tests were used for statistical analyses between two
groups in RT2 Profiler PCR Arrays and quantitative real-time-PCR. Experimental
values are described as the mean±standard deviation, P-values<0.05 indicated a
significant difference between two groups. Statistical analysis was performed
using Graphpad Prism 9.0.
9.3 Results and discussion
We studied the differences in cytokine and chemokine signaling of human
macrophages when LAM was presented under three different conditions (Figure
9.1): condition 1- LAM presented in 20 % human serum supplemented culture

Figure 9.1. Schematic representation of research approach. LAM/No LAM was exposed to THP-1
cells under 3 different conditions. Condition 1 association of LAM with some of the common lipoproteins
present in serum: HDL, LDL, VLDL and chylomicrons. Condition 2 shows presentation of LAM to cells
with de-lipidated serum, when lipoproteins such as HDL, LDL, VLDL and chylomicrons are inactivated by
182
de-lipidation. Condition 3 is when LAM is presented to cells in a) just serum- free media or with either b)
HDL c) LDL d) VLDL e) Chylomicrons. Schematic via Biorender.com.

media, condition 2- LAM presented in 20 % de-lipidated human serum and
media, and condition 3a- LAM presented in just media (serum-free), or with either
3b- HDL, 3c- LDL, 3d- VLDL and 3e- chylomicrons. These three experimental
conditions will be referred to as 1, 2, and 3a, b, c, d and e, respectively. The
conditions of the study were chosen after extensive literature review, and a LAM
concentration of 10 µg/mL and exposure time of LAM to THP-1 cells for 24 hours
were used38,61,64,181,572,578–590.
Before commencing on the experimental evaluation, an intrinsic assessment of
toxicity of LAM to THP-1 cells was measured. Cells were exposed to 10 and 50
µg/mL of ManLAM for 24 hours. Figure S1 shows that LAM was not cytotoxic to
THP-1 cells at either concentration, validating the use of the cell line with the
given concentration of LAM for this study. Cells were adapted to minimum serum
(2.5%) conditions to assess cytokine signaling when exposed to conditions 1, 2
and 3 as described in detail in the methods section. Cells were then differentiated
using PMA to assess cytokine expression under different physiological
conditions.
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Initially, we examined LAM/no LAM- dependent expression using a highthroughput array of 94 cytokines and chemokines expressed by the THP-1

Figure 9.2. Cytokine profile in media and serum. a) Heat map shows fold regulation in
gene expression under conditions 3a (just media) and 1 (serum) with 10 µg/ml LAM, incubated
overnight. Bar graph represents cytokine response of THP-1 cells with b) buffer and c) serum.
Values are plotted as fold regulation, n=3 with error bars indicating standard deviation of the
mean. * indicates significant values with p < 0.05.

human macrophage cell line following 24 hours of LAM pre-incubation in media
or serum. Pre-incubation of LAM with the serum lipoproteins prior to exposure to
the cells allows for their uptake. Figure 9.2a demonstrates differential expression
of cytokines induced by macrophages, measured using qPCR, in the presence of
10 µg/mL of Man LAM in either condition 3a (media) or condition 1 (serum).
Table S3 shows the CT values and raw data. Cells growth in the absence of LAM
are used as a baseline for gene expression. Our results demonstrate peak
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expression of several cytokines in condition 3a (LAM in media). Three cytokines,
CCL3, CXCL2 and CXCL8 show significant (p-value < 0.05) up regulation in
condition 3a (media) (Figure 9.2b). We observed upregulation of CCL1, CCL20,
CCL3, CCL5, CSF2, CSF3, IL1B and CXCL8 in condition 3a (LAM in media,
Figure 2b) as compared to condition 1 (LAM in serum, Figure 9.2c). Figure 9.2b
shows increased expression of TNF in condition 3a (LAM in media), compared to
condition 1 (LAM in serum). This is in stark contrast to the literature, wherein Man
LAM is described as an anti-inflammatory molecule that inhibits TNF and IL-12
while stimulating IL-10 production39,65,591,592. We did not observe changes in IL-12
and IL-10 between the different conditions tested either. When comparing the
two conditions (3a and 1), it is evident that condition 3a (LAM in media) elicits a
much greater cytokine and chemokine response (5-10X increase with select
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cytokines) compared to condition 1 (LAM in serum, Figure 9.2b and c). Yet,
LAM is “presented” to TLRs in serum under physiological conditions, rather than
blood. Figure 9.2 shows that the secretion of cytokines is markedly reduced
when LAM is presented in association with serum lipoproteins, suggesting a
strong protective effect of serum on LAM-mediated cytokine production (n=3).
Further analysis of this response was performed using a set of genes selected
based on these initial observations. We assessed cytokine expression in de-
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TLR2 (+) cells in conditions 1, 2, 3 a, b, c, d and e with LAM
stimulation against no LAM as control. Scale bar indicates
that -10 is the lowest and 40 is the highest intensity. Values
are plotted as fold regulation from 3 independent
experiments, n=3.
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difference in
cytokine/chemokine
signaling between

conditions 1 (LAM in serum), 2 (LAM in delipidated serum), 3a (LAM in just
media), 3b-e (various lipoproteins associated with LAM in media). The heat map
indicates an increase in cytokine expression between condition 2 (LAM in
delipidated serum) and 3a (LAM in media), compared to condition 1 (LAM in
serum) and 3b-e (varied lipoproteins associated with LAM, in media).
Interestingly both lipid-free exposure conditions - condition 2 (LAM in delipidated
serum) and 3a (LAM in media) - demonstrate a dramatic induction of
chemokine/cytokine expression for CCL3, CXCL2 and CXCL8. Condition 2 (LAM
in delipidated serum) also shows increase in IL1B and TNF. On the other hand,
conditions 3b-e (various lipoproteins associated with LAM in media) show several
folds down regulation of most cytokine/chemokines as compared to conditions 2
(LAM in delipidated serum) and 3a (LAM in media). Interestingly, VLDL and
chylomicrons show greater suppression of cytokine signaling than HDL and LDL.
This could be due to larger particle size of VLDL (30-90 nm) and chylomicrons
(200-600 nm) compared to HDL (7-13 nm) and LDL (21-27 nm) which might
provide them with greater surface area to associate with LAM593–596. Another
reason for difference in cytokine expression could be different concentrations of
various lipoproteins used based on normal physiological concentration as
described in detail in methods section. Delipidated serum can induce cellular
stress, which in itself can contribute to inflammatory signaling. To discriminate
between LAM-mediated, TLR2 dependent signaling and other stress induced
responses, cytokine expression should be compared between TL2 (+) and TLR2
(-) cell lines.
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9.4 Conclusion
The results from this study support the overarching hypothesis that immune
responses are affected by the presentation of amphiphilic biomarkers such as
LAM, and this physiological context should be considered in the design of in vitro
experimental systems to study innate immune recognition. Arguably, all bacterial
PAMPs are amphiphilic – and this natural biochemistry is critical to their ability to
navigate two mutually incompatible regimes – hydrophilic and hydrophobic – in
the host. Several chronic inflammatory diseases such as psoriasis, systemic
lupus erythematosus, rheumatoid arthritis and infections such as HIV are
associated with altered lipoprotein levels596. The most common changes are
decrease in serum HDL and LDL and increase in serum VLDL. These altered
lipoprotein levels and interaction with amphiphilic PAMPs influence the cytokine
and chemokine profile. Therefore, it is important to consider this presentation of
amphiphiles for accurate understanding of its role in interacting with the host
immune system during various inflammatory diseases and infections including
TB.
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Chapter 10.
Conclusions and Future Directions
This dissertation work has explored the development of novel strategies for the
blood-based diagnosis of TB via better understanding of host-pathogen
interactions, specifically associated with mycobacterial virulence factor LAM.
Previous work from our lab demonstrated that LAM associates with host carriers
such as HDL. Based on these findings, we optimized and validated lipoprotein
capture assay in adult patients with TB and HIV from Uganda as discussed in
chapter 6 of this manuscript. This initial evaluation of serum showed successful
detection of LAM in serum but we also saw that a variety of factors can impact
host lipoprotein concentrations, including HIV/AIDS which can cause differences
in LAM detection by lipoprotein capture assay. Therefore, we developed a
membrane insertion assay with sample processing method that is independent of
host serum lipoproteins. Compared to lipoprotein capture, the membrane
insertion method resulted in higher sensitivity in adult TB patients. Once we
established higher sensitivity of membrane insertion in adult cohort, we tested
the feasibility of LAM detection and validated the membrane insertion assay in
pediatric TB and HIV positive or negative and age matched control serum
samples from Kenya as described in chapter 7. We were able to successfully
measure LAM in all pediatric samples irrespective of presence or absence of
comorbidities. But the sample processing method used to separate lipoproteins
from LAM in membrane insertion assay is a crude extraction method which uses
chloroform and methanol. To make the method more field and user friendly, our
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engineering team has developed a microfluidic chip to be integrated into portable
biosensor device. We validated the successful separation of blood from serum
and LAM retention using microfluidic device as compared to benchtop method as
described in chapter 8. Our results from clinical study in chapter 6 showed
dependence of LAM detection on host lipoprotein levels which clearly indicated
the need to better understand host- pathogen interaction. Previous work from our
lab shows that immune signaling of cells in response to LPS dramatically
changes based on its presentation in media versus serum. Therefore, we
investigated the impact of LAM- lipoprotein association on immune signaling in a
cell-based system as discussed in chapter 9. We successfully demonstrated that
the expression profiles of cytokines and chemokines generated in response to
LAM induction vary significantly depending on the type of buffer LAM is
presented in. This interaction is important to consider while designing studies for
LAM in vitro and also during development of LAM detection strategies.
In conclusion, this dissertation work far and wide describes the process and
considerations for developing LAM detection strategies to diagnose TB in adult
and pediatric populations in presence and absence of comorbidities such as HIV.
The assays we have developed here can be transitioned to other amphiphiles
which are expressed by pathogens in other infectious diseases and also for noninfectious diseases and used with other detection platforms. Summarized below
are some suggested advancements and applications for this technology.
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We have shown successful detection of serum LAM using membrane insertion
method in both adult and pediatric TB patients. This was first ever serum LAM
detection in pediatric patients in presence and absence of co-morbidities.
In future, we would like to evaluate bigger cohort for both adult and pediatric
clinical studies. To be able to make more comprehensive comparison, other
diagnostics such as culture and GeneXpert and other clinical variables including
comorbidities with similarly matched controls would be studied. As the urine LAM
assays have already been commercialized and endorsed by WHO, we would like
to do a side-by-side assessment of urine and serum detection of LAM on same
patient using the waveguide biosensor. To further evaluate the use of LAM in
immunocompromised and immunocompetent patients and as a prognostic
biomarker, we would perform LAM detection on a longitudinal cohort and
correlate the results with CD4 counts and treatment/mortality/morbidity. Since we
started these clinical evaluations, FIND has developed much more sensitive
antibodies against LAM epitopes. To enhance the sensitivity of LAM detection
using membrane insertion, new FIND antibodies would be evaluated
We envisage that in future, we would be able to deploy biosensor device at the
point of care in resource limited settings for diagnosis of TB using membrane
insertion method. Currently, the separation of amphiphilic biomarkers from
blood/lipoproteins is very complicated and almost unattainable in resource limited
settings. After successful validation of blood separation from serum and
retention of LAM using microfluidic device, the team is working on LAM release
from lipoproteins on microfluidic chip. This will automatize the whole process to
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be used at the point of care. The engineering and chemistry team is also working
on plastic fabrication of multichannel waveguides for multiplexed detection of
amphiphiles which will make the chip disposable and usable for several patient
samples at one time making the process cheaper and faster.
This whole assay has the advantage of detecting TB by using a prick of blood
which will be automatically processed by microfluidic device and detected by
using portable biosensor platform attached to a mini computer where the results
could be read by a clinician remotely.
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Appendix 2
Additional information for Chapter 6
Supplemental Information
Section S1
Selection of antibodies for assay development
In order to determine the optimal antibodies for use in the lipoprotein capture
assay, we systematically assessed the performance of several antibodies that
were available to us, including two from BEI Resources (monoclonal antibody
CS40, anti-LAM polyclonal antibody (LAM-pab), and five different monoclonal
antibody clones (24, 27, 29, 31 and 171) that were generously provided by the
Foundation for Innovative New Diagnostics (FIND) (Figure S1) using a
conventional sandwich ELISA. Although reagent intensive and associated with
lower sensitivity for detection of LAM (LoD 300-500 nM)72,211 compared to the
waveguide platform364, ELISA is a useful tool for the high-throughput screening of
antibodies.
A typical ELISA experiment for the detection of LAM at various concentrations
using FIND clones 24, 29 and 31 as the capture, and clone 171 as the reporter is
shown in Fig S1. The limit of detection (LoD) for LAM using this assay was found
to be 62.5 nM (assuming a molecular weight of 19 KDa for LAM) (n=3, per
experimental condition) using clone 31 as the capture and clone 171 as the
reporter. LoD was defined as 3 (s/n) where s/n is the standard deviation in
observed measurements, and summary of s/n for the measurements is shown in
Fig S1. Statistical significance was determined using one-way ANOVA with
Fisher’s least significant different test used for post-hoc analysis (**P<0.05).
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Antibodies were assessed for suitability for use in the lipoprotein capture assay
based on three parameters (Table S1): a) stability (>6 weeks after labeling with
either horse radish peroxidase (HRP) or Alexa fluor 647, under refrigeration), b)
specificity (no cross reactivity with M. smegmatis LAM), and c) sensitivity (use of
<30 nM of antibody to obtain a limit of detection of ≤ 62.5 nM of LAM, which is
the maximal sensitivity obtainable for this antigen by ELISA in our hands).
Antibodies that did not satisfy all three criteria were not used in the waveguideassays. For instance, the best sensitivity for detection of LAM using this method
incorporated clone 31 as capture, and clone 171 as the reporter (Fig S1).
However, clone 31 was unstable upon HRP labeling, and demonstrated cross
reactivity with M. smegmatis LAM, and therefore, was not selected for further
development. Using a similar assessment metric (Fig S1), FIND clones 171 and
24 were chosen for use in the lipoprotein capture assay.
Table S1. Selection of monoclonal antibodies
Antibody

Source

Properties

Parameter
Stability

Specificity

Sensitivity

CS40

BEI

Monoclonal

***

***

**

Pab

BEI

Polyclonal

*

*

**

24

FIND

Monoclonal

***

***

***

27

FIND

Monoclonal

***

**

***

29

FIND

Monoclonal

***

*

**

31

FIND

Monoclonal

*

**

***

171

FIND

Monoclonal

***

***

***
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Characterization, selection, labeling and preparation of antibodies
Five different FIND monoclonal antibodies (clones 24, 27, 29, 31 and 171) were
evaluated for sensitivity and specificity of detection of LAM by Enzyme Linked
Immunosorbent Assays (ELISA), and optimal antibodies were selected for further
use. For ELISA screening, a sandwich assay protocol was used. The conditions
described for this screening assay were shown to provide good sensitivity for
detection from early screening measurements at various antibody concentrations
using the BEI antibodies, and H37RV LAM. All the FIND antibodies evaluated in
the screening ELISA were first labelled with Horse Radish Peroxidase (HRP)
using the EZ-Link Plus Activated Peroxidase Kit from ThermoFisher.
Rabbit polyclonal anti-LAM antibody from BEI Resources was diluted 100-fold in
carbonate buffer, and 100µl of this dilution was added to each well of a 96 well
polystyrene ELISA plate, sealed, and incubated overnight at 4°C. Then, plates
were washed thrice with PBS-0.5% Tween 20 (PBST, room temperature (RT), 2
min each), and PBS containing 2% BSA was added to each well as a blocking
agent 2 hr, RT). After washing (2X, PBST and 2X, PBS), LAM (500nM), diluted
fresh in PBS in silanized plastic tubes was added and incubated for 2 hrs at
37°C. Following wash, varying concentrations (20-150 nM each, based on the
manufacturer’s recommendation) of each of the reporter antibodies being
evaluated were added and incubated for 2 hours at 37°C. It was determined that
100 nM of the reporter antibody offers maximal sensitivity of detection. Following
the quantification of binding affinity and signal resolution with individual
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antibodies, combinations of antibodies were evaluated (all five, sets of 2, 3 and
4). From this antibody characterization, performance sensitivities were found to
be even better using a cocktail of two antibodies, FIND clones 24 and 171. With
this choice of antibodies, cross-reactivity studies were performed to determine
binding of these antibodies with H37RV LAM, ara-LAM from M. smegmatis and
Lipomannan from M. bovis.
For use in the waveguide assay, the chosen reporter antibodies, FIND clones
24 and 171, were labeled using Alexa Fluor 647 fluorescent labeling kit from Life
Technologies Inc, as per manufacturer’s instructions. Each antibody was purified
by gel filtration, and tested for binding activity (immunoblot). The concentration
of the labeled antibody, and the degree of labeling were measured by ultra-violet
visible (UV-Vis) spectroscopy. Three different batch aliquots were prepared and
characterized. The degree of labeling for FIND 171 was 6, 7.6, 5.2 for each of
these batches, and for FIND 24 was 7.5, 9.1 and 5.03. Aliquots of each antibody
were prepared and stored at 4 °C. They were combined to make a cocktail of
15nM total antibody concentration before each experiment. Lipoprotein capture
assay is a sandwich immunoassay, where the capture antibody targets the coatprotein of HDL nanodiscs, namely Apolipoprotein A1. This capture antibody, goat
polyclonal anti-ApoA1 (1mg/ml), was purchased in biotinylated form and activity
was measured by ELISA, and subsequently evaluated by immunoblot at periodic
intervals (once every month). Aliquots of the capture antibody were stored at -20
°C, 100nM of the antibody being used as effective concentration in each
experiment.
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Table S2: Patient demographics
Patient
ID
1

Sex
FEMALE

2

FEMALE

58

57

3

FEMALE

39

1

4

MALE

31

5

5

FEMALE

38

202

6

MALE

35

125

7

MALE

35

32

8

FEMALE

25

25

YES

YES

NO

1

9

MALE

30

18

YES

NO

NO

1

10

MALE

45

230

YES

NO

NO

1

11

MALE

37

2

12

FEMALE

35

313

YES

NO

NO

0

13

FEMALE

27

59

YES

NO

NO

1

14

FEMALE

29

10

YES

YES

NO

1

15

MALE

43

10

YES

NO

NO

1

16

FEMALE

21

138

YES

NO

NO

1

17

FEMALE

38

27

18

MALE

25

14

YES

NO

NO

1

19

FEMALE

38

28

YES

YES

NO

1

20

MALE

30

61

YES

YES

NO

1

21

FEMALE

30

31

YES

YES

NO

0

22

FEMALE

305

YES

NO

YES

0

23

MALE

28

109

YES

NO

NO

0

24

FEMALE

21

199

YES

NO

NO

0

25

MALE

50

2

YES

NO

NO

0

26

FEMALE

32

348

YES

NO

NO

0

27

FEMALE

28

117

YES

NO

NO

0

28

FEMALE

34

7

29

FEMALE

29

616

YES

NO

YES

0

30

FEMALE

18

13

YES

NO

NO

0

31

FEMALE

48

56

YES

YES

NO

0

32

FEMALE

24

81

YES

NO

NO

0

33

MALE

33

14

YES

NO

NO

0

.

CD4
cells/mm3

Infiltrates

Miliary
infiltrates

Urine
LAM
result

Age
(years)
28

Cavity

32

237

1
YES

NO

NO

1
1

YES

NO

NO

1
1

YES

NO

NO

1
1

1

1

0

34

FEMALE

24

354

35

MALE

50

54

YES

NO

NO

0

36

FEMALE

37

67

YES

NO

NO

1

37

FEMALE

40

25

38

MALE

44

36

YES

YES

NO

0

39

FEMALE

29

40

MALE

626

YES

NO

NO

1

41

FEMALE

19

19

42

FEMALE

29

635

43

FEMALE

20

73

44

MALE

.

28

YES

NO

NO

0

45

MALE

.
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NO

NO

NO

0

46

FEMALE

30

138

YES

NO

NO

0

47

FEMALE

28

36

YES

NO

NO

0

48

FEMALE

33

140

YES

NO

NO

0

.

0

1

.
0
YES

NO

0
0

. represents missing data, Urine LAM result- positive=1, negative=0
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NO

Appendix 3
Additional information for Chapter 9
Supplemental Information
Table S3- CT values for gene expression analysis in THP-1 cells under different
physiological conditions
HDL +
Sample HDL
HDL
HDL
LAM
HDL + LAM
HDL + LAM
Round

1

2

3

1

2

3

BMP2

32.01

35.38

31.96

32.14

35.35

32.66

CCL1

33.71

36.28

30.68

31.57

34.22

37.11

CCL2

30.23

35.83

35.45

31.31

37.01

35.93

CCL20

31.38

31.92

31.17

30.31

31.67

30.00

CCL3

30.80

32.91

30.92

29.70

32.32

29.47

CCL5

29.43

31.47

28.60

28.90

31.86

25.97

CSF2

33.76

UD

36.47

37.14

37.12

35.31

CSF3

35.58

36.31

36.71

34.02

35.97

35.57

CXCL1

31.96

35.39

33.96

31.01

33.72

31.73

CXCL2

28.91

31.79

28.18

28.23

30.91

26.38

CXCL5

29.58

37.04

36.51

28.69

35.90

34.35

IL15

34.97

34.12

33.47

34.52

37.06

32.48

IL16

37.09

36.93

35.36

35.62

UD

35.24

IL18

32.97

35.47

33.49

33.60

35.40

32.50

IL1A

35.88

36.97

35.88

35.89

36.92

35.63

IL1B

33.04

33.77

34.59

31.93

32.93

32.23

CXCL8

22.90

24.68

22.49

22.23

24.27

20.66

TNF

32.96

36.42

31.92

32.94

33.97

31.49

ACTB

21.91

25.40

21.59

22.51

24.69

20.92

HPRT1

30.19

33.38

30.91

30.62

33.47

29.92

RPLP0

23.36

25.90

22.87

23.84

26.67

21.88

GDC

31.83

UD

UD

33.75

36.99

UD

RTC

24.71

24.11

23.90

24.96

23.91

23.43
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Sample

LDL

LD

LD

LDL + LAM

LDL + LAM

LDL + LAM

Round

1

2

3

1

2

3

BMP2

33.45

29.59

29.90

37.05

29.92

30.34

CCL1

34.00

37.93

34.20

37.13

37.15

33.25

CCL2

33.19

36.63

36.66

37.11

36.90

35.74

CCL20

33.91

31.62

31.01

34.15

30.90

27.91

CCL3

33.88

30.29

31.17

34.92

30.40

28.91

CCL5

30.74

29.95

28.72

31.94

29.69

27.55

CSF2

39.30

36.63

UD

UD

36.37

37.12

CSF3

36.98

36.87

36.92

36.29

36.53

35.86

CXCL1

36.45

35.94

33.91

36.95

35.24

32.48

CXCL2

33.48

32.30

29.84

34.93

31.57

27.91

CXCL5

34.91

33.61

37.07

37.24

34.01

34.65

IL15

35.42

34.09

33.90

36.90

34.93

33.88

IL16

UD

UD

33.16

UD

36.99

32.91

IL18

34.19

32.92

31.92

36.91

33.34

31.50

IL1A

35.83

34.14

35.87

UD

34.77

34.47

IL1B

36.33

32.57

32.14

36.93

31.87

29.93

CXCL8

25.45

23.26

23.90

26.79

22.91

21.81

TNF

36.90

34.91

32.49

UD

34.92

31.34

ACTB

25.18

22.85

20.84

28.70

22.91

20.68

HPRT1

32.36

30.61

30.33

34.92

30.91

29.87

RPLP0

24.79

24.45

22.19

26.90

24.80

21.91

GDC

37.14

UD

UD

UD

UD

UD

RTC

24.89

23.48

23.84

26.75

23.41

23.77
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Sample

media + LAM

media +
LAM

media + LAM

media

media

media

Round

1

2

3

1

2

3

BMP2

29.90

29.91

28.91

31.90

31.90

28.97

CCL1

31.91

33.91

21.94

35.92

37.13

30.24

CCL2

30.92

33.92

32.93

32.91

34.92

34.74

CCL20

22.91

23.91

23.92

24.91

25.90

26.71

CCL3

23.90

24.90

24.92

26.91

26.90

28.61

CCL5

23.93

26.96

24.97

26.91

28.93

27.36

CSF2

31.90

32.90

29.60

35.91

35.90

37.11

CSF3

30.91

31.91

32.68

33.91

33.90

35.76

CXCL1

25.90

26.91

28.92

28.90

28.90

33.05

CXCL2

25.90

25.92

25.91

28.90

28.90

29.83

CXCL5

31.90

31.90

30.54

33.90

34.90

33.14

IL15

34.89

36.89

33.93

36.89

37.01

34.82

IL16

33.92

34.91

31.91

33.91

36.91

31.00

IL18

33.91

34.92

31.98

32.91

34.91

30.64

IL1A

31.89

32.89

31.90

33.88

34.90

33.43

IL1B

20.91

20.92

23.93

22.92

23.91

26.88

CXCL8

19.91

20.90

19.92

22.90

22.89

23.63

TNF

27.93

26.91

27.22

29.91

30.93

30.60

ACTB

21.91

22.94

20.92

21.90

22.91

19.95

HPRT1

29.91

30.92

29.18

30.91

31.91

28.91

RPLP0

22.91

23.91

21.89

23.91

24.91

21.60

GDC

UD

36.97

UD

UD

UD

UD

RTC

23.89

21.91

23.90

23.89

22.89

23.64
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Sample

VLDL

VLDL

VLDL

VLDL +
LAM

VLDL +
LAM

VLDL +
LAM

Round

1

2

3

1

2

3

BMP2

33.89

35.94

30.44

31.36

33.39

30.46

CCL1

37.11

37.16

UD

UD

35.61

37.14

CCL2

37.09

35.28

35.21

33.11

34.25

34.24

CCL20

32.81

30.91

29.52

29.91

28.98

26.85

CCL3

32.71

33.88

31.27

29.64

31.80

28.58

CCL5

30.55

33.86

29.13

27.95

31.81

28.28

CSF2

UD

UD

UD

37.11

36.67

35.82

CSF3

36.73

35.95

34.92

34.83

36.84

35.33

CXCL1

34.92

36.87

35.90

33.46

33.92

32.82

CXCL2

30.91

33.73

31.43

28.74

30.92

28.62

CXCL5

37.06

37.05

37.09

33.47

34.84

34.32

IL15

35.06

36.99

33.91

32.63

35.40

33.74

IL16

37.00

37.00

34.13

37.00

34.86

33.97

IL18

33.53

36.91

32.05

31.45

34.46

31.92

IL1A

35.17

UD

35.41

33.99

34.46

36.37

IL1B

35.59

32.25

32.82

32.93

28.92

30.23

CXCL8

22.76

27.57

24.63

20.29

25.15

22.25

TNF

35.02

35.95

33.91

32.91

33.52

31.30

ACTB

23.37

26.36

21.91

21.52

23.91

21.88

HPRT1

31.89

34.18

30.77

29.38

31.91

30.56

RPLP0

24.26

27.44

22.91

21.92

25.62

22.82

GDC

UD

UD

UD

UD

UD

UD

RTC

24.62

23.92

23.86

22.91

23.91

23.94
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Sample

serum

serum

serum

serum +
LAM

serum +
LAM

serum +
LAM

Round

1

2

3

1

2

3

BMP2

30.90

33.44

34.94

31.92

34.45

32.64

CCL1

36.92

UD

UD

37.06

37.80

UD

CCL2

28.92

37.08

36.94

33.91

35.64

35.24

CCL20

25.90

27.30

27.76

25.90

27.45

25.87

CCL3

27.90

32.77

30.92

27.90

32.92

28.06

CCL5

27.96

31.51

29.76

26.91

31.95

27.74

CSF2

37.03

UD

37.12

36.89

37.11

32.98

CSF3

33.90

35.74

35.61

34.92

35.92

33.97

CXCL1

26.91

36.86

33.33

26.90

34.95

29.70

CXCL2

26.91

31.82

29.98

26.91

30.97

26.96

CXCL5

32.90

34.89

35.92

32.89

35.74

32.25

IL15

34.89

36.28

34.94

33.89

36.62

33.86

IL16

32.91

34.71

36.97

35.91

UD

34.19

IL18

31.92

33.29

32.17

30.90

33.91

30.92

IL1A

32.88

34.57

36.37

33.88

37.05

33.33

IL1B

25.91

29.95

30.93

25.91

29.58

28.18

CXCL8

26.90

24.91

24.15

21.90

24.90

21.83

TNF

30.91

34.96

33.41

31.91

34.90

31.10

ACTB

20.91

24.53

23.84

21.92

24.93

21.66

HPRT1

28.90

32.89

31.55

29.90

33.32

29.91

RPLP0

22.91

25.91

23.33

23.92

26.34

22.47

GDC

UD

UD

UD

UD

UD

UD

RTC

24.90

23.60

23.78

24.89

23.66

23.58
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Sample

de-lip

de-lip

de-lip

de-lip +
LAM

de-lip +
LAM

de-lip +
LAM

Round

1

2

3

1

2

3

BMP2

33.20

35.90

29.45

31.27

32.62

31.91

CCL1

UD

UD

37.04

29.00

33.20

31.62

CCL2

33.34

32.72

32.05

29.12

32.49

32.40

CCL20

27.13

28.45

26.95

23.65

23.91

23.91

CCL3

30.73

31.41

27.92

25.91

26.39

25.01

CCL5

29.40

31.98

27.74

26.52

28.78

25.95

CSF2

35.97

UD

35.40

29.37

28.74

29.33

CSF3

36.93

32.92

34.78

30.41

29.91

29.53

CXCL1

31.93

35.92

33.06

29.75

29.72

27.93

CXCL2

28.75

31.36

28.91

25.12

26.62

25.31

CXCL5

32.74

36.92

36.27

29.39

32.16

31.56

IL15

35.91

36.99

33.91

33.76

34.07

34.11

IL16

34.28

36.94

32.60

32.17

36.39

33.91

IL18

31.15

35.73

31.05

32.93

34.92

33.23

IL1A

35.93

37.00

33.86

31.78

31.88

31.90

IL1B

30.61

30.96

29.53

24.93

25.35

24.31

CXCL8

23.06

25.91

23.90

20.91

21.46

20.83

TNF

33.04

33.56

30.51

27.59

28.46

27.91

ACTB

22.80

25.71

20.92

21.91

23.88

22.48

HPRT1

30.45

33.25

28.95

28.92

30.76

29.65

RPLP0

23.71

26.24

21.79

23.29

24.55

22.91

GDC

UD

UD

37.08

35.92

29.94

UD

RTC

25.82

23.65

23.76

24.66

23.44

23.89
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Sample

chyl

chyl

chyl

chyl +
LAM

chyl + LAM

chyl + LAM

Round

1

2

3

1

2

3

BMP2

29.92

35.94

30.91

30.89

30.94

30.55

CCL1

37.08

UD

33.38

35.83

37.14

31.15

CCL2

36.70

37.11

21.32

37.05

34.84

19.91

CCL20

32.26

34.92

37.14

32.27

32.50

UD

CCL3

28.91

33.62

28.78

29.08

29.91

26.90

CCL5

29.95

33.34

31.92

30.20

31.48

30.68

CSF2

37.13

UD

30.27

35.70

37.00

30.18

CSF3

34.39

35.92

35.80

33.55

35.01

35.75

CXCL1

35.42

37.04

21.18

35.30

34.09

20.76

CXCL2

32.17

35.96

29.65

32.90

33.27

27.97

CXCL5

35.88

UD

32.91

34.96

36.96

32.75

IL15

34.27

36.96

29.91

34.54

35.92

29.57

IL16

35.42

UD

29.80

35.92

37.07

27.92

IL18

33.91

36.94

34.92

34.78

34.14

34.89

IL1A

32.76

36.41

21.91

34.53

34.92

21.55

IL1B

30.92

35.69

27.97

30.84

31.60

27.25

CXCL8

23.27

27.75

30.26

23.54

24.61

29.88

TNF

35.12

UD

37.20

35.90

36.90

31.23

ACTB

22.61

27.63

37.10

22.89

23.90

35.48

HPRT1

30.90

35.30

34.94

31.26

31.92

33.66

RPLP0

23.91

27.19

23.12

24.32

25.42

22.91

GDC

38.18

UD

36.92

37.16

UD

36.96

RTC

24.89

23.99

31.93

25.39

23.68

30.04

UD- Undetermined, Chyl- Chylomicrons, De-lip- Delipidataed serum
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150
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LAM 50ug/ml

100
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Figure S2: Cell viability assay for THP-1 cells exposed to
LAM
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